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CRISPR-Cas: Development and Applications for Mammalian 
Genome Editing 
Abstract 
The ability to introduce targeted modifications into genomes and engineer model organisms holds 
enormous promise for biomedical and technological applications, and has driven the development of 
tools such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). 
To facilitate genome engineering in mammalian cells, we have engineered the CRISPR (clustered 
regularly interspaced short palindromic repeats)-Cas9 programmable nuclease systems from 
Streptococcus pyogenes SF370 (SpCas9) and S. thermophilus LMD-9 (St1Cas9) for mouse and human 
cell gene editing through heterologous expression of the minimal protein and RNA components. We 
have demonstrated that Cas9 nucleases can be guided by several short RNAs (sgRNAs) to introduce 
double stranded breaks (DSB) in the mammalian genome and induce efficient, multiplexed gene 
modification through non-homologous end-joining-mediated indels or homology-directed repair. 
Furthermore, we have engineered SpCas9 into a nicking enzyme (SpCas9n) to facilitate recombination 
while minimizing mutagenic DNA repair processes, and show that SpCas9n can be guided by pairs of 
appropriately offset sgRNAs to induce DSBs with high efficiency and specificity. In collaboration with 
Drs. Osamu Nureki and Hiroshi Nishimasu at the University of Tokyo, we further report the crystal 
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structure of SpCas9 in complex with the sgRNA and target DNA, and elucidate the structure-function 
relationship of the ribonucleoprotein complex. Finally, through a metagenomic screen of orthologs, we 
have identified an additional small Cas9 from Staphylococcus aureus subsp. aureus (SaCas9) that cleaves 
mammalian endogenous DNA with high efficiency. SaCas9 can be packaged into adeno-associated virus 
for effective gene modification in vivo. Together, these technologies open up exciting possibilities for 
applications across basic science, biotechnology, and medicine. 
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Chapter 1 An introduction to genome 
engineering 
 
Principles of gene targeting 
The understanding that the phenotype of an organism is governed by its genes lies at the foundation of modern 
biology. Through meticulous observation, selection, and cataloguing, early biologists began to ascribe traits and 
variations to certain genes in simple model organisms. The need for ways of making desired, precise modifications 
in the genomes of more complex organisms, then, unsurprisingly, began to drive an ongoing quest for developing 
ever more versatile and efficient tools for studying both normal biology and disease. 
Eukaryotic gene manipulation was first begun over three decades ago in yeast, a system where exogenous gene 
fragments could be introduced with relative ease; the “gene targeting” technique involved building a vector with a 
desired modification flanked by arms bearing sequence homology to a given locus, and relying on the native DNA 
repair pathway of the organism to recombine the modification into the genome(1-5). Around the same time, 
developments in the experimental manipulation of mouse embryos led to the observation that a similar process 
might occur in mammalian cells(6, 7). Over the next several years, a series of landmark papers by Capecchi and 
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others established the technique of generating transgenic animals by gene targeting in pluripotent mouse 
embryonic stem (ES) cells via donor template-mediated homologous directed repair (HDR)(6, 8-11). 
Remarkably, leveraging HDR for targeted insertion, deletion, or other modification of genes continues to be one 
of fundamental tools allowing the generation of countless genetically modified cell lines and organisms. 
Powerful as it was, the successful targeting of an endogenous locus is an exceedingly rare event, occurring at the 
frequency of approximately 1 per 105 or more cells(12, 13). While in mouse ES cells, a correctly targeted cell line 
can be selected or screened for, isolated, expanded, and injected into blastocysts to generate chimeric animals, 
other cell types may not be so amenable to such manipulation. Likewise, any potential of using HDR for in vivo 
gene therapy would be hindered by such frequencies. 
What limits the efficiency of HDR? Optimizing the length of homology arms and linearization of the donor 
plasmid can aid targeting to a modest extent, though surprisingly, increasing the copy number of the donor 
template seemed to have little effect(7, 8). Rather, experiments from flies and yeast yielded the insight that 
double-stranded breaks (DSB) in the DNA at the target locus can dramatically increase the probability of an HDR 
event(14-16).  
Occurring commonly as a result of stalled or collapsed replication forks, DSB in cells are repaired primarily 
through a couple of pathways (Figure 1-1). The high fidelity pathway typically uses the undamaged sister 
chromatid as a template, which can be substituted by a donor vector. Alternatively, DSBs can undergo the error-
prone non-homologous end joining (NHEJ) process, where broken ends are resected in situ. In this way, NHEJ 
can produce small insertion or deletion (indel) mutations at the site of the break, and less frequently, 
chromosomal translocations. Indels occurring within the coding region of a gene can in turn result in frameshift 
mutations that lead to the loss of gene function(17, 18).  
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Figure 1-1 DNA double-stranded break repair pathways 
The insight that DNA repair mechanisms stimulated by DSBs can be exploited for different types of targeted 
modification was not lost upon the pioneers of genome engineering. In a simplified conceptual framework, the 
control of how to effect precision gene editing has become a problem of how to precisely control the timing and 
location of a DSB. This idea began the development of designed proteins that would allow one to cleave the 
genome in a controlled manner. 
Designer nucleases for genome modification 
Taking advantage of the “recombinogenic” nature of DSBs was a family of homing endonucleases already existing 
naturally in certain unicellular organisms. Such enzymes act similarly as transposons, cleaving DNA in specifically 
recognized 14 to 40-bp loci and copying (hence homing) its genetic template through damage-induced 
recombination(19). The yeast homing meganuclease I-SceI, so called for its long, rare-cutting 18-bp recognition 
sequence, became the first such protein to be developed for highly site-specific DNA cleavage for the purpose of 
gene editing in mammalian cells(20). 
When Jasin and colleagues transfected I-SceI stably into mouse 3T3 cells, they observed robust cleavage of I-SceI 
recognition sites; these lesions are then repaired by NHEJ, which could result in deletion of chromosomal 
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sequences in between two sites. When paired with an HDR donor, I-SceI induced more than 100-fold increase in 
gene targeting over background(13). This result was impressively recapitulated in a transient transfection into 
mouse ES cells, and subsequently in human cells, fly, zebrafish, and sea anemone among other species, as well as 
mouse hepatocytes through adenoviral delivery in vivo, demonstrating the potential universal applicability of such 
a system(12, 20-22). 
Importantly, because their recognition sequences are highly specific, I-SceI appeared to produce little cytotoxicity 
from off-target cleavage in mammalian cells(13). Its exceptional specificity, however, meant on the other hand a 
handicap for generalized applications, as there are few sites in the mammalian endogenous genome for which the 
native I-SceI would be useful for targeting. To solve this, several groups sought to reprogram its specificity by re-
engineering the enzyme and its homologs (e.g. I-CreI, I-AniI, etc.) using both rational design and combinatorial 
approaches(23-26). Nevertheless, the challenging nature of predictably altering protein recognition spurred the 
development of alternative technologies. 
DNA targeting by ZFNs and TALENs 
A key feature, modularity – the ability of each protein subdomain to function independently yet assemble to work 
together – that would render proteins much more amenable to redesign was missing in homing meganucleases, 
but not so with zinc fingers (ZF) proteins. Discovered initially in 1985 as a structural motif within a small 
transcription factor, zinc fingers constitute one of the most abundant DNA recognition modules in metazoans, 
making up approximately 2% of the human genome(27-30). Each finger, approximately 30 amino acids long, 
specifically contacts 3-bp of DNA in the major groove(31, 32); in theory, this means that for a chosen target 
sequence multiple units of ZFs could be strung together to specifically recognize a longer sequence. 
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Figure 1-2 Designer nucleases: ZFNs and TALENs 
The idea that a fusion protein comprising such a programmable DNA-binding domain and a non-specific 
nuclease could be created for site-specific cleavage was thus conceived, catalyzing the development of a new 
generation of synthetic “designer nucleases” (Figure 1-2A). The first demonstration employed a pair of fingers 
and the catalytic domain of the type II restriction endonuclease FokI, and successfully cleaved predetermined 
sequences in vitro as “chimeric restriction enzymes(28, 33, 34).” Others quickly followed by showing the efficacy 
of zinc finger nucleases (ZFNs) for cleaving endogenous genes and stimulating HDR in Xenopus oocytes as well as 
human embryonic kidney (HEK 293) cells(35-39). Importantly, these experiments showed that FokI cleaved as 
inverted dimers(35, 37): that two inversely and appropriately positioned ZFN units directed the cutting of each 
locus, which could accord it a high degree of specificity since sequence recognition by each half of the ZFN would 
need to occur together temporally and in defined spatial relationship for cleavage. 
Since these groundbreaking demonstrations, a number of developments have enhanced and broadened the use of 
ZFN for gene targeting. First, finger combinations have been found or designed to recognize many of the 64 
triplet nucleotide combinations, though some, such as 5’-GNN-3’ triplets, are more reliably recognized(28). 
Related to this, advances in construction of longer ZF arrays allowed recognition of longer stretches of DNA up to 
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18-bp in length, sufficient for unique targeting of complex genomes(40, 41). Secondly, the development of FokI 
obligate heterodimers(42, 43) has ameliorated some of the off-target toxicity arising from unintended 
homodimerization of the nuclease domains(44). With these advances, new methods of efficiently synthesizing 
ZFNs further paved the way for broader and easier ZFN technology adoption(45, 46). 
Concomitantly, alternatives to traditional HDR vector designs also expanded the techniques available for precise 
gene modification. The use of single stranded DNA oligonucleotides (ssDNAs or ssODNs) as donor templates 
for small changes enabled significant improvements in the efficiency of gene editing and mediating long distance 
(up to 100-kb) chromosomal microdeletions(47, 48). Reminiscent of restriction cloning, donor DNAs with 
engineered overhangs that match the staggered cleavage patterns generated by ZFNs have been successfully 
inserted into mammalian chromosomes via NHEJ-based ligation(49, 50). 
A powerful tool, ZFN has been applied successfully across a multitude of plant and animal species for targeted 
gene disruption, correction, and addition ranging from single nucleotides to kilobases(46, 51, 52). Microinjection 
of DNA or RNA encoding ZFN targeting endogenous genes into fertilized rat zygotes, for instance, produced 
animals with 20-100% gene disruptions in a single step; this represents a tremendous advance over traditional ES 
cell targeting-based transgenic animal generation, not just impressive for the greatly shortened timeframe, but 
particularly crucial for organisms such as rats where ES cells are not germ line-competent(53, 54). ZFNs have thus 
opened the initial door to genome manipulation of whole organisms, generation of human cell lines for modeling 
development and disease, as well as a feasible pathway towards gene therapy in vivo(46, 55-57). Promisingly, one 
of the early demonstrations of targeted disruption of the CCR5 gene encoding a co-receptor required for HIV 
infection is currently in clinical trials, with others sure to follow(58-61). 
Nonetheless, such a carefully engineered technology is not without its caveats and some significant drawbacks. 
Early studies of cytotoxicity showed potential lethality in cell lines overexpressing ZFNs(36, 39), though 
improvements in architecture and bioinformatics-based design has ameliorated off-target activity(42, 43, 46). In 
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repairing damaged DNA, HDR and NHEJ pathways can compete and differ in efficiency amongst cell types, thus 
producing unwanted indels in place of template-based modification. Towards addressing this, ZF-nickases have 
been engineered by inactivating one of the FokI domains, which reduces mutagenic effects of unwanted DSBs but 
still allows HDR to occur(62, 63). Furthermore, the effect of epigenetics, such as heterochromatin, on ZFN 
targeting has yet to be fully appreciated. 
Perhaps most importantly, ZFs suffer from not being truly independent modular proteins in that the specificities 
and efficiencies of neighboring modules can influence one another(64, 65). Because of this context dependency, 
the design of ZFNs for new targets isn’t straightforward and can often require labor-intensive rounds of screening 
for optimal ZF domains(45, 65). Coupled with difficulty and cost of protein synthesis, the need to pre-validate 
ZFNs remains a serious barrier for widespread, large-scale adoption. Indeed, much of the ZFN platform used for 
human endogenous gene editing remains proprietary. 
A further step towards both true modularity and universal access in design came with a newer generation of 
engineered nucleases. Transcription activator-like effectors (TALEs) are proteins secreted by the rice pathogen 
Xanthomonas that are capable of binding promoter sequences and altering the expression of plant genes to aid 
infection(66, 67). The DNA recognition domain of TALEs consists of repetitive monomers that each recognizes 
a single DNA base pair, which could accord these proteins a much better degree of flexibility in targeting. Within 
each monomer, typically 33-35 residues in length, DNA recognition is bestowed by two amino acids known as the 
repeat variable di-residue (RVD), and “cracking the TALE code” became a crucial step in adapting TALEs for 
genome engineering(68-70). 
The development of FokI-based TALE-nucleases (TALENs, Figure 1-2B) as a gene editing platform progressed 
similarly as ZFNs. The modular re-assembly of TALEs and use of TALEN for DNA cleavage was demonstrated 
first in yeast(71-73), followed rapidly in mammalian cells for both NHEJ and HDR applications with efficiencies 
matching those of ZFNs(74). Subsequently, the invariant regions flanking the repeat monomers in the original 
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TALE scaffold has been further optimized for a simplified architecture(74, 75). Like ZFNs, TALENs were swiftly 
and successfully applied in organisms as diverse as cricket, frog, zebrafish, silkworm, in addition to human somatic 
and pluripotent stem cells(76). 
Yet also just like ZFNs or any other technology that can irreversibly modify the genome, questions regarding the 
specificity of TALENs abounded. In theory, TALENs can achieve a substantial degree of specificity since a 
minimum of 13-bp of recognition is required for each arm(77). Indeed, a few studies examining TALEN targeting 
of sequences similar to the intended cleavage sites in yeast, human cells, and zebrafish have shown little activity at 
predicted off-target loci(73, 75, 78). Nevertheless, at least two other groups have reported off-target activities(79, 
80), underlining the need for a genome-wide, unbiased survey of TALEN specificity. 
Logistically, the high degree of homology among TALEN monomers presented challenges in protein synthesis 
and expression. Since PCR-based construction methods are ineffective for such repetitive sequences, the 
development of alternative cloning strategies became critical(81-84). In addition, the possibility of recombination 
in some situations (e.g. lentiviral expression) precludes TALENs from certain applications(85). Compounding 
this, TALENs are much larger than ZFNs per recognized base, and not suitable for delivery via the otherwise 
promising adeno-associated virus (AAV) vehicle. Finally, though much more modular and predictable, TALEs are 
not immune from contextual effects(74). 
More broadly than enabling chimeric nuclease applications, both ZFs and TALEs can provide a generalized 
platform for customizable DNA binding domains. A number of exciting developments have synthesized this idea 
with orthogonal functional domains to create sequence-specific ligand-binding proteins, integrases, and histone 
and DNA modifiers(77, 86-88). In this expanded set of tools, some of the most effective and well-characterized 
technologies are ZF- and TALE-transcriptional modulators that can effect activation or repression of endogenous 
genes(41, 74, 82, 89-94); some of these tools have been additionally engineered to be under chemical or optical 
control(88, 95). Provided the targeting specificity of single ZF or TALE units can be improved to match that of 
   
 9 
obligate dimers(77), such methods of perturbing endogenous gene expression allows the preservation of natural 
splicing variants and circumvents the need for delivery of large transgenes, showing promise as therapeutic 
agents(86, 96, 97).  
Together, these technologies have already expanded our abilities to alter and modulate the genomes of cell lines 
and species far beyond those of traditional model systems; they have yielded valuable insights into biological 
processes, disease modeling, and in vivo therapeutics. Where is there room for improvement then? Fundamentally, 
ZFNs and TALENs share the same principle of relying on decoding and reassembling DNA-binding modules for 
targeting. Because DNA-protein contacts rely on highly evolved interactions, manipulating their recognition and 
specificity can be challenging. This is demonstrated by the contextual effects of both ZFs and TALEs, but more 
generally, the efficacy and specificity of a given ZFN or TALEN pair can be difficult to predict(45, 65, 81, 83, 98). 
Coupled with the need for de novo protein synthesis for every construct, the initial validation of targeting can 
present a hurdle in time and resources and become prohibitive for high-throughput applications. Finally, while 
both are adept at effecting changes in single genes, the ability to deliver multiple ZFN or TALEN pairs to target 
several loci (e.g. diseases of polygenic origins or studies on epitasis) presents a significant barrier. All of these 
reasons lead to one question: are there ways to manipulate genomes using principles wholly different from the 
existing designer nucleases? 
Among the molecular biology techniques used for dissecting functional genetics, one stood out for its potency, 
versatility, and ease of application. The observation from C. elegans that introduction of double-stranded RNAs 
into cells triggers an antiviral innate immune response to destroy RNA molecules bearing complementary 
sequences revolutionized our ability to transcriptionally silence genes(99). The method is efficient as it’s simple: 
small interfering RNAs (siRNAs) locate their targets by Watson-Crick base-pairing, whose predictability allows 
the optimization of design parameters for activity and specificity(100, 101). Moreover, the RNAi mechanism 
makes use of conserved endogenous machinery, requiring only the delivery of small RNAs for validation(102). 
This latter point is key to allowing multiplexed and synergistic gene silencing(103, 104) as well as creation of 
   
 10 
genome-wide siRNA libraries for high throughput screening applications(105, 106). For the field of genome 
engineering, these are enviable qualities, and yet such a system already exists in microbes. 
CRISPR-Cas: a programmable RNA-guided endonuclease system 
In 1987, a search for the gene encoding a proteolytic enzyme in E. coli uncovered a series of regularly spaced 
repetitive elements containing a “dyad symmetry” or partially palindromic sequences that shared no homology 
with any known genes(107). Even as similar motifs were identified in diverse species of bacteria and archaea, the 
function of these invariably 21 to 37-bp “direct repeats” and similarly sized non-repetitive “spacers” remained a 
mystery(108-111) and they came to be named clustered regularly interspaced short palindromic repeats 
(CRISPR) after their most salient structural characteristic(112). 
The first major breakthrough came about with the increasing availability of bioinformatics data on bacterial and 
viral genomes. In 2005, three groups independently discovered that bacterial CRISPR spacers shared a high 
degree of homology with extrachromosomal elements, such as DNA from other species or bacteriophages(113-
115). Importantly, the spacers seemed to be actively acquired from phages that commonly attacked the bacteria, 
and those strains that incorporated the spacers into their genomes became resistant to further infection(113, 115, 
116). It was thus hypothesized that CRISPR served as a kind of “genetic memory of infection,” a type of adaptive 
immune system based on a mechanism then thought to be similar to RNA interference(117).  
 
Figure 1-3 Spacer acquisition in the type II CRISPR-Cas adaptive immune system 
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More thorough analyses revealed that additions of ~30-bp spacers to the CRISPR repeat array always occurred in 
a polarized manner accompanied by reduplication of repeats(115, 116, 118) and additionally required their phage 
DNA templates or “protospacers” to contain a downstream consensus sequence known as a protospacer adjacent 
motif (PAM, Figure 1-3)(119, 120). For instance, protospacer sequences from phages of the lactobacterium 
Streptococcus thermophilus always immediately preceded a 5’-NNAGAAW-3’ PAM sequence, and phages could 
evolve out of resistance by acquiring mutations in the PAM(119). The specific nucleotide composition of the 
PAM, which is always present in the foreign genetic element but never incorporated into the CRISPR array, vary 
among the multitude of CRISPR systems(121). Though the process of spacer acquisition is not entirely 
understood, the preclusion of PAMs from the CRISPR array likely plays a role in distinguishing between self vs. 
non-self(121-123). 
The mechanism of how target destruction occurred required the identification and understanding of the other 
components in the CRISPR system. When Schouls and colleagues christened CRISPRs as a new class of repetitive 
sequences, they also noted that sets of CRISPR-associated (cas) protein-coding genes always existed near the 
repeat arrays, and some of them bore sequence similarity to known helicases and nucleases(112, 117). Based on 
the composition of the cas genes, genome architecture of the arrays and their leader sequences, CRISPRs have 
been subsequently divided into three families that each employ distinct functional mechanisms for spacer 
incorporation and target cleavage(124, 125). Type I systems are defined by a family of proteins that assemble into 
a multi-subunit CRISPR-associated complex for antiviral defense (Cascade), each of which is essential for a 
particular function from processing the array transcripts to target degradation. Type III systems are more 
common in archaea and use additional repeat-associated proteins, with family III-A targeting DNA and III-B 
single-stranded RNA(124-127). 
The simplest system, Type II, has thus far been found in bacteria alone and relies solely on its signature protein 
Cas9 to carry out the adaptation or interference phase(116, 124, 128). Here, the CRISPR array is transcribed as a 
single long mRNA comprising multiple spacers flanked by repeats, which are subsequently processed into discrete 
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CRISPR RNA (crRNA) units of single spacers followed by direct repeats(127, 129-131). A last-to-be-discovered 
but crucial auxiliary component, transactivating crRNA (tracrRNA), shares partial homology with the crRNA; 
their duplex assembly, along with Cas9, are required for this co-maturation process(132). Mature 
crRNA:tracrRNA pairings then direct Cas9 proteins to target complementary DNA sequences, with the spacer or 
guide region of the crRNAs determining specificity by Watson-Crick base pairing (Figure 1-4)(130). 
 
Figure 1-4 Adaptation and target destruction phase in the Type II CRISPR-Cas immune system 
As CRISPR systems are identified in more species, sequence analysis reveals extensive horizontal transfer among 
phylogenetically distant species(133, 134). Indeed, the CRISPR locus from S. thermophilus could be transplanted 
into E. coli and provide protection against plasmid transformation(128). In an in vitro cell-free assay, spacer 
sequences could likewise be altered and allow Cas9 to cleave any sequence, provided the target bears the 
appropriate PAM. In a further simplification of the native system, crRNA and tracrRNA can be fused via an 
artificial tetraloop into a chimeric RNA as a single guide RNA (sgRNA) to direct Cas9. Given the sequence 
homology of Cas9 to other known nucleases of the RuvC and HNH families, catalytic residues on Cas9 have also 
   
 13 
been mapped, enabling development of Cas9 nickases as well(135, 136). These observations provided the 
anticipation that CRISPR-Cas could be used for eukaryotic gene editing. 
 
 
Figure 1-5 Metagenomic diversity of Cas9 
S. pyogenes
S. thermophilus
CRISPR1
S. thermophilus
CRISPR3
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In this thesis, I will first describe our efforts at demonstrating the adaptation of Cas9 from S. pyogenes and S. 
thermophilus CRISPR1 (SpCas9 and St1Cas9, respectively) for mammalian genome engineering, as we define the 
minimal set of components needed for a RNA-guided programmable nuclease system(137). I will then show the 
further characterization and optimization of the system for gene disruption and precision editing applications(138, 
139). As with its predecessors, the specificity of Cas9 raises a significant concern for its suitability for broad and 
sensitive applications. Many groups, including my colleagues, have attempted to present an accurate and detailed 
answer to this question(138, 140-143). To improve upon SpCas9 specificity, I will describe the development of 
ZFN- and TALEN-inspired Cas9 double nicking strategy for high fidelity gene editing(144). Since solving the 
crystal structure of Cas9 would prove invaluable in informing further rational mutagenesis and functional 
alteration of Cas9, I will then present our study in collaboration with Drs. Hiroshi Nishimasu and Osamu Nureki 
at exploring the structure-function relationship of SpCas9 protein subdomains and their interactions with sgRNA 
and target DNA(145). Finally, I will describe our ongoing efforts at delivering Cas9 for in vivo somatic gene 
editing as we explore the metagenomic diversity of Cas9 (Figure 1-5) for suitable, virally deliverable orthologs. 
However, the field of CRISPR-Cas has at the same time been developing with stunning rapidity, and many 
notable advances have taken place since its first eukaryotic DNA cleavage demonstrations(137, 146-149). In 
technology development, Cas9 has both retraced the path of ZFNs and TALENs as well as inspired novel, 
inventive applications. These include the development of CRISPR-based transcriptional modulators using 
catalytically dead Cas9 (dCas9) as well as fusions to natural and synthetic transcription factors while 
simultaneously taking advantage of the unprecedented multiplex capability of sgRNAs(88, 89, 142, 150-153). As a 
general genome-targeting scaffold, dCas9 has also been adapted for in vivo imaging using fluorescence protein 
fusions(154, 155). The ease of oligo synthesis and delivery as well as the modularity of Cas9 targeting has further 
enabled high-throughput, genome-wide screens to uncover new biology(156-158). 
In the span of the last year and half, CRISPR has been applied towards de novo generation of new transgenic 
models for a multitude of organisms, including wheat, drosophila, mouse, pig, and marmoset, a truly remarkable 
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feat(159-164). Moreover, demonstrations that Cas9 can be delivered in vivo have opened up additional avenues 
for functional and therapeutic studies(165, 166). As we worked to develop double nicking strategy, understand 
the structure of sgRNA:DNA:SpCas9 complex, and characterize Cas9 orthologs, similar studies have emerged 
concurrently(150, 167-170). The excitement in the field is palpable, surely with more inspiring innovations yet to 
come for biology, medicine, and technology. 
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Introduction 
Precise and efficient genome targeting technologies are needed to enable systematic reverse engineering of causal 
genetic variations by allowing selective perturbation of individual genetic elements. Although genome-editing 
technologies such as designer zinc fingers (ZFs) (1-4), transcription activator-like effectors (TALEs) (4-10), and 
homing meganucleases (12) have begun to enable targeted genome modifications, there remains a need for new 
technologies that are scalable, affordable, and easy to engineer. Here, we report the development of a new class of 
precision genome engineering tools based on the RNA-guided Cas9 nuclease (13-15) from the type II 
prokaryotic CRISPR adaptive immune system(16-19). 
The Streptococcus pyogenes SF370 type II CRISPR locus consists of four genes, including the Cas9 nuclease, as 
well as two non-coding RNAs: tracrRNA and a pre-crRNA array containing nuclease guide sequences (spacers) 
interspaced by identical direct repeats (DRs) (20). We sought to harness this prokaryotic RNA-programmable 
nuclease system to introduce targeted double stranded breaks (DSBs) in mammalian chromosomes through 
heterologous expression of the key components. It has been previously shown that expression of tracrRNA, pre-
crRNA, host factor RNase III, and Cas9 nuclease are necessary and sufficient for cleavage of DNA in vitro (13, 14) 
and in prokaryotic cells (21, 22).  
Adaptation of CRISPR-Cas for multiplexed mammalian gene 
editing 
We codon optimized the S. pyogenes Cas9 (SpCas9) and RNase III (SpRNase III) and attached nuclear localization 
signals (NLS) to ensure nuclear compartmentalization in mammalian cells. Expression of these constructs in 
human 293FT cells revealed that two NLSs are most efficient at targeting SpCas9 to the nucleus (Figure 2-1A). 
To reconstitute the non-coding RNA components of CRISPR, we expressed an 89-nucleotide (nt) tracrRNA 
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(Supplementary Figure 1A) under the RNA polymerase III U6 promoter (Figure 2-1B). Similarly, we used the 
U6 promoter to drive the expression of a pre-crRNA array comprising a single guide spacer flanked by DRs 
(Figure 2-1B). We designed our initial spacer to target a 30-basepair (bp) site (protospacer) in the human EMX1 
locus that precedes an NGG, the requisite protospacer adjacent motif (PAM) (Figure 2-1C) (23, 24). 
 
Figure 2-1 Reconstitution of the Type II CRISPR locus from Streptococcus pyogenes SF370 for mammalian gene 
targeting. 
(A) Engineering of SpCas9 and SpRNase III with NLSs enables import into the mammalian nucleus. (B) 
Mammalian expression of SpCas9 and SpRNase III are driven by the EF1a promoter, whereas tracrRNA and pre-
crRNA array (DR-Spacer-DR) are driven by the U6 promoter. A protospacer (blue highlight) from the human 
EMX1 locus with PAM is used as template for the spacer in the pre-crRNA array. (C) Schematic representation 
of base pairing between target locus and EMX1-targeting crRNA. Red arrow indicates putative cleavage site. 
 
To test whether heterologous expression of the CRISPR system (SpCas9, SpRNase III, tracrRNA, and pre-
crRNA) can achieve targeted cleavage of mammalian chromosomes, we transfected 293FT cells with different 
combinations of CRISPR components. Since DSBs in mammalian DNA are partially repaired by the indel-
forming non-homologous end joining (NHEJ) pathway, we used the SURVEYOR assay (Supplementary Figure 
2) to detect endogenous target cleavage (Figure 2-2A and Supplementary Figure 1B). Co-transfection of all four 
required CRISPR components resulted in efficient cleavage of the protospacer (Figure 2-2A and Supplementary 
Figure 1B), which is subsequently verified by Sanger sequencing (Figure 2-2B). Interestingly, SpRNase III was 
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not necessary for cleavage of the protospacer (Figure 2-2A), and the 89-nt tracrRNA is processed in its absence 
(Supplementary Figure 1C). Similarly, maturation of pre-crRNA does not require RNase III (Figure 2-2A and 
Supplementary Figure 3), suggesting that there may be endogenous mammalian RNases that assist in pre-crRNA 
maturation (25-27). Removing any of the remaining RNA or Cas9 components abolished the genome cleavage 
activity of the CRISPR system (Figure 2-2A). These results define a minimal three-component system for 
efficient CRISPR-mediated genome modification in mammalian cells.  
 
 
Figure 2-2 SpCas9-mediated indels 
(A) SURVEYOR assay for SpCas9-mediated indels. (B) An example chromatogram showing a micro-deletion, as 
well as representative sequences of mutated alleles identified from 187 clonal amplicons. Red dashes, deleted 
bases; red bases, insertions or mutations. Scale bar = 10µm. 
 
Next, we explored the generalizability of CRISPR-mediated cleavage in eukaryotic cells by targeting additional 
protospacers within the EMX1 locus (Figure 2-3A). To improve co-delivery, we designed an expression vector to 
drive both pre-crRNA and SpCas9 (Supplementary Figure 4). In parallel, we adapted a chimeric crRNA-
tracrRNA hybrid (Figure 2-3B, top) design recently validated in vitro (13), where a mature crRNA is fused to a 
partial tracrRNA via a synthetic stem-loop to mimic the natural crRNA:tracrRNA duplex (Figure 2-3B, bottom). 
We observed cleavage of all protospacer targets when SpCas9 is co-expressed with pre-crRNA (DR-spacer-DR) 
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and tracrRNA. However, not all chimeric RNA designs could facilitate cleavage of their genomic targets (Figure 
2-3C, Supplementary Table 1). We then tested targeting of additional genomic loci in both human and mouse 
cells by designing pre-crRNAs and chimeric RNAs targeting the human PVALB and the mouse Th loci 
(Supplementary Figure 5). We achieved efficient modification at all three mouse Th and one PVALB targets using 
the crRNA:tracrRNA design, thus demonstrating the broad applicability of the CRISPR system in modifying 
different loci across multiple organisms (Supplementary Table 1). For the same protospacer targets, cleavage 
efficiencies of chimeric RNAs were either lower than those of crRNA:tracrRNA duplexes or undetectable. This 
may be due to differences in the expression and stability of RNAs, degradation by endogenous RNAi machinery, 
or secondary structures leading to inefficient Cas9 loading or target recognition. 
Effective genome editing requires that nucleases target specific genomic loci with both high precision and 
efficiency. To investigate the specificity of CRISPR-mediated cleavage, we analyzed single-nucleotide mismatches 
between the spacer and its mammalian protospacer target (Figure 2-4A). We observed that single-base mismatch 
up to 12-bp 5’ of the PAM completely abolished genomic cleavage by SpCas9, whereas spacers with mutations 
farther upstream retained activity against the protospacer target (Figure 2-4B). This is consistent with previous 
bacterial and in vitro studies of Cas9 specificity (13, 21). Furthermore, CRISPR is able to mediate genomic 
cleavage as efficiently as a pair of TALE nucleases (TALEN) targeting the same EMX1 protospacer (Figure 2-5). 
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Figure 2-3 SpCas9 can be reprogrammed to target multiple genomic loci in mammalian cells. 
(A) Schematic of the human EMX1 locus showing the location of five protospacers, indicated by blue lines with 
corresponding PAM in magenta. (B) Schematic of the pre-crRNA:tracrRNA complex (top) showing 
hybridization between the direct repeat (gray) region of the pre-crRNA and tracrRNA. Schematic of a chimeric 
RNA design (12) (bottom). tracrRNA sequence is shown in red and the 20bp spacer sequence in blue. (C) 
SURVEYOR assay comparing the efficacy of Cas9-mediated cleavage at five protospacers in the human EMX1 
locus. Each protospacer is targeted using either processed pre-crRNA:tracrRNA complex (crRNA) or chimeric 
RNA (chiRNA). 
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Figure 2-4 Evaluation of Cas9 specificity 
(A) EMX1-targeting chimeric crRNAs with single point mutations were generated to evaluate the effects of 
spacer-protospacer mismatches. (B) SURVEYOR assay comparing the cleavage efficiency of different mutant 
chimeric RNAs. 
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Figure 2-5 Comparison of TALEN and Cas9 efficiency 
Schematic showing the design of TALENs targeting EMX1 and SURVEYOR gel comparing the efficiency of 
TALEN and SpCas9 (N = 3). 
 
Targeted modification of genomes ideally avoids mutations arising from the error-prone NHEJ mechanism. The 
wild-type SpCas9 is able to mediate site-specific DSBs, which can be repaired through either NHEJ or homology-
directed repair (HDR). We engineered an aspartate-to-alanine substitution (D10A) in the RuvC I domain of 
SpCas9 to convert the nuclease into a DNA nickase (SpCas9n, Figure 2-6A) (13, 14, 21), because nicked 
genomic DNA is typically repaired either seamlessly or through high-fidelity HDR. SURVEYOR (Figure 2-6B) 
and sequencing of 327 amplicons did not detect any indels induced by SpCas9n. However, it is worth noting that 
nicked DNA can in rare cases be processed via a DSB intermediate and result in a NHEJ event (28). We then 
tested Cas9-mediated HDR at the same EMX1 locus with a homology repair template to introduce a pair of 
restriction sites near the protospacer (Figure 2-6C). SpCas9 and SpCas9n catalyzed integration of the repair 
template into EMX1 locus at similar levels (Figure 2-6D), which we further verified via Sanger sequencing (Figure 
2-6E). These results demonstrate the utility of CRISPR for facilitating targeted genomic insertions. Given the 14-
bp (12-bp from the seed sequence and 2-bp from PAM) target specificity (Figure 2-4B) of the wild type SpCas9, 
the use of a nickase may reduce off-target mutations.  
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Finally, the natural architecture of CRISPR loci with arrayed spacers suggests the possibility of multiplexed 
genome engineering. Using a single CRISPR array encoding a pair of EMX1- and PVALB-targeting spacers, we 
detected efficient cleavage at both loci (Figure 2-7A). We further tested targeted deletion of larger genomic 
regions through concurrent DSBs using spacers against two targets within EMX1 spaced by 119-bp, and observed 
a 1.6% deletion efficacy (3 out of 182 amplicons; Figure 2-7B), thus demonstrating the CRISPR system can 
mediate multiplexed editing within a single genome.  
 
Figure 2-6 SpCas9 applications for homologous recombination 
(A) Mutation of the RuvC I domain converts Cas9 into a nicking enzyme (SpCas9n) (B) Co- expression of 
EMX1-targeting chimeric RNA with SpCas9 leads to indels, whereas SpCas9n does not (N = 3). (C) Schematic 
representation of the recombination strategy. A repair template is designed to insert restriction sites into EMX1 
locus. Primers used to amplify the modified region are shown as red arrows. (D) Restriction fragments length 
polymorphism gel analysis. Arrows indicate fragments generated by HindIII digestion. (E) Example 
chromatogram showing successful recombination. 
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Figure 2-7 SpCas9 mediates multiplexed genome editing 
(A) SpCas9 can facilitate multiplex genome modification using a crRNA array containing two spacers targeting 
EMX1 and PVALB. Schematic showing the design of the crRNA array (top). Both spacers mediate efficient 
protospacer cleavage (bottom). (B) SpCas9 can be used to achieve precise genomic deletion. Two spacers 
targeting EMX1 (top) mediated a 118bp genomic deletion (bottom). 
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The ability to use RNA to program sequence-specific DNA cleavage defines a new class of genome engineering 
tools. Here, we have shown that the S. pyogenes CRISPR system can be heterologously reconstituted in 
mammalian cells to facilitate efficient genome editing; an accompanying study has independently confirmed high 
efficiency CRISPR-mediated genome targeting in several human cell lines(29). However, several aspects of the 
CRISPR system can be further improved to increase its efficiency and versatility. The requirement for an NGG 
PAM restricts the S. pyogenes CRISPR target space to every 8-bp on average in the human genome 
(Supplementary Figure 6), not accounting for potential constraints posed by crRNA secondary structure or 
genomic accessibility due to chromatin and DNA methylation states. Some of these restrictions may be overcome 
by exploiting the family of Cas9 enzymes and its differing PAM requirements (23, 24) across the microbial 
diversity (18). Indeed, other CRISPR loci are likely to be transplantable into mammalian cells; for example, the 
Streptococcus thermophilus LMD-9 CRISPR1 can also mediate mammalian genome cleavage (Supplementary 
Figure 7). Finally, the ability to carry out multiplex genome editing in mammalian cells enables powerful 
applications across basic science, biotechnology, and medicine (30). 
Optimization of sgRNA and characterization of SpCas9 
methylation sensitivity 
Although a single guide RNA (sgRNA) design consisting of a truncated crRNA and tracrRNA had been 
previously shown to mediate efficient cleavage in vitro(13), it failed to achieve detectable cleavage at several loci 
that were efficiently modified by crRNA-tracrRNA duplexes bearing identical guide sequences(31). Because the 
major difference between this sgRNA design and the native crRNA-tracrRNA duplex is the length of the 
tracrRNA sequence, we tested whether extension of the tracrRNA tail would improve SpCas9 activity. 
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Figure 2-8 Optimization of guide RNA architecture for SpCas9-mediated mammalian genome editing 
(A) Schematic of bicistronic expression vector (PX330) for U6 promoter-driven single guide RNA (sgRNA) and 
CBh promoter-driven human codon-optimized Streptococcus pyogenes Cas9 (hSpCas9) used for all subsequent 
experiments. The sgRNA consists of a 20-nt guide sequence (blue) and scaffold (red), truncated at various 
positions as indicated. (B) SURVEYOR assay for SpCas9-mediated indels at the human EMX1 and PVALB loci. 
Arrows indicate the expected SURVEYOR fragments (n = 3). (C) Northern blot analysis for the four sgRNA 
truncation architectures, with U1 as loading control. 
 
We generated a set of sgRNAs targeting multiple sites within the human EMX1 and PVALB loci with different 
tracrRNA 3’ truncations (Figure 2-8A). Using the SURVEYOR nuclease assay(32), we assessed the ability of each 
Cas9-sgRNA complex to generate indels in HEK 293FT cells through the induction of DNA double-stranded 
breaks (DSBs) and subsequent non-homologous end joining (NHEJ) DNA damage repair. sgRNAs with +67 or 
+85 nucleotide (nt) tracrRNA tails mediated DNA cleavage at all target sites tested, with up to 5-fold higher levels 
of indels than the corresponding crRNA-tracrRNA duplexes (Figure 2-8B, Supplementary Figure 9A). 
Furthermore, both sgRNA designs efficiently modified PVALB loci that were previously not targetable using 
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crRNA-tracrRNA duplexes(31) (Figure 2-8B and Supplementary Figure 9B). For all five tested targets, we 
observed a consistent increase in modification efficiency with increasing tracrRNA length. We performed 
Northern blots for the guide RNA truncations and found increased levels of expression for the longer tracrRNA 
sequences, suggesting that improved target cleavage was due to higher sgRNA expression or stability (Figure 
2-8C). Furthermore, co-transfection of cells with Cas9 and two optimized sgRNAs with the +85 tail led to robust 
cleavage of both targets (Supplementary Figure 8A). Using a pair of (+85) sgRNAs flanking an exon in the human 
EMX1 gene, we further saw highly efficient deletion of the exon, resulting in approximately ~50% and ~10% of 
transfected clones with mono- and bi-allelic deletions, respectively (Supplementary Figure 8B, C). Taken 
together, these data indicate that the tracrRNA tail is important for optimal SpCas9 expression and activity in vivo. 
To explore whether the genome targeting ability of sgRNA(+85) is influenced by epigenetic factors(33, 34) that 
constrain the alternative transcription activator-like effector nuclease (TALENs)(5, 35-38) and potentially also 
zinc finger nuclease (ZFNs)(1-4, 39) technologies, we further tested the ability of SpCas9 to cleave methylated 
DNA. Using either unmethylated or M.SssI-methylated pUC19 as DNA targets (Figure 2-9A, B) in a cell-free 
cleavage assay, we showed that SpCas9 efficiently cleaves pUC19 regardless of CpG methylation status in either 
the 20-bp target sequence or the PAM (Figure 2-9C). To test whether this is also true in vivo, we designed 
sgRNAs to target a highly methylated region of the human SERPINB5 locus (Figure 2-10A, B). All three sgRNAs 
tested were able to mediate indel mutations in endogenously methylated targets (Figure 2-10C). 
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Figure 2-9 Cas9 targeting of methylated DNA in vitro 
(A) Sequence of CpG dinucleotide-containing targets in pUC19 plasmid methylated in vitro by M.SssI. Methyl-
CpGs in either the target sequence or PAM are indicated; arrows indicate expected cleavage site. (B) 
Unmethylated (U) or methylated (M) pUC19 was subjected to restriction digest by the methylation-sensitive 
restriction enzyme HpaII. Unmethylated pUC19 is digested into a ladder while M.SssI-treated pUC19 is 
protected from HpaII digestion. (C) Cleavage of either unmethylated or methylated targets 1 and 2 on linearized 
pUC19 by SpCas9. No sgRNAs are present in negative control lanes. 
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Figure 2-10 Cas9 targeting of methylated DNA in vivo 
(A) Schematic of the human SERPINB5 locus. sgRNAs and PAMs are indicated by colored bars above sequence; 
methylcytosine (Me) are highlighted (pink) and numbered relative to the transcriptional start site (TSS, +1). (B) 
Methylation status of SERPINB5 assayed by bisulfite sequencing of 16 clones. Filled circles, methylated CpG; 
open circles, unmethylated CpG. (C) Modification efficiency by three sgRNAs targeting the methylated region of 
SERPINB5, assayed by deep sequencing (n = 2). Error bars indicate Wilson intervals. 
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Single-stranded DNA repair templates for high efficiency gene 
modification 
Having optimized the sgRNA scaffold for Cas9 cleavage, we sought to further improve Cas9-mediated HDR. 
Traditionally, targeted DNA modifications have required use of plasmid-based donor repair templates that 
contain homology arms flanking the site of alteration(40, 41) (Figure 1-1). The homology arms on each side can 
vary in length, but are typically longer than 500-bp(41, 42). This method can be used to generate large 
modifications, including insertion of reporter genes such as fluorescent proteins or antibiotic resistance markers. 
The design and construction of targeting plasmids has been described elsewhere(43). 
More recently, single-stranded DNA oligonucleotides (ssODNs) have been used in place of targeting plasmids for 
short modifications within a defined locus without cloning(44). To achieve high HDR efficiencies, ssODNs 
contain flanking sequences of at least 40 bp on each side that are homologous to the target region, and can be 
oriented in either the sense or antisense direction relative to the target locus. 
We sought to test here the use of ssODNs and targeting vector to mediate HDR (Figure 2-11, B) with both 
wildtype and nickase mutant of Cas9 in HEK 293FT and HUES9 cells (Figure 2-11C). We have not been able to 
detect HDR in HUES9 cells using the Cas9 nickase, which may be due to low efficiency or a potential difference 
in repair activities in HUES9 cells. It is worth noting that there is some variability in the cleavage efficiency of a 
given sgRNA, and on rare occasions certain sgRNAs may not work for reasons yet unknown.  
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Figure 2-11 Single-stranded oligonucleotide (ssODN)-mediated HDR  
(A) A targeting plasmid or ssODNs (sense or antisense) with homology arms can be used to edit the sequence 
(red bar) at a target genomic locus cleaved by Cas9 (red triangle). To assay the efficiency of HDR, a HindIII site 
was introduced into the target locus and the target locus was PCR amplified using primers that anneal outside of 
the region of homology. Digestion of the PCR amplicon with HindIII reveals the occurrence of HDR events. (B) 
ssODNs, oriented in either the sense or the antisense direction relative to locus of interest, can be used in 
combination with Cas9 to achieve efficient HDR-mediated editing at the target locus. A minimal homology 
region of 40-bp, preferably 90-bp, is recommended on either side of modification (red bar). (C) Example 
ssODNs for recombination in the EMX1 locus are shown. Each ssODN contains homology arms of 90-bp each 
flanking a 12-bp insertion of two restriction sites. 
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Figure 2-12 Pipeline for rapid generation of cell lines using Cas9 
Steps for reagent design, construction, validation, and cell line expansion. Custom sgRNAs (light blue bars) for 
each target, as well as genotyping primers, are designed in silico. sgRNA expression vectors are then cloned into a 
plasmid containing Cas9 (PX330) and verified via DNA sequencing. Completed plasmids (pCRISPRs), and 
optional repair templates for facilitating homology directed repair, are then transfected into cells and assayed for 
ability to mediate targeted cleavage. Finally, transfected cells can be clonally expanded to derive isogenic cell lines 
with defined mutations. 
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Discussion 
Here, we have presented a human codon-optimized, nuclear localization sequence-flanked Cas9 to facilitate gene 
editing in mammalian cells. We have demonstrated multiplexed cleavage of endogenous loci using Cas9 guided by 
both crRNA:tracrRNA duplex and a chimeric single guide RNA. We’ve further engineered a mutant Cas9 
carrying a disruption in one of its catalytic domains(13, 14) to nick rather than cleave DNA, allowing for single-
stranded breaks and preferential repair through HDR(31), which could potentially ameliorate unwanted indel 
mutations from off-target DSBs. Lastly, we have optimized the sgRNA for robust activity across a number of loci 
previously unable to be targeted, and shown that single-stranded DNA donor templates can be used to mediate 
HDR at high efficiencies. In summary, we have optimized a pipeline from in silico design of target sites to rapidly 
generating cell lines in the span of a few weeks (Figure 2-12). 
Given its ease of implementation and multiplex capability, Cas9 has already been used to generate engineered 
eukaryotic cells carrying specific mutations via both NHEJ and HDR(29, 31, 45-47). In addition, direct injection 
of sgRNA and mRNA encoding Cas9 into embryos has enabled the rapid generation of transgenic mice with 
multiple modified alleles(48, 49); these results hold immense promise for editing organisms that are otherwise 
genetically intractable. 
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Introduction 
The ability to perturb the genome in a precise and targeted fashion is crucial for understanding genetic 
contributions to biology and disease. Genome engineering of cell lines or animal models has traditionally been 
accomplished through random mutagenesis or low-efficiency gene targeting. To facilitate genome editing, 
programmable sequence-specific DNA nuclease technologies have enabled targeted modification of endogenous 
genomic sequences with high efficiency, particularly in species that have proven genetically intractable (1-4). The 
RNA-guided Cas9 nucleases from the microbial CRISPR (clustered regularly interspaced short palindromic 
repeat)-Cas systems are robust and versatile tools for stimulating targeted double-stranded DNA breaks (DSBs) 
in eukaryotic cells (5-15), where the resulting cellular repair mechanisms – non-homologous end joining (NHEJ) 
or homology-directed repair (HDR) pathways – can be exploited to induce error-prone or defined alterations 
(16-18). 
The Cas9 nuclease from Streptococcus pyogenes can be directed by a chimeric single guide RNA (sgRNA) (19) to 
any genomic locus preceding a 5’-NGG protospacer-adjacent motif (PAM). A 20-nt guide sequence within the 
sgRNA directs Cas9 to the genomic target via Watson-Crick base pairing and can be easily programmed to target 
a desired genomic locus (9, 10, 19, 20). Recent studies of Cas9 specificity have demonstrated that although each 
base within the 20-nt guide sequence contributes to overall specificity, multiple mismatches between the guide 
RNA and its complementary target DNA sequence can be tolerated depending on the quantity, position, and base 
identity of mismatches (5, 21-23), leading to potential off-target DSBs and indel formation. These unwanted 
mutations can potentially limit the utility of Cas9 for genome editing applications that require high levels of 
precision, such as generation of isogenic cell lines for testing causal genetic variations (24) or in vivo and ex vivo 
genome editing-based therapies. 
To improve the specificity of Cas9-mediated genome editing, we developed a novel strategy that combines the 
D10A mutant nickase version of Cas9 (Cas9n) (5, 19, 20) with a pair of offset sgRNAs complementary to 
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opposite strands of the target site. While nicking of both DNA strands by a pair of Cas9 nickases leads to site-
specific DSBs and NHEJ, individual nicks are predominantly repaired by the high-fidelity base excision repair 
pathway (BER) (25). A paired nickase strategy was described while this manuscript was under review which 
suggests the possibility for engineering a system to ameliorate off-target activity (26). In a manner analogous to 
dimeric zinc finger nucleases (ZFNs) (27-30) and transcription activator-like effector nucleases (TALENs) (30-
36), where DNA cleavage requires synergistic interaction of two independent specificity-encoding DNA-binding 
modules directing FokI nuclease monomers, this double nicking strategy minimizes off-target mutagenesis by 
each individual Cas9n-sgRNA complex while maintaining on-target modification rates similar to those of wild 
type Cas9. Here we define crucial parameters for the selection of sgRNA pairs that facilitate effective double 
nicking, compare the specificity of wildtype Cas9 and Cas9n with double nicking, and demonstrate a variety of 
experimental applications that can be achieved using double nicking in cells as well as in mouse zygotes.  
Extension of guide sequence does not improve Cas9 targeting 
specificity 
Cas9 targeting is facilitated by base-pairing between the 20-nt guide sequence within the sgRNA and the target 
DNA (9, 10, 19, 20). We reasoned that cleavage specificity might be improved by increasing the length of base-
pairing between the guide RNA and its target locus. To test this, we generated U6-driven expression cassettes 
(22) to express three sgRNAs with 20-nt (sgRNA 1) or 30-nt guide sequences (sgRNAs 2 and 3) targeting a locus 
within the human EMX1 gene (Figure 3-1A). 
We and others have previously shown that while single-base mismatches between the PAM-distal region of the 
guide sequence and target DNA are well-tolerated by Cas9, multiple mismatches in this region can significantly 
affect on-target activity (21, 22, 37, 38). To determine whether additional PAM-distal bases (21-30) could 
influence overall targeting specificity, we designed sgRNAs 2 and 3 to contain 10 additional bases consisting of 
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either 10 perfectly matched or 8 mismatched bases (bases 21-28). Surprisingly, we observed that these extended 
sgRNAs mediated similar levels of modification at the target locus in HEK 293FT cells regardless of whether the 
additional bases were complementary to the genomic target (Figure 3-1B). Subsequent Northern blots revealed 
that the majority of both sgRNA 2 and 3 were processed to the same length as sgRNA 1, which contains the same 
20-nt guide sequence without additional bases (Figure 3-1C).  
 
 
Figure 3-1 Effect of guide sequence extension on Cas9 activity 
(A) Schematic showing Cas9 with matching or mismatching sgRNA sequences targeting a locus (target 1) within 
the human EMX1 gene. (B) SURVEYOR assay gel showing comparable modification of target 1 by sgRNAs 
bearing 20- and 30-nt long guide sequences. (C) Northern blot showing that extended sgRNAs are largely 
reverted to 20-nt guide-length sgRNAs in HEK 293FT cells. 
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Cas9 nickase generates efficient NHEJ with paired, offset guide 
RNAs 
Given that extension of the guide sequence failed to improve Cas9 targeting specificity, we sought an alternative 
strategy for increasing the overall base-pairing length between the guide sequence and its DNA target. Cas9 
enzymes contain two conserved nuclease domains, HNH and RuvC, which cleave the DNA strand 
complementary and non-complementary to the guide RNA, respectively. Mutations of the catalytic residues 
(D10A in RuvC and H840A in HNH) convert Cas9 into DNA nickases (5, 19, 20). As single-strand nicks are 
preferentially repaired by the high-fidelity BER pathway (25), we reasoned that two Cas9 nicking enzymes 
directed by a pair of sgRNAs targeting opposite strands of a target locus could mediate DSBs while minimizing 
off-target activity (Figure 3-2A). 
A number of factors may affect cooperative nicking leading to indel formation, including steric hindrance 
between two adjacent Cas9 molecules or Cas9-sgRNA complexes, overhang type, and sequence context; some of 
these may be characterized by testing multiple sgRNA pairs with distinct target sequences and offsets (the 
distance between the PAM-distal (5’) ends of the guide sequence of a given sgRNA pair). To systematically assess 
how sgRNA offsets might affect subsequent repair and generation of indels, we first designed sets of sgRNA pairs 
targeted against the human EMX1 genomic locus separated by a range of offset distances from approximately -200 
to 200 bp to create both 5’- and 3’-overhang products (Figure 3-2A, Supplementary Table 2). We then assessed 
the ability of each sgRNA pair, with the D10A Cas9 mutant (referred to as Cas9n; H840A Cas9 mutant is referred 
to as Cas9H840A), to generate indels in human HEK 293FT cells. Robust NHEJ (up to 40%) was observed for 
sgRNA pairs with offsets from -4 to 20 bp, with modest indels forming in pairs offset by up to 100-bp (Figure 3-2B, 
left panel). We subsequently recapitulated these findings by testing similarly offset sgRNA pairs at two other 
genomic loci, DYRK1A and GRIN2B (Figure 3-2B, right panels). Notably, across all three loci examined, only 
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sgRNA pairs creating 5’ overhangs with less than 8bp overlap between the guide sequences (offset greater than -8 
bp) were able to mediate detectable indel formation (Figure 3-2C). Importantly, each guide used in these assays is 
able to efficiently induce indels when paired with wildtype Cas9 (Supplementary Table 2), indicating that the 
relative positions of the guide pairs are the most important parameters in predicting double nicking activity. 
Since Cas9n and Cas9H840A nick opposite strands of DNA, substitution of Cas9n with Cas9H840A with a given 
sgRNA pair should result in the inversion of the overhang type. For example, a pair of sgRNAs that will generate a 
5’ overhang with Cas9n should in principle generate the corresponding 3’ overhang instead. Therefore, sgRNA 
pairs that lead to the generation of a 3’ overhang with Cas9n might be used with Cas9H840A to generate a 5’ 
overhang. Unexpectedly, we tested Cas9H840A with a set of sgRNA pairs designed to generate both 5’ and 3’ 
overhangs (offset range from –278 to +58 bp), but were unable to observe indel formation. Further work will be 
needed to identify the necessary design rules for sgRNA pairing to allow double nicking by Cas9H840A. 
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Figure 3-2 Double nicking facilitates efficient genome editing in human cells 
 (A) Schematic illustrating DNA double-stranded breaks using a pair of sgRNAs guiding Cas9 D10A nickases 
(Cas9n). The D10A mutation renders Cas9 able to cleave only the strand complementary to the sgRNA; a pair of 
sgRNA-Cas9n complexes can nick both strands simultaneously. sgRNA offset is defined as the distance between 
the PAM-distal (5’) ends of the guide sequence of a given sgRNA pair; positive offset requires the sgRNA 
complementary to the top strand (sgRNA a) to be 5’ of the sgRNA complementary to the bottom strand (sgRNA 
b). (B) Efficiency of double nicking induced NHEJ as a function of the offset distance between two sgRNAs. (n = 
3; error bars show mean ± s.e.m.) (C) Representative sequences of the human EMX1 locus targeted by Cas9n. 
sgRNA target sites and PAMs are indicated by blue and magenta bars respectively. Below, selected sequences 
showing representative indels. 
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Double nicking mediates genome editing with improved specificity 
Having established that double nicking (DN) mediates high efficiency NHEJ at levels comparable to those 
induced by wildtype Cas9, we next studied whether DN has improved specificity over wildtype Cas9 by 
measuring their off-target activities. We co-delivered Cas9n with sgRNAs 1 and 9, spaced by a +23 bp offset, to 
target the human EMX1 locus in HEK 293FT cells (Figure 3-3A). This DN configuration generated on-target 
indel levels similar to those generated by the wildtype Cas9 paired with each sgRNA alone (Figure 3-3B, left 
panel). Strikingly, unlike with wildtype Cas9, DN did not generate detectable modification at a previously 
validated sgRNA 1 off-target site, OT-4, by SURVEYOR assay (22) (Figure 3-3B, right panel), suggesting that 
DN can potentially reduce the likelihood of off-target modifications. Using deep sequencing to assess 
modification at 5 different sgRNA 1 off-target loci (Figure 3-3A), we observed significant mutagenesis at all sites 
with wild type Cas9 + sgRNA 1 (Figure 3-3C). In contrast, cleavage by Cas9n at 5 off-target sites tested was barely 
detectable above background sequencing error. 
Using the ratio of on- to off-target modification levels as a metric of specificity, we found that Cas9n with a 
pair of sgRNAs was able to achieve over 100-fold greater specificity relative to wild type Cas9 with one of the 
sgRNAs (Figure 3-3D). We conducted additional off-target analysis by deep sequencing for two sgRNA pairs 
(offsets of +16 and +20 bp) targeting the VEGFA locus, with similar results (Figure 3-3E). DN at these off-target 
loci was able to achieve 200 to over 1500-fold greater specificity than the wild-type Cas9 (Figure 3-3F, 
Supplementary Table 2). Taken together, these results demonstrate that Cas9-mediated double nicking 
minimizes off-target mutagenesis and is suitable for genome editing with increased specificity. 
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Figure 3-3 Double nicking enables high precision genome editing in human cells 
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(A) Schematic illustrating Cas9n double nicking (red arrows) the human EMX1 locus. Five off-target loci with 
sequence homology to EMX1 target 1 were selected to screen for Cas9n specificity. (B) On-target modification 
rate by Cas9n and a pair of sgRNAs is comparable to those mediated by wildtype Cas9 and single sgRNAs (left 
panel). Cas9-sgRNA 1 complexes generate significant off-target mutagenesis, while no off-target locus 
modification is detected with Cas9n (right panel). (C) Five off-target loci of sgRNA 1 are examined for indel 
modifications by deep sequencing of transfected HEK 293FT cells. (n = 3, error bars show mean ± s.e.m.) (D) 
Specificity comparison of Cas9n with double nicking and wildtype Cas9 with sgRNA 1 alone at the off-target sites. 
Specificity ratio is calculated as on-target/off-target modification rates. (n = 3; error bars show mean ± s.e.m.) (E, 
F) Double nicking minimizes off-target modification at two additional human VEGFA loci while maintaining high 
specificity (on/off target modification ratio; n = 3, error bars show mean ± s.e.m.). 
 
Double nicking facilitates high-efficiency homology directed repair, 
NHEJ-mediated DNA insertion, and genomic microdeletions 
DSBs can stimulate homology directed repair (HDR) to enable highly precise editing of genomic target sites. To 
evaluate DN-induced HDR, we targeted the human EMX1 locus with pairs of sgRNAs offset by -3 and +18 bp 
(generating 31- and 52-bp 5’ overhangs), respectively, and introduced a single-stranded oligodeoxynucleotide 
(ssODN) bearing a HindIII restriction site as the HDR repair template (Figure 3-4A). Each DN sgRNA pair 
successfully induced HDR at frequencies higher than those of single-guide Cas9n nickases and comparable to 
those of wild-type Cas9 (Figure 3-4B). Furthermore, genome editing in embryonic stem cells or patient derived 
induced pluripotent stem cells represents a key opportunity for generating and studying new disease paradigms as 
well as developing new therapeutics. Since single nick approaches to inducing HDR in human embryonic stem 
cells (hESCs) have met with limited success (22), we attempted DN in the HUES62 hES cell line and observed 
successful HDR (Figure 3-4C). 
To further characterize how offset sgRNA spacing affects the efficiency of HDR, we next tested in HEK 293FT 
cells a set of sgRNA pairs where the cleavage site of at least one sgRNA is situated near the site of recombination 
(overlapping with the HDR ssODN donor template arm). We observed that sgRNA pairs generating 5’ overhangs 
and having at least one nick occurring within 22 bp of the homology arm are able to induce HDR at levels 
   
 60 
comparable to those of wildtype Cas9-mediated HDR, and significantly greater than those of single Cas9n-sgRNA 
nicking. In contrast, we did not observe HDR with sgRNA pairs that generated 3’-overhangs or double nicking of 
the same DNA strand (Figure 3-4D). 
The ability to create defined overhangs could enable precise insertion of donor repair templates containing 
compatible overhangs via NHEJ-mediated ligation (39). To explore this alternative strategy for transgene 
insertion, we targeted the EMX1 locus with Cas9n and an sgRNA pair designed to generate a 43 bp 5’-overhang 
near the stop codon, and supplied a double-stranded oligonucleotide (dsODN) duplex with matching overhangs 
(Figure 3-5A). The annealed dsODN insert, containing multiple epitope tags and a restriction site, was 
successfully integrated into the target at a frequency of 3% (1/37 screened by Sanger sequencing of cloned 
amplicons). This ligation-based strategy thus illustrates an effective approach for inserting dsODNs encoding 
short modifications such as protein tags or recombination sites into an endogenous locus. 
Additionally, we targeted combinations of sgRNA pairs (4 sgRNAs per combination) to the DYRK1A locus in 
HEK 293FT cells to facilitate genomic microdeletions. We generated a set of sgRNAs to mediate 0.5 kb, 1 kb, 2 kb, 
and 6 kb deletions (Figure 3-5B, Supplementary Table 3: sgRNAs 32, 33, 54-61) and verified successful multiplex 
nicking-mediated deletion over these ranges via PCR screen of predicted deletion sizes. 
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Figure 3-4 Double nicking allows insertion into the genome via HDR in human cells    
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(A) Schematic illustrating HDR mediated via a single stranded oligodeoxynucleotide (ssODN) template at a DSB 
created by a pair of Cas9n enzymes. A 12-nt sequence (red), including a HindIII restriction site, is inserted into 
the EMX1 locus at the position marked by the gray dashed lines; distances of Cas9n-mediated nicks from the 
HDR insertion site is indicated on top in italics. (B) Restriction digest assay gel showing successful insertion of 
HindIII cleavage sites by double nicking-mediated HDR in HEK 293FT cells. Upper bands are unmodified 
template; lower bands are HindIII cleavage product. (C) Double nicking promotes HDR in the HUES62 human 
embryonic stem cell line. HDR frequencies are determined by deep sequencing. (n = 3; error bars show mean ± 
s.e.m.). (D) HDR efficiency depends on the configuration of Cas9 or Cas9n-mediated nicks. HDR is facilitated 
when a nick occurs near the center of the ssODN homology arm (HDR insertion site) leading to a 5’-resulting 
overhang. Nicking configurations are annotated with position and strand (red arrows) and length of overhang 
(black lines) (left panel). The distance (bp) of each nick from the HDR insertion site is indicated at the end of the 
black lines in italics, and the positions of the sgRNAs are illustrated in bold on the schematic of the EMX1 locus. 
HDR efficiency mediated by double nicking with paired sgRNAs (top panel) or single sgRNAs with either Cas9 
or Cas9n are shown (bottom panel, Supplementary Table 3; n = 3, error bars show mean ± s.e.m.).  
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Figure 3-5 Multiplexed nicking facilitates non-HR mediated gene integration and genomic deletion 
(A) Schematic showing insertion of a double-stranded oligodeoxynucleotide (dsODN) donor fragment bearing 
overhangs complementary to 5’ overhangs created by Cas9 double nicking. The dsODN was designed to remove 
the native EMX1 stop codon and contains a HA tag, 3X FLAG tag, HindIII restriction site, Myc epitope tag, and a 
stop codon in frame, totaling 148 bp. Successful insertion was verified by Sanger sequencing as shown (1/37 
clones screened). Amino acid translation of the modified locus is shown below the DNA sequence. (B) Co-
delivery of four sgRNAs with Cas9n generate long-range genomic deletions in the DYRK1A locus (from 0.5 kb up 
to 6 kb). Deletion was detected using primers spanning the target region. 
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Efficient genome modification in mouse zygotes 
Recent work demonstrated that co-delivery of wildtype Cas9 mRNA along with multiple sgRNAs can mediate 
single-step generation of transgenic mice carrying multiple allelic modifications (6). Given the ability to achieve 
genome modification in vivo using several sgRNAs at once, we sought to assess the efficiency of multiple nicking 
by Cas9n in mouse zygotes. Cytoplasmic co-injection of wildtype Cas9 or Cas9n mRNA and sgRNAs into single-
cell mouse zygotes allowed successful targeting of the Mecp2 locus (Figure 3-6A). To identify the optimal 
concentration of Cas9n mRNA and sgRNA for efficient gene targeting, we titrated Cas9 mRNA from 100 ng/uL 
to 3 ng/uL while maintaining the sgRNA levels at a 1:20 Cas9:sgRNA molar ratio. All concentrations tested for 
Cas9 double nicking mediated modifications in at least 80% of embryos screened, similar to levels achieved by 
wildtype Cas9 (Figure 3-6B). Taken together, these results suggest a number of applications for double nicking-
based genome editing. 
 
 
Figure 3-6 Cas9 double nicking mediates efficient indel formation in mouse embryos 
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(A) Schematic illustrating Cas9n double nicking the mouse Mecp2 locus. Representative indels are shown for 
mouse blastocysts co-injected with in vitro transcribed Cas9n-encoding mRNA and sgRNA pairs matching targets 
92 and 93. (B) Efficient blastocyst modification is achieved at multiple concentrations of sgRNAs (1.5 to 50 
ng/uL) and wildtype Cas9 or Cas9n (ng/uL to 100 ng/uL). 
Discussion 
Given the permanent nature of genomic modifications, specificity is of paramount importance to sensitive 
applications such as studies aimed at linking specific genetic variants with biological processes or disease 
phenotypes and gene therapy. Here, we have explored strategies to improve the targeting specificity of Cas9. 
Although simply extending the guide sequence length of sgRNA failed to improve targeting specificity, combining 
two appropriately offset sgRNAs with Cas9n effectively generated indels while minimizing unwanted cleavage 
since individual off-target single-stranded nicks are repaired with high fidelity via base excision repair. Given that 
significant off-target mutagenesis has been previously reported for Cas9 nucleases in human cells (21, 22), the 
DN approach could provide a generalizable solution for rapid and accurate genome editing.  
The characterization of spacing parameters governing successful Cas9 double nickase-mediated gene 
targeting reveals an effective offset window over 100-bp long, allowing for a high degree of flexibility in the 
selection of sgRNA pairs. Previous computational analyses have revealed an average targeting range of every 12-
bp for the Streptococcus pyogenes Cas9 in the human genome based on the 5’-NGG PAM (5), which suggest that 
appropriate sgRNA pairs should be readily identifiable for most loci within the genome. We have additionally 
demonstrated DN-mediated indel frequencies comparable to wild type Cas9 modification at multiple genes and 
loci in both human and mouse cells, confirming the reproducibility of this strategy for high-precision genome 
engineering (Supplementary Table 2). 
The Cas9 double nicking approach is in principle similar to ZFN and TALEN-based genome editing systems, 
where cooperation between two hemi-nuclease domains is required to achieve double-stranded break at the target 
site. Systematic studies of ZFN and TALEN systems have revealed that the targeting specificity of a given ZFN 
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and TALEN pair can be highly dependent on the nuclease architecture (homo- or heterodimeric nucleases) or 
target sequence, and in some cases TALENs can be highly specific (40). Although the wildtype Cas9 system has 
been shown to exhibit high levels of off-target mutagenesis, the DN system is a promising solution and brings 
RNA-guided genome editing to similar specificity levels as ZFNs and TALENs. 
Additionally, the ease and efficiency with which Cas9 can be targeted renders the DN system especially attractive. 
However, DNA targeting using DN will likely face similar off-target challenges as ZFNs and TALENs, where 
cooperative nicking at off-target sites might still occur, albeit at a significantly reduced likelihood. Given the 
extensive characterization of Cas9 specificity and sgRNA mutation analysis (21, 22), as well as the NHEJ-
mediating sgRNA offset range identified in this study, computational approaches may be used to evaluate the 
likely off-target sites for a given pair of sgRNAs. To facilitate sgRNA pair selection, we developed an online web 
tool that identifies sgRNA combinations with optimal spacing for double nicking applications 
(http://www.genome-engineering.org/). 
Although Cas9n has been previously shown to facilitate HDR at on-target sites (5), its efficiency is substantially 
lower than that of wildtype Cas9. The double nicking strategy, by comparison, maintains high on-target 
efficiencies while reducing off-target modifications to background levels. Nevertheless, further characterizations 
of DN off-target activity, particularly via whole genome sequencing and targeted deep sequencing of cells or 
whole organisms generated using the DN approach, are urgently needed to evaluate the utility of Cas9n DN in 
biotechnological or clinical applications that require ultra-high precision genome editing. Additionally, Cas9n has 
been shown to induce low levels of indels at on-target sites for certain sgRNAs (7), which may result from residual 
double-strand break activities and be circumvented by further structure-function studies of Cas9 catalytic activity. 
Overall, Cas9n-mediated multiplex nicking serves as a customizable platform for highly precise and efficient 
targeted genome engineering and promises to broaden the range of applications in biotechnology, basic science, 
and medicine. 
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Introduction 
The CRISPR (clustered regularly interspaced palindromic repeat)-Cas system is a naturally occurring, adaptive 
microbial immune system for defense against invading phages and other mobile genetic elements (1-4). Three 
types (I–III) of CRISPR-Cas systems have been functionally identified across a wide range of microbial species 
(5-7), and each contains a cluster of CRISPR-associated (Cas) genes and its corresponding CRISPR array. These 
characteristic CRISPR arrays consist of repetitive sequences (direct repeats, referred to as repeats) interspaced by 
short stretches of non-repetitive sequences (spacers) derived from short segments of foreign genetic material 
(protospacers). The CRISPR array is transcribed and processed into short CRISPR RNAs (crRNAs), which 
direct the Cas proteins to the target nucleic acids via Watson-Crick base pairing to facilitate nucleic acid 
destruction. 
The Type I and III CRISPR systems utilize ensembles of Cas proteins complexed with crRNAs to mediate the 
recognition and subsequent degradation of target nucleic acids (8, 9). In contrast, the Type II CRISPR system 
recognizes and cleaves the target DNA (10) via the RNA-guided endonuclease Cas9 (11) along with two non-
coding RNAs, the crRNA and the trans-activating crRNA (tracrRNA) (13). The crRNA hybridizes with the 
tracrRNA to form a crRNA:tracrRNA duplex, which is loaded onto Cas9 to direct the cleavage of cognate DNA 
sequences bearing appropriate protospacer adjacent motifs (PAM) (15). Cas9 contains two nuclease domains, 
HNH and RuvC, which cleave the DNA strands that are complementary and non-complementary to the 20-
nucleotide (nt) guide sequence in crRNAs, respectively (16, 17). 
The Type II CRISPR system was the first to be adapted for facilitating genome editing in eukaryotic cells (18, 19). 
The Cas9 protein from Streptococcus pyogenes, along with a single guide RNA (sgRNA), a synthetic fusion of 
crRNA and tracrRNA (16), could be programmed to cleave virtually any sequence preceding a 5′-NGG-3′ PAM 
sequence in mammalian cells (18, 19). This unprecedented flexibility has enabled a broad range of applications, 
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including rapid generation of genetically modified cells and animal models (20-23), and genome-scale genetic 
screening (24, 25). 
However, despite the brisk progress in the development of Cas9 technology, the mechanism by which the Cas9–
sgRNA complex recognizes and cleaves its target DNA remains to be elucidated. Biochemical analyses at the 
domain levels have enabled site-specific engineering to convert the native Cas9 into a DNA nicking enzyme (11, 
16, 17) that facilitates homology-directed repair in eukaryotic cells (Cong et al., 2013; Mali et al., 2013b) and 
cleaves DNA with improved specificity, given appropriately paired sgRNAs (26, 27). Moreover, a catalytically 
inactive Cas9 can serve as an RNA-guided DNA-binding platform to target effector domains and modulate 
endogenous transcription (28-32). These advances in Cas9 engineering represent just the first steps toward fully 
realizing the potential of this flexible RNA-guided genome positioning system. Precise structural information 
about Cas9 will thus not only enhance our understanding of how this elegant RNA-guided, adaptive microbial 
immune system functions, but also facilitate further improvements in the Cas9 targeting specificity, the in vitro 
and in vivo delivery, and the engineering of Cas9 for novel functions and optimized features. 
Here, we report the crystal structure of S. pyogenes Cas9 in complex with sgRNA and its target DNA at 2.5 Å 
resolution. This high-resolution structure, along with functional analyses, reveals the key functional interactions 
that integrate the guide RNA, the target DNA, and the Cas9 protein, thus paving the way towards enhancing Cas9 
function as well as engineering novel applications. 
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Overall structure of the Cas9–sgRNA–DNA ternary complex 
We solved the crystal structure of full-length S. pyogenes Cas9 (residues 1–1368; D10A/C80L/C574E/H840A), 
in complex with a 98-nt sgRNA and a 23-nt target DNA, at 2.5 Å resolution by the SAD (single-wavelength 
anomalous dispersion) method, using a SeMet-labeled protein (Figure 4-1, Supplementary Figure 10, and 
Supplementary Table 4). To improve the solution behavior of Cas9, we replaced two less conserved cysteine 
residues (Cys80 and Cys574) with leucine and glutamic acid, respectively. This C80L/C574E mutant retained 
the ability to efficiently cleave genomic DNA in human embryonic kidney 293FT (HEK293FT) cells, confirming 
that these mutations have no effects on the Cas9 nuclease function (Supplementary Figure 11). Additionally, to 
prevent target DNA cleavage during crystallization, we replaced two catalytic residues, Asp10 from the RuvC 
domain and His840 from the HNH domain, with alanines. 
The crystallographic asymmetric unit contained two Cas9–sgRNA–DNA ternary complexes (Mol A and Mol B). 
Although there are conformational differences between the two complexes, the sgRNA and the DNA are 
recognized by Cas9 in similar manners. Most notably, while the HNH domain in Mol A is connected to the RuvC 
domain by a disordered linker, the HNH domain in Mol B is not visible in the electron density map, indicating the 
flexible nature of the HNH domain. Thus, we will first describe the structural features of Mol A unless otherwise 
stated, and then discuss the structural differences between the two complexes, which suggest the conformational 
flexibility of Cas9. 
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Figure 4-1 Overall structure of the Cas9–sgRNA–DNA ternary complex. 
(A) Domain organization of S. pyogenes Cas9. BH, Bridge helix. (B) Schematic representation of the 
sgRNA:target DNA complex. (C) Ribbon representation of the Cas9–sgRNA–DNA complex. Disordered linkers 
are shown as red dotted lines. (D) Surface representation of the Cas9–sgRNA–DNA complex. The active sites of 
the RuvC (D10A) and HNH (H840A) domains are indicated by dashed yellow circles. (E) Electrostatic surface 
potential of Cas9. The HNH domain is omitted for clarity. Molecular graphic images were prepared using 
CueMol (http://www.cuemol.org). 
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The crystal structure revealed that Cas9 consists of two lobes, a recognition (REC) lobe and a nuclease (NUC) 
lobe (Figure 4-1A–D). The REC lobe can be divided into three regions, a long α-helix referred to as the Bridge 
helix (residues 60–93), the REC1 (residues 94–179 and 308–713) domain, and the REC2 (residues 180–307) 
domain (Figure 4-1A–D). The NUC lobe consists of the RuvC (residues 1–59, 718–769 and 909–1098), HNH 
(residues 775–908), and PAM-interacting (PI) (residues 1099–1368) domains (Figure 4-1A–D). The 
negatively-charged sgRNA:target DNA heteroduplex is accommodated in a positively-charged groove at the 
interface between the REC and NUC lobes (Figure 4-1E). In the NUC lobe, the RuvC domain is assembled from 
the three split RuvC motifs (RuvC I–III), and interfaces with the PI domain to form a positively-charged surface 
that interacts with the 3′ tail of the sgRNA (Figure 4-1E). The HNH domain lies in between the RuvC II–III 
motifs and forms only a few contacts with the rest of the protein. 
The REC lobe interacts with the repeat:anti-repeat duplex 
The REC lobe includes the REC1 and REC2 domains. REC1 adopts an elongated, α-helical structure comprising 
25 α-helices (α2–α5 and α12–α32) and two β-sheets (β6 and β10, and β7–β9), whereas REC2 adopts a six-
helix bundle structure (α6–α11) (Figure 4-2A and Supplementary Figure 12). A Dali search (33) revealed that 
the REC lobe does not share structural similarity with other known proteins, indicating that it is a Cas9-specific 
functional domain. 
The REC lobe is one of the least conserved regions across the three Cas9 families within the Type II CRISPR 
system (IIA, IIB and IIC), and many Cas9 orthologs contain significantly shorter REC lobes (Supplementary 
Figure 13 and Supplementary Figure 14). In the present structure, the REC2 domain does not contact the bound 
guide:target heteroduplex. We thus hypothesized that truncations in the REC lobe could be tolerated. As 
expected, a Cas9 mutant lacking the REC2 domain (Δ175–307) retained ~50% of the wild-type Cas9 activity 
(Figure 4-2B), indicating that the REC2 domain is not critical for DNA cleavage. The lower cleavage efficiency 
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may be attributed in part to the reduced expression levels of the Δ175–307 mutant relative to that of the wild-type 
protein (Figure 4-2C). In striking contrast, the deletion of either the repeat-interacting region (Δ97–150) or the 
anti-repeat-interacting region (Δ312–409) of the REC1 domain abolished the DNA cleavage activity (Figure 
4-2B), indicating that the recognition of the repeat:anti-repeat duplex by the REC1 domain is critical for the Cas9 
function.  
The PAM-interacting (PI) domain confers PAM specificity 
The NUC lobe contains the PI domain, which forms an elongated structure comprising seven α-helices (α46–
α52), a three-stranded antiparallel β-sheet (β18–β20), a five-stranded antiparallel β-sheet (β21–β23, β26 and 
β27), and a two-stranded antiparallel β-sheet (β24 and β25) (Figure 4-2D and Supplementary Figure 12). 
Similar to the REC lobe, the PI domain also adopts a novel protein fold unique to the Cas9 family.  
The locations of the bound complementary DNA strand and the active site of the RuvC domain in the present 
structure suggested that the PI domain is positioned to recognize the PAM sequence on the non-complementary 
DNA strand. We tested whether the replacement of the PI domain of S. pyogenes Cas9 (SpCas9; Cas9 in this 
study) with that of an orthologous Cas9 protein, recognizing a different PAM, would be sufficient to alter their 
PAM specificities. The Streptococcus thermophilus CRISPR-3 Cas9 (St3Cas9) shares ~60% sequence identity with 
SpCas9. While their crRNA repeats and tracrRNAs are interchangeable (34), SpCas9 and St3Cas9 require 
different PAM sequences (5′-NGG-3′ for SpCas9 and 5′-NGGNG-3′ for St3Cas9) for target DNA cleavage (34).  
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Figure 4-2 REC lobe and PI domain 
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(A) Structure of the REC lobe. The REC2 domain and the Bridge helix are colored dark gray and green, 
respectively. The REC1 domain is colored gray, with the repeat-interacting and anti-repeat-interacting regions 
colored pale blue and pink, respectively. The bound sgRNA:DNA is shown as a semi-transparent ribbon 
representation. 
(B) Mutational analysis of the REC lobe. Schematics show the truncation mutants. The bar graph shows indel 
mutations generated by the truncation mutants, measured by the SURVEYOR assay (n = 3, error bars show mean 
± S.E.M., N.D., not detectable). 
(C) Western blot showing the expression of the truncation mutants in HEK 293FT cells. 
(D) Structure of the PI domain. The bound sgRNA is shown as a semi-transparent ribbon representation. 
(E) Mutational analysis of the PI domain. Schematics show wild-type SpCas9 and St3Cas9, chimeric Sp-St3Cas9 
and St3-SpCas9, and the SpCas9 PI domain truncation mutant. Cas9s were assayed for indel generation at target 
sites upstream of either NGG (left bar graph) or NGGNG (right bar graph) PAMs (n = 3, error bars show mean ± 
S.E.M., N.D., not detectable). 
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We swapped their PI domains to generate two chimeras, Sp-St3Cas9 (SpCas9 with the PI domain of St3Cas9) 
and St3-SpCas9 (St3Cas9 with the PI domain of SpCas9), and examined their cleavage activities for target DNA 
sequences bearing 5′-NGG-3′ PAM (5′-GGGCT-3′) or 5′-NGGNG-3′ PAM (5′-GGGCG-3′) (Figure 4-2E). 
SpCas9 and St3-SpCas9, but not St3Cas9, cleaved the target DNA with 5′-NGG-3′ PAM (Figure 4-2E), 
indicating that the PI domain of SpCas9 is required for the recognition of 5′-NGG-3′ PAM and is sufficient to alter 
the PAM specificity of St3Cas9. Sp-St3Cas9 retained the cleavage activity for the target DNA with 5′-NGG-3′ 
PAM, albeit at a lower level than that of SpCas9 (Figure 4-2E). Additionally, the deletion of the PI domain 
(Δ1099–1368) abolished the cleavage activity (Figure 4-2E), indicating that the PI domain is critical for the Cas9 
function. These results revealed that the PI domain is a major determinant of the PAM specificity. 
The RuvC domain has an RNase H fold 
The RuvC domain consists of a six-stranded mixed β-sheet (β1, β2, β5, β11, β14 and β17) flanked by α-helices 
(α33, α34 and α39–α45) and two additional two-stranded antiparallel β-sheets (β3/β4 and β15/β16) (Figure 
4-3A and Supplementary Figure 12). It shares structural similarity with the retroviral integrase superfamily 
members characterized by an RNase H fold, such as Escherichia coli RuvC (35) (PDB code 1HJR, 14% identity, 
root-mean-square deviation (rmsd) of 3.6 Å for 126 equivalent Cα atoms) and Thermus thermophilus RuvC 
(Gorecka et al., 2013) (PDB code 4LD0, 12% identity, rmsd of 3.4 Å for 131 equivalent Cα atoms) (Figure 4-3B). 
The RuvC nucleases have four catalytic residues (e.g., Asp7, Glu70, His143 and Asp146 in T. thermophilus RuvC), 
and cleave Holliday junctions through a two-metal mechanism (35-37). Asp10 (Ala), Glu762, His983 and 
Asp986 of the Cas9 RuvC domain are located at positions similar to those of the catalytic residues of T. 
thermophilus RuvC (Figure 4-3A, B), consistent with previous results showing that Asp10 is critical for the 
cleavage of the non-complementary DNA strand, and that Cas9 requires Mg2+ ions for the cleavage activity (16, 
17). Moreover, the alanine substitution of Glu762, His983 or Asp986 also converted Cas9 into a nickase (Figure 
4-3C, D). Each nickase mutant was able to facilitate targeted double strand breaks using a pair of juxtaposed 
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sgRNAs (Figure 4-3C, D, Supplementary Table 5), as previously demonstrated with the D10A nickase (26). This 
combination of structural observations and mutational analyses suggested that the Cas9 RuvC domain cleaves the 
non-complementary strand of the target DNA through the two-metal mechanism, as previously observed for 
other retroviral integrase superfamily nucleases. 
It is important to note that there are key structural dissimilarities between the Cas9 RuvC domain and the RuvC 
nucleases, which explain their functional differences. Unlike the Cas9 RuvC domain, the RuvC nucleases form 
dimers and recognize Holliday junctions (36) (Figure 4-3B). In addition to the conserved RNase H fold, the Cas9 
RuvC domain has other structural elements involved in interactions with the guide:target heteroduplex (an end-
capping loop between α42 and α43) and the PI domain/stem loop 3 (β-hairpin formed by β3 and β4) (Figure 
4-3A). 
The HNH domain has a ββα-metal fold 
The HNH domain comprises a two-stranded antiparallel β-sheet (β12 and β13) flanked by four α-helices (α35–
α38) (Figure 4-3E). It shares structural similarity with the HNH endonucleases characterized by a ββα-metal 
fold, such as phage T4 endonuclease VII (Endo VII) (38) (PDB code 2QNC, 20% identity, rmsd of 2.7 Å for 61 
equivalent Cα atoms) and Vibrio vulnificus nuclease (39) (PDB code 1OUP, 8% identity, rmsd of 2.7 Å for 77 
equivalent Cα atoms) (Figure 4-3F). HNH nucleases have three catalytic residues (e.g., Asp40, His41, and Asn62 
in Endo VII), and cleave nucleic acid substrates through a single-metal mechanism (38, 39). In the structure of 
the Endo VII N62D mutant in complex with a Holliday junction, a Mg2+ ion is coordinated by Asp40, Asp62, and 
the oxygen atoms of the scissile phosphate group of the substrate, while His41 acts as a general base to activate a 
water molecule for catalysis (Figure 4-3F). Asp839, His840, and Asn863 of the Cas9 HNH domain correspond to 
Asp40, His41, and Asn62 of Endo VII, respectively (Figure 4-3E), consistent with the observation that His840 is 
critical for the cleavage of the complementary DNA strand (16, 17). The N863A mutant functions as a nickase 
   
 82 
(Figure 4-3C, D), indicating that Asn863 participates in catalysis. These observations suggested that the Cas9 
HNH domain may cleave the complementary strand of the target DNA through a single-metal mechanism, as 
observed for other HNH superfamily nucleases. However, in the present structure, Asn863 of Cas9 is located at a 
different position from that of Asn62 in Endo VII, whereas Asp839 and His840 (Ala) of Cas9 are located at 
positions similar to those of Asp40 and His41 in Endo VII, respectively (Figure 4-3G). This might be due to the 
absence of divalent ions, such as Mg2+, in our crystallization solution, and Asn863 may point towards the active 
site and participate in catalysis. Although the HNH domain shares a ββα-metal fold with other HNN 
endonucleases, their overall structures are distinct (Figure 4-3E, F), consistent with the differences in their 
substrate specificities. 
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Figure 4-3 NUC lobe 
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(A) Structure of the RuvC domain. The core structure of the RNase H fold is highlighted in cyan. The active-site 
residues are shown as stick models. (B) Structure of the T. thermophilus RuvC dimer in complex with a Holliday 
junction (PDB ID 4LD0). The two protomers are colored cyan and gray, respectively. (C) Mutational analysis of 
the RuvC and HNH domains. The sequences (top) illustrate Cas9 nicking targets on opposite strands of DNA. 
Targets 1 and 2 are offset by a distance of 4-bp in between. The cleavage sites by the HNH and RuvC domains are 
indicated by pink and cyan triangles, respectively. The heatmap (bottom) shows the ability of each catalytic 
mutant to induce double- (with either sgRNA 1 or 2) or single-stranded breaks (only with both sgRNAs together). 
Gray boxes, not assayed. (D) Indel formation by Cas9 nickases depends on the off-set distance between sgRNA 
pairs. The off-set distance is defined as the number of base pairs between the PAM-distal (5′) ends of the guide 
sequence of a given sgRNA pair (n = 3, error bars show mean ± S.E.M., N.D., not detectable). (E) Structure of the 
HNH domain. The core structure of the bba-metal fold is highlighted in magenta. The active-site residues are 
shown as stick models. (F) Structure of the T4 Endo VII dimer in complex with a Holliday junction (PDB ID 
2QNC). The two protomers are colored pink and gray, respectively, with the bba-metal fold core highlighted in 
magenta. The bound Mg2+ ion is shown as an orange sphere. (G) Superimposition of the Cas9 HNH domain and 
T4 Endo VII (PDB ID 2QNC). 
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The sgRNA:DNA complex adopts a T-shaped architecture 
The sgRNA consists of crRNA- and tracrRNA-derived sequences connected by an artificial tetraloop (Figure 
4-4A). The crRNA sequence can be divided into guide (20-nt) and repeat (12-nt) regions, while the tracrRNA 
sequence can be divided into anti-repeat (14-nt) and three tracrRNA stem loops (Figure 4-4A). The crystal 
structure revealed that the sgRNA binds the target DNA to form a T-shaped architecture comprising a 
guide:target heteroduplex, a repeat:anti-repeat duplex, and stem loops 1–3 (Figure 4-4A, B). The repeat:anti-
repeat duplex and stem loop 1 are connected by a single nucleotide (A51), while stem loops 1 and 2 are connected 
by a 5-nt single-stranded linker (nucleotides 63–67). 
The guide (nucleotides 1–20) and target DNA (nucleotides 1′–20′) form the guide:target heteroduplex via 20 
Watson-Crick base pairs (Figure 4-4A, B). The conformation of the heteroduplex is distorted from that of the 
canonical A-form RNA duplex (Supplementary Figure 15). The repeat (nucleotides 21–32) and the anti-repeat 
(nucleotides 37–50) form the repeat:anti-repeat duplex via nine Watson-Crick base pairs (U22:A49–A26:U45 
and G29:C40–A32:U37) (Figure 4-4A, B). Within this region, G27, A28, A41, A42, G43 and U44 are unpaired, 
with A28 and U44 flipped out from the duplex (Figure 4-4C). The G27 and A41 nucleobases stack with the 
A26:U45 and G29:C40 pairs, respectively, and the 2-amino group of G27 interacts with the backbone phosphate 
group between G43 and U44, stabilizing the duplex structure (Figure 4-4C). G21 and U50 form a wobble base 
pair at the three-way junction between the guide:target heteroduplex/repeat:anti-repeat duplexes and stem loop 1, 
contributing to the formation of the T-shaped architecture (Figure 4-4C). 
As expected from the RNA-fold predictions based on the nucleotide sequence, the tracrRNA 3′ tail (nucleotides 
68–81 and 82–96) forms stem loops 2 and 3 via four and six Watson-Crick base pairs (A69:U80–U72:A77 and 
G82:C96–G87:C91), respectively (Figure 4-4A, B). In addition, nucleotides 52–62 form the newly detected stem 
loop (stem loop 1) via three Watson-Crick base pairs (G53:C61, G54:C60 and C55:G58), with U59 flipped out 
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from the stem (Figure 4-4A, B). Stem loop 1 is stabilized by the G62–G53:C61 stacking interaction and the G62–
A51/A52 polar interactions (Figure 4-4C). 
The guide:target and repeat:anti-repeat duplexes are deeply buried in a positively-charged groove at the interface 
of the two lobes, while the rest of the sgRNA extensively interacts with the positively-charged surface on the back 
side of the protein (Figure 4-1). In Mol A, the three nucleotides at the 5′ end of the target DNA (3′-ACC-5′, 
complementary to the PAM) are not visible in the electron density map. Although the two adjacent nucleotides 
(3′-AC-5′) in Mol B are structurally ordered due to the crystal packing interactions, and are visible in the electron 
density map, these nucleotides are not recognized by Cas9 (data not shown). These observations suggested that 
the 3′-NCC-5′ sequence complementary to the 5′-NGG-3′ PAM is not recognized by Cas9, and are consistent 
with previous biochemical data showing that Cas9-catalyzed DNA cleavage requires the 5′-NGG-3′ PAM on the 
non-complementary strand but not the 3′-NCC-5′ sequence on the complementary strand (16). 
Previous studies showed that, although sgRNA with a 48-nt tracrRNA tail [referred to as sgRNA(+48)] is the 
minimal region for the Cas9-catalyzed DNA cleavage in vitro (16), sgRNAs with extended tracrRNA tails, 
sgRNA(+67) and sgRNA(+85), dramatically improved the Cas9 cleavage activity in vivo (40). The present 
structure revealed that sgRNA(+48), sgRNA(+67) and sgRNA(+85) contain stem loop 1, stem loops 1–2 and 
stem loops 1–3, respectively (Figure 4-1A, B). These observations indicated that, whereas stem loop 1 is essential 
for the formation of the functional Cas9–sgRNA complex, stem loops 2 and 3 further support the stable complex 
formation and enhance the stability of the sgRNA, thus improving the in vivo activity. 
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Figure 4-4 sgRNA and target DNA structure 
 
 
(A) Schematic representation of the sgRNA:target DNA complex. The guide and repeat regions of the crRNA 
sequence are colored sky blue and blue, respectively. The tracrRNA sequence is colored red, with the linker 
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region colored violet. The target DNA and the tetraloop are colored yellow and gray, respectively. The numbering 
of the 3′ tails of the tracrRNA is shown on a red background. Watson-Crick and non-Watson-Crick base pairs are 
indicated by black and gray lines, respectively. Disordered nucleotides are boxed by dashed lines. (B) Structure of 
the sgRNA:target DNA complex. (C) Close-up view of the repeat:anti-repeat duplex and the three-way junction. 
Key interactions are shown with gray dashed lines. (D) Effects of sgRNA mutations on the ability to induce indels. 
Base changes from the sgRNA(+85) scaffold are shown at the respective positions, with dashes indicating 
unaltered bases (n = 3, error bars show mean ± S.E.M., p values based on unpaired Student’s t-test, N.D., not 
detectable). 
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Figure 4-5 Schematic representation of sgRNA:target DNA recognition by Cas9 
Residues that interact with the sgRNA:DNA via their main chain are shown in parentheses. Note that water-
mediated hydrogen-bonding interactions are not shown, for clarity. 
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To determine the significance of each sgRNA structural component on the Cas9 function, we tested a number of 
sgRNAs with mutations in the repeat:anti-repeat duplex, stem loops 1–3, and the linker between stem loops 1 and 
2. Our results revealed that, whereas stem loops 2 and 3 as well as the linker region can tolerate a large number of 
mutations, the repeat:anti-repeat duplex and stem loop 1 are critical for the Cas9 function (Figure 4-1D). 
Moreover, the sgRNA sequence can tolerate a large number of mutations (Figure 4-1D, reconstructed sgRNA). 
These results highlight the functional significance of the structure-dependent recognition of the repeat:anti-repeat 
duplex by Cas9. 
The conserved arginine cluster on the Bridge helix is critical for 
sgRNA:DNA recognition 
The sgRNA guide region is primarily recognized by the REC lobe (Figure 4-5). The backbone phosphate groups 
of the guide region (nucleotides 2, 4–6 and 13–20) interact with the REC1 domain (Arg165, Gly166, Arg403, 
Asn407, Lys510, Tyr515 and Arg661) and the Bridge helix (Arg63, Arg66, Arg70, Arg71, Arg74 and Arg78) 
(Figure 4-6A). The 2′-hydroxyl groups of G1, C15, U16 and G19 hydrogen bond with Val1009, Tyr450, 
Arg447/Ile448 and Thr404, respectively (Figure 4-6A). These observations suggested that the Watson-Crick 
faces of eight PAM-proximal nucleotides in the Cas9-bound sgRNA are exposed to the solvent, thus serving as a 
nucleation site for pairing with the complementary strand of the target DNA. This is consistent with previous 
reports that the 10–12 bp PAM-proximal “seed” region is critical for the Cas9-catalyzed DNA cleavage (16, 18, 27, 
40-42). 
A mutational analysis demonstrated that the R66A, R70A and R74A mutations on the Bridge helix markedly 
reduced the DNA cleavage activities (Figure 4-6B), highlighting the functional significance of the recognition of 
the sgRNA “seed” region by the Bridge helix. Although Arg78 and Arg165 also interact with the “seed” region, the 
R78A and R165A mutants showed only moderately decreased activities (Figure 4-6B). These results are 
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consistent with the fact that Arg66, Arg70 and Arg74 form multiple salt bridges with the sgRNA backbone, while 
Arg78 and Arg165 form a single salt bridge with the sgRNA backbone (Figure 4-6A). The cluster of arginine 
residues on the Bridge helix is highly conserved among the Cas9 proteins in the Type II-A–C systems 
(Supplementary Figure 13 and Supplementary Figure 14), suggesting that the Bridge helix is a universal structural 
feature of the Cas9 proteins. This notion is supported by the previous observation that a strictly conserved 
arginine residue, equivalent to Arg70 of S. pyogenes Cas9, is essential for the function of Francisella novicida Cas9 
in the Type II-B system (43). Moreover, the alanine mutations of the repeat:anti-repeat duplex-interacting 
residues (Arg75 and Lys163) and the stem loop 1-interacting residue (Arg69) resulted in decreased DNA 
cleavage activity (Figure 4-6B), confirming the functional importance of the recognition of the repeat:anti-repeat 
duplex and stem loop 1 by Cas9. 
The sgRNA guide region is recognized by Cas9 in a sequence-independent manner, except for the U16–Arg447 
and G18–Arg71 interactions (Figure 4-5, Figure 4-6A). This base-specific G18–Arg71 interaction may partly 
explain the observed preference of Cas9 for sgRNAs with guanines in the four PAM-proximal guide region (25). 
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Figure 4-6 sgRNA:target DNA recognition by Cas9 
(A and C–J) Recognition of the guide (A), the guide:target heteroduplex (C), the repeat (D), the anti-repeat (E), 
the three-way junction (F), stem loop 1 (G), the linker (H), stem loop 2 (I) and stem loop 3 (J). Hydrogen bonds 
and salt bridges are shown as dashed lines. In (A), the target DNA is omitted, for clarity. (B) Effects of Cas9 (top) 
and sgRNA (bottom) mutations on the ability to induce indels (n = 3, error bars show mean ± S.E.M., p values 
based on unpaired Student’s t-test. N.D., not detectable). 
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The REC1 and RuvC domains facilitate RNA-guided DNA 
targeting 
Cas9 recognizes the 20-bp guide:target heteroduplex in a sequence-independent manner (Figure 4-5). The 
backbone phosphate groups of the target DNA (nucleotides 1′, 9′–11′, 13′ and 20′) interact with the REC1 
(Asn497, Trp659, Arg661 and Gln695), RuvC (Gln926), and PI (Glu1108) domains. The C2′ atoms of the target 
DNA (nucleotides 5′, 7′, 8′, 11′, 19′ and 20′) form van der Waals interactions with the REC1 domain (Leu169, 
Tyr450, Met495, Met694 and His698) and the RuvC domain (Ala728) (Figure 4-5). These interactions are likely 
to contribute toward the ability of Cas9 to discriminate between DNA and RNA targets. The terminal base pair of 
the guide:target heteroduplex (G1:C20′) is recognized by the RuvC domain via end-capping interactions (Figure 
4-6C); the sgRNA G1 and target DNA C20′ nucleobases interact with the Tyr1013 and Val1015 side chains, 
respectively, whereas the 2′-hydroxyl and phosphate groups of sgRNA G1 interact with Val1009 and Gln926, 
respectively. These end-capping interactions are consistent with the previous observation that Cas9 recognizes a 
17–20-bp guide:target heteroduplex, and that extended guide sequences are degraded in cells and do not 
contribute to improving sequence specificity (26). Taken together, these structural findings explain the RNA-
guided DNA targeting mechanism of Cas9. 
The repeat:anti-repeat duplex is recognized by the REC and NUC 
lobes in a sequence-dependent manner 
In contrast to the sequence-independent recognition of the sgRNA guide region, sequence-dependent 
interactions exist between Cas9 and the repeat:anti-repeat duplex (Figure 4-5, Figure 4-6D and 6E). The 
nucleobases of U23/A49 and A42/G43 hydrogen bond with the side chain of Arg1122 and the main-chain 
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carbonyl group of Phe351, respectively (Figure 4-6D). The nucleobase of the flipped U44 is sandwiched between 
Tyr325 and His328, with its N3 atom hydrogen bonded with Tyr325, while the nucleobase of the unpaired G43 
stacks with Tyr359 and hydrogen bonds with Asp364 (Figure 4-6E). 
The present structure revealed that the repeat:anti-repeat duplex is recognized by the REC lobe, which is 
divergent in both sequence and length among the Cas9 orthologs within the Type II-A–C systems 
(Supplementary Figure 13Supplementary Figure 14). This structural finding explains the previous observation 
that Cas9 and sgRNA are interchangeable only between closely related Type II systems (34). The three PAM-
distal base pairs (C30:G39–A32:U37) are not recognized by Cas9 and protrude from the complex (Figure 4-5 
Schematic representation of sgRNA:target DNA recognition by Cas9), consistent with a proposed model in 
which the Cas9-bound repeat:anti-repeat duplex is processed by the host RNase III enzyme (13). 
The nucleobases of G21 and U50, in the G21:U50 wobble pair, stack with the terminal C20:G1′ pair in the 
guide:target heteroduplex and Tyr72 on the Bridge helix, respectively, with the U50 O4 atom hydrogen bonded 
with Arg75 (Figure 4-6D). Notably, A51 adopts the syn-conformation, and is oriented in the direction opposite to 
U50 (Figure 4-4C and Figure 4-6F). The nucleobase of A51 is sandwiched between Phe1105 and U63, with its 
N1, N6 and N7 atoms hydrogen bonded with G62, Gly1103 and Phe1105, respectively (Figure 4-6F). Whereas 
the repeat:anti-repeat duplexes have diverse sequences and lengths among the Type II-A–C systems, the G:U 
base pair at the three-way junction is highly conserved among the repeat:anti-repeat duplexes in these three 
systems (34), suggesting that this wobble pairing is a universal structural feature involved in the three-way 
junction formation. 
To verify the importance of the sequence-dependent recognition of the repeat:anti-repeat duplex by Cas9, we 
evaluated the effects of repeat:anti-repeat mutations on the Cas9-mediated DNA cleavage (Figure 4-6B). The 
replacement of G43, which forms base-specific hydrogen bonds with Phe351 and Asp364, with cytosine reduced 
the Cas9 activity by over 3-fold. In addition, the replacement of the flipped U44 with guanine resulted in an over 
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5-fold drop in the cleavage activity, whereas the replacement of U44 with another pyrimidine base (cytosine) did 
not significantly affect the cleavage activity (Figure 4-6B). These results confirmed the functional importance of 
the base-specific recognition of G43 and U44 by Cas9. 
Stem loops 1–3 reinforce the interaction between Cas9 and 
sgRNA 
Stem loop 1 is primarily recognized by the REC lobe, together with the PI domain (Figure 4-5). The backbone 
phosphate groups of stem loop 1 (nucleotides 52, 53 and 59–61) interact with the REC1 domain (Leu455, 
Ser460, Arg467, Thr472 and Ile473), the PI domain (Lys1123 and Lys1124), and the Bridge helix (Arg70 and 
Arg74), with the 2′-hydroxyl group of G58 hydrogen bonded with Leu455 (Figure 4-6G). A52 interacts with 
Phe1105 through a face-to-edge π–π stacking interaction (Figure 4-6F), and the flipped U59 nucleobase 
hydrogen bonds with Asn77 (Figure 4-6G). 
The single-stranded linker and stem loops 2 and 3 are primarily recognized by the NUC lobe (Figure 4-5); in 
contrast, stem loop 1 and the guide:target/repeat:anti-repeat duplexes are recognized by both the REC and NUC 
lobes. The backbone phosphate groups of the linker (nucleotides 63–65 and 67) interact with the RuvC domain 
(Glu57, Lys742 and Lys1097), the PI domain (Thr1102), and the Bridge helix (Arg69), with the 2′-hydroxyl 
groups of U64 and A65 hydrogen bonded with Glu57 and His721, respectively (Figure 4-6H). The C67 
nucleobase forms two hydrogen bonds with Val1100 (Figure 4-6H). 
Stem loop 2 is recognized by Cas9 via the interactions between the NUC lobe and the non-Watson-Crick 
A68:G81 pair, which is formed by direct (between the A68 N6 and G81 O6 atoms) and water-mediated (between 
the A68 N1 and G81 N1 atoms) hydrogen-bonding interactions (Figure 4-6I). The A68 and G81 nucleobases 
contact Ser1351 and Tyr1356, respectively, while the A68:G81 pair interacts with Thr1358 via a water-mediated 
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hydrogen bond (Figure 4-6I). The 2′-hydroxyl group of A68 hydrogen bonds with His1349, while the G81 
nucleobase hydrogen bonds with Lys33 (Figure 4-6I). 
Stem loop 3 interacts with the NUC lobe more extensively, as compared to stem loop 2 (Figure 4-5). The 
backbone phosphate groups of C91 and G92 interact with the RuvC domain (Arg40 and Lys44), while the G89 
and U90 nucleobases hydrogen bond with Gln1272 and Glu1225/Ala1227, respectively (Figure 4-6J). The A88 
and C91 nucleobases are recognized by Asn46 via multiple hydrogen-bonding interactions (Figure 4-6J). 
Structural flexibility of Cas9 and sgRNA 
Although the HNH domain cleaves the complementary strand of the target DNA at a position three nucleotides 
upstream of the PAM sequence (16, 17), in the present structure, the HNH domain is located away from the 
scissile phosphate group of the bound complementary strand (Figure 4-7A). A structural comparison of Mol A 
and Mol B provided mechanistic insights into complementary strand cleavage by the HNH domain. In Mol A, the 
HNH domain is followed by the α39 helix of the RuvC domain, which is connected to the α40 helix by the α39–
α40 linker (residues 919–925) (Figure 4-7A). In Mol A, residues 913–925 form the C-terminal portion of the 
α39 helix and the α39–α40 linker, while in Mol B, these residues form an extended α-helix, which is directed 
toward the cleavage site of the complementary strand (Figure 4-7A). These observations suggested that the HNH 
domain can approach and cleave the target DNA through conformational changes in the segment connecting the 
HNH and RuvC domains. 
The structural comparison further revealed the conformational flexibility between the REC and NUC lobes 
(Figure 4-7B). As compared to Mol A, Mol B adopts a more open conformation, in which the two lobes are 
rotated by 15° at a hinge loop between the Bridge helix and strand β5 in the RuvC domain (Figure 4-7B). The 
bound sgRNA also undergoes an accompanying conformational change at the linker, which interacts with the 
hinge loop (Figure 4-7C). We also observed the concomitant displacement of the β17–β18 loop of the PI domain, 
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which interacts with the repeat:anti-repeat duplex and the α2–α3 loop of the REC1 domain (Figure 4-7B). 
Notably, there is no direct contact between the two lobes in the present structure, except for the interactions 
between the α2–α3 and β17–β18 loops (Figure 4-7D), suggesting that Cas9 is highly flexible in the absence of 
the sgRNA. The flexible nature of Cas9 is likely to play a role in the assembly of the Cas9–sgRNA–DNA ternary 
complex.  
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Figure 4-7 Structural flexibility of the complex and a model for RNA-guided DNA cleavage by Cas9 
(A) Structural comparison of Mol A and Mol B. In Mol A (left), the disordered linker between the RuvC and 
HNH domains is indicated by a dotted line. In Mol B (right), the disordered HNH domain is shown as a dashed 
circle. The flexible connecting segment (a39 and a40) in the RuvC domain is colored orange. (B) 
Superimposition of the Cas9 proteins in Mol A and Mol B. The two complexes are superimposed based on the 
core b-sheet of the two RuvC domains. The HNH domain and the bound sgRNA:target DNA complex were 
omitted, for clarity. (C) Superimposition of the sgRNA:target DNA complex in Mol A and Mol B. After 
superimposition of the two complexes as in (B), the Cas9 proteins were omitted to show the sgRNA:target DNA 
complex. (D) Molecular surface of Cas9. The HNH domain and the sgRNA:target DNA complex were omitted, 
for clarity. (E) Model of RNA-guided DNA cleavage by Cas9. 
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Discussion 
The present structure revealed that the 20-bp heteroduplex, formed by the sgRNA guide region and the 
complementary strand of the target DNA, is accommodated in the positively-charged groove at the interface 
between the REC and NUC lobes, with the scissile phosphate group of the target DNA properly positioned for 
cleavage by the HNH domain. Although the present structure does not contain the non-complementary DNA 
strand, the position of the bound complementary strand suggested that the scissile phosphate of the non-
complementary strand is located in the vicinity of the active site of the RuvC domain, consistent with previous 
biochemical data (16, 17). Furthermore, our structural and functional analyses indicated that the PI domain 
participates in the PAM recognition. 
Based on these observations, we propose a model for the Cas9-catalyzed RNA-guided DNA cleavage (Figure 
4-7E). Cas9 recognizes the PAM-proximal guide region and the repeat:anti-repeat duplex of sgRNA, to form the 
Cas9–sgRNA binary complex. The binary complex subsequently recognizes the DNA sequence complementary 
to the 20-nt guide region of the bound sgRNA, to form the final Cas9–sgRNA–target DNA ternary complex. Prior 
to the ternary complex formation, the PI domain recognizes the PAM sequence on the non-complementary 
strand, thereby triggering the R-loop formation. Upon the assembly of the ternary complex, the mobile HNH 
domain approaches and cleaves the complementary strand in the guide:target heteroduplex, whereas the RuvC 
domain cleaves the single-stranded, non-complementary strand. Biochemical studies indicated that PAM 
recognition by Cas9 is important for both the binding and cleavage of the target DNA, suggesting that the Cas9–
sgRNA complex may indeed undergo an inactive-to-active conformational transition upon PAM recognition (17, 
44). This notion is consistent with the fact that the present structure is likely to represent an inactive state, where 
the HNH domain is located away from the complementary strand. 
The present crystal structure provides a critical step towards understanding the molecular mechanism of RNA-
guided DNA targeting by Cas9. Further structural and functional studies with S. pyogenes Cas9 or related 
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orthologs, including the structural elucidation of the Cas9–sgRNA–DNA ternary complex containing the non-
complementary strand, will be important for illuminating the mechanisms of PAM recognition, the 
conformational changes occurring upon PAM recognition, and the mismatch tolerance between the guide:target 
heteroduplex. However, this study has provided a useful scaffold for the rational engineering of Cas9-based 
genome modulating technologies. For example, we created an S. pyogenes Cas9 truncation mutant (Figure 4-2B) 
that will facilitate the packaging of Cas9 into size-constrained viral vectors for in vivo and therapeutic applications. 
Moreover, future engineering of the PI domain may allow us to program the PAM specificity, improve the target 
site recognition fidelity, and increase the versatility of the Cas9 genome engineering platform. 
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Introduction 
The CRISPR (clustered regularly interspaced short palindromic repeats)-Cas system is a RNA-guided 
endonuclease system from bacteria and archaea that provides adaptive immunity against exogenous nucleic 
acids(1-6). Of the three CRISPR-Cas classes, the Type II system has to date attracted the most interest as a 
genome engineering platform because of its relatively simple and well-characterized mechanism – a single 
endonuclease (Cas9) and two small RNAs, the CRISPR RNA (crRNA) that contains the DNA-targeting guide 
sequence (spacer) and the auxiliary trans-activating crRNA (tracrRNA)(7), mediate cleavage of the target DNA 
(protospacer)(7-9); this dual RNA complex has been further engineered into a chimeric single-guide RNA 
(sgRNA)(10-12). An additional requirement critical to Cas9 activity is the presence of a protospacer adjacent 
motif (PAM) in the target DNA, which differs among the CRISPR-Cas systems(5, 13). 
The ability to harness Cas9 for broad applications in vivo in somatic tissue, while obviating the need for embryonic 
manipulation, would prove enormously useful for accelerating basic research and enabling clinical applications(14, 
15). One major challenge is the delivery of the Cas9 genome editing system to animals. Adeno-associated virus 
(AAV) vectors are attractive candidates for efficient gene delivery in vivo because of their low immunogenic 
potential, reduced oncogenic risk from host-genome integration(16), and well-characterized serotype 
specificity(17-20). However, the limited cargo size of ~4.5kb for optimal transgene delivery renders the packaging 
of SpCas9 (~4.2kb) and appropriate control elements (promoter, polyA signal) difficult. While several smaller 
Cas9 orthologs have been used for mammalian genome editing(10, 21), they are nonetheless relatively limited in 
availability of targeting sequences due to the requirement for lengthier and more specific PAMs, and cannot 
match SpCas9 in cleavage efficiency. This highlights the potential as well as the need to further explore the 
ecological diversity of Type II CRISPR systems for additional suitable Cas9s. 
Here, we have identified six small Cas9 orthologs and their corresponding protospacer adjacent motifs (PAM), 
which could be optimized for mammalian genome editing. In particular, we show that Cas9 from Staphylococcus 
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aureus (SaCas9), which is 23% smaller than SpCas9, can edit the mammalian genome with high efficiency on par 
with SpCas9, and be packaged along with its single-guide RNA (sgRNA) into adeno-associated virus (AAV) as a 
single vector for delivery into adult mice. We demonstrate targeting of the mouse liver and observed 30% gene 
modification in vivo within 3 weeks of injection.  
Metagenomic search for small Cas9 orthologs 
To identify a diverse set of small Cas9 proteins, we selected six representative Cas9 orthologs from over 800 
known Cas9s from GenBank and optimized their sequences for mammalian expression (Figure 5-1a). These 
Cas9s belong to the Type IIA and IIC subfamilies(22, 23). Using the characteristic direct repeat motifs found 
within the CRISPR array(2, 3, 24), we searched a 2-kb window flanking the CRISPR locus for potential 
tracrRNAs that contained strong sequence homology to the repeats, at least two additional predicted stemloops, 
and a Rho-independent transcriptional termination signal within 150-nt. From these we constructed sgRNA 
scaffolds for each ortholog (Supplementary Figure 16 and Supplementary Table 6). Since the full 3’ end of 
tracrRNA improves sgRNA abundance in cells(25) and mediates interaction with Cas9(26), we included the full 
tracrRNA 3’ end for each ortholog. We then cleaved a library of plasmids containing a fixed-sequence target 
followed by a randomized 7-mer as PAM (5’-NNNNNNN) in an in vitro cell lysate assay, and identified the 
putative PAMs by sequencing the targets that were successfully cleaved (Figure 5-1b, c). We observed that similar 
to SpCas9, the Cas9 orthologs cleaved targets 3 bp upstream of PAM (Supplementary Figure 17). To validate the 
consensus PAMs from the library, we subsequently cleaved a DNA template bearing the putative PAMs in a 
biochemical lysate reaction and showed that the sgRNA designs, in combination with the Cas9 orthologs, can 
indeed target sites bearing appropriate consensus PAMs, albeit with differing efficiencies (Figure 5-1d and 
Supplementary Table 7). 
. 
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Figure 5-1 Biochemical screen for small Cas9 orthologs 
(A) Phylogenetic tree of Cas9 orthologs, with subfamily and sizes (amino acids) indicated. Conserved nuclease 
domains are highlighted in colored boxes, black residues represent conserved sequences. (B) Schematic 
illustrating in vitro cleavage-based method used to identify protospacer adjacent motifs (PAMs). (C) Consensus 
PAMs for eight Cas9 orthologs from sequencing of cleaved fragments. (D) Biochemical cleavage reaction using 
orthologs and sgRNAs targeting different loci bearing the putative PAMs (shown in red). Red triangles indicate 
cleavage fragments. 
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Characterization of SaCas9 in vitro 
Having validated the activity of Cas9 orthologs using cell lysates, we sought to test their ability to induce double 
stranded breaks in mammalian cells. We co-transfected in human embryonic kidney (HEK 293FT) cells the Cas9 
orthologs and their respective sgRNAs targeting endogenous human genomic loci with the appropriate PAMs. 
However, of the six Cas9 orthologs tested, only the Cas9 from Staphylococcus aureus (referred to as SaCas9) 
reproducibly yielded indels by SURVEYOR assay (Supplementary Figure 18 and Supplementary Table 8). Thus, 
we focused on optimizing SaCas9 and sgRNA for application in in vivo mammalian genome editing. 
Although many Type II CRISPR systems share a common feature of having ~36-bp direct repeats and ~30-bp 
spacers(22), previous studies have reported different lengths for spacer as well as direct repeat sequences in the 
mature crRNA among different systems(7, 21, 27). We therefore sought to test the optimal lengths of these two 
parameters for the SaCas9 sgRNA (Figure 5-2a). We found that while a range of spacer or guide length is 
tolerated for SaCas9, there is a marked decrease in cleavage efficiency when it is 18-nt or below (Figure 5-2b), in 
contrast to SpCas9 where shorter sgRNA lengths can be used(28). Similarly, a range of lengths for direct 
repeat:tracrRNA antirepeat duplex is tolerated (Figure 5-2c). Based on these results, we chose the shorter 20-nt 
guide, 14-bp repeat:antirepeat duplex sgRNA architecture for downstream applications. 
Since there might be potential differences between the cell lysate and the endogenous mammalian nuclei 
environment that may affect DNA cleavage specificity, we wanted to verify whether the in vitro 5’-NNGRR(T) 
consensus PAM held for SaCas9 cleavage in mammalian cells. From SURVEYOR analysis of endogenous genome 
cleavage based on 116 distinct genomic target sites, we determined that SaCas9 could efficiently cleave genomic 
targets with a 5'-NNGRR PAM, with no requirement for the T in the 6th position (Figure 5-2d and 
Supplementary Table 9). On average, the 5'-GRR motif occurs in the human genome every 7.6-bp, allowing the 
SaCas9 to have a wide range of available targets (Supplementary Figure 19). 
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Among the Cas9 orthologs used for mammalian genome editing, SpCas9 remains the best characterized in 
targeting specificity, with consistently high editing efficiency across multiple cell types and species. For three 
targets in mouse hematoma (Hepa1-6) cells, the editing efficiency of SaCas9 performed comparably with that of 
SpCas9 (Figure 5-2e). Furthermore, we assayed genomic off-target indel mutations at highly similar genomic 
sequences(25) for both SaCas9 and SpCas9, targeting a common locus bearing an overlapping 5’-NGGRR PAM. 
At 31 genome-wide loci with sequence similarity to intended target, SaCas9 cleaved off-target sites with 
comparable activity as SpCas9 (Figure 5-2f and Supplementary Table 10). 
Adeno-associated virus delivery of SaCas9 in vivo 
Having established and validated the optimal sgRNA architecture for SaCas9 in mammalian cells, we sought to 
incorporate SaCas9 into AAV vector for in vivo use. In AAV, the small size of SaCas9 (3.2kb) leaves sufficient 
room for promoters of up to 600-bp in a dual-cassette design co-expressing SaCas9 and U6-driven sgRNA (Figure 
5-3a). The ability to apply Cas9 protein to modify endogenous loci in somatic tissues or adult animals enables 
rapid testing of gene function in the relevant tissue type and therapeutic applications for gene correction. Of the 
organs targetable by AAV, the liver is particularly attractive for demonstrating the feasibility and therapeutic 
potential of CRISPR-Cas mediated in vivo genome engineering because of its accessibility by intravascular 
delivery and its central role in many metabolic pathways important for human disease(29). We chose to target the 
mouse locus encoding proprotein convertase subtilisin/kexin type 9 (Pcsk9), an enzyme that is predominantly 
expressed in the liver and involved in cholesterol homeostasis, whose reduction has shown promise in lowering 
the risk of cardiovascular disease(30, 31).   
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Figure 5-2 in vitro characterization of Staphylococcus aureus Cas9 
(A) Schematic showing the structure of S. aureus sgRNA. Indels vary depending on (B) length of guide sequence 
or (C) repeat:anti-repeat duplex. (D) Consensus PAM for SaCas9 in HEK 293FT cells. Pooled indel values for all 
putative PAM 4-base combinations (top, n ≥ 3) and overall sequence logo (n = 116, bottom) are shown. SpCas9 
and SaCas9 cleavage efficiency comparison for (E) genomic target sites and (F) genome-wide off-target loci 
(error bars indicate Wilson intervals). Off-target (OT) sequences with significant indels are highlighted above 
graph. n = 3, error bars S.E.M unless otherwise noted; N.D. not detectable. 
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 Using AAV2/8, a highly efficient hepatotropic AAV serotype, we delivered via tail-vein injection 8×1010 viral 
particles using single-vector design containing a cytomegalovirus (CMV) promoter-driven SaCas9 and a U6 
promoter-driven sgRNA targeting Pcsk9 (Figure 5-3a, b). The percentage indel formation increased from 
approximately 5% at 1 week to 28% at 11 weeks, demonstrating the in vivo editing capabilities of SaCas9 and the 
single-vector design (Figure 5-3c). To further increase the efficiency of genome modification, we screened 
additional guides targeting Pcsk9 in Hepa1-6 cells (Supplementary Figure 20) and used a liver-specific thyroid-
binding globulin (TBG) promoter to provide greater hepatocyte specificity and expression(32, 33). After 
intravascular delivery of 2×1011 viral particles, we observed indel formation in the liver ranging from 11% at 1-
week post injection to approximately 30% at 3 weeks (Figure 5-3c-e). The Pcsk9 gene modification level remained 
consistent across samples from multiple locations within the liver, suggesting that the delivery was uniform 
throughout the target organ (Figure 5-3d). All mice survived the AAV injection and did not exhibit any signs of 
physical distress for the entire duration of the experiment. 
Discussion 
The small size and efficiency of the novel Cas9 ortholog from S. aureus paves the way for rapid and versatile in vivo 
editing while maintaining target specificity through promoter and AAV serotype selection. Furthermore, the 
method of PAM identification described here presents a generalizable approach to PAM identification amongst 
all Type II CRISPR systems. While certain Cas9 orthologs are more readily adapted for mammalian genome 
editing than others, SaCas9 cleaves endogenous targets in cells with robust efficiencies similar to those of SpCas9 
and additionally exhibits a similar degree of specificity. However, additional studies are necessary to fully 
characterize the specificity of SaCas9 as well as the effects of prolonged Cas9 in vivo expression. 
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Figure 5-3 AAV delivery of S. aureus Cas9 into live animals 
(A) Schematics illustrating AAV single-vector system (top) and experimental timeline (bottom). (B) Mouse 
Pcsk9 locus showing SaCas9 target locations. Guide sequences are highlighted in blue with PAM in magenta. (C) 
Time course of liver tissue indel formation at targets 1 and 6 post injection of AAV2/8 particles (up to 2 animals 
each; error bars represent liver tissue pieces). (D) Indel formation at target 6 at 1 and 3 weeks post-injection. Each 
lane represents a piece of liver tissue. Red triangles indicate cleavage fragments. (E) Representative 
chromatogram and indels generated by SaCas9 in vivo. 
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While the AAV-delivery of the Cas9 system is a promising step towards gene therapy applications, the more 
immediate impact lies in the efficient interrogation of genetic contributions to both normal biology and disease in 
animals beyond cell lines and transgenic models. Such somatic or postnatal genetic manipulation allows 
unprecedented spatial and temporal control of targeted gene modifications that may be developmentally 
important or inadequately controlled by conditional expression systems, as well as the ability to simulate a gradual 
accumulation of genetic mutations that could better model the natural progression of certain pathogenic 
processes. Lastly, viral vector mediated gene modification allows for significantly higher throughput of studying 
genetic variants of disease than transgenic animal generation, particularly in organisms with lengthy gestational 
and developmental periods. The in vivo opportunities made possible by the AAV delivery of the S. aureus Cas9 
described here represents another piece of the continually expanding Cas9 genome engineering toolbox that 
promises to allow rapid advances across basic science, medical, and biotechnology applications. 
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Chapter 6 Perspectives and future 
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The processes of life – an extraordinarily intricate balance of development and differentiation, adaptation and 
homeostasis, replication and senescence – are governed by an equally complex network of genetic interactions 
coupled with environmental influences. The quest to understand the causal relationships between genotype and 
phenotype in both normalcy and aberrancy has continually driven the development of technologies that have 
allowed us to ask ever more fine-mapped questions about the genome. In the past several decades, two avenues of 
advancements have had enormous impacts on our ability to study molecular processes at a more refined level. 
Accompanying the exponential growth of computing capacity, revolutions in sequencing technology, particularly 
the development of deep-sequencing platforms, have enabled the whole-genome mapping of an ever-increasing 
number of species far beyond the ensemble of traditional model organisms. As the depth of coverage increases, we 
are also able to attain a more refined understanding of the nucleotide differences among members within a 
species, tissue types within an individual, and health and disease within a cell type. This wealth of information is 
only beginning to be analyzed by groups worldwide, including the tremendously exciting and ambitious effort to 
annotate the human genome by the ENCODE consortium. However, our ability to functionally parse the 
sequences relies not only on making associations with existing variations, but observing phenotypic changes 
arising from targeted, deliberate alterations. Concurrent with the development of sequencing technologies, the 
molecular biology tools and techniques we use for interrogating gene function have been greatly expanded and 
refined. This thesis is then an account of just a part of this continued evolution, and what follows is an overview of 
the current state of the field, the continued effort at improving the technology by myself, my colleagues, and 
others, and some of my personal thoughts on exciting possibilities these technologies have opened up as well as 
some of the challenges facing genome editing. 
A new approach to genome engineering 
In the last year and half, we and others in the field have spent much of our effort focusing on the development, 
characterization, and validation of CRISPR-Cas as a viable and robust genome engineering tool. The qualities we 
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looked for in a truly useful genome editing technology were efficiency, versatility, and specificity. Though both 
ZFNs and TALENs were efficient and potentially quite specific at mediating DNA DSB, their major weaknesses 
came from their relatively high barrier to entry: a considerable amount of design and cloning was involved in the 
construction and testing of each new pair. At the time, even the most accessible TALEN technology cost about 
$5000 per target site per our own calculations. 
The groundbreaking Science study from Emmanuelle Charpentier and Jennifer Doudna on the in vitro 
characterization of the CRISPR nuclease system on the other hand had raised a tantalizing possibility for more 
generalized applications (1). The idea of a mechanism similar to RNAi for gene editing, dubbed “DNAi” by 
Virginijus Siksnys, one of the pioneers of CRISPR biology (2), had drawn enormous interest in the field, 
promising a new tool that could potentially overcome many of the challenges facing earlier generation designer 
nucleases in customizability, affordability, and simplicity of design. CRISPR technology would make it possible to 
target specific sites in the mammalian genome with merely a pair of DNA oligos designed with minimal effort that 
cost less than $30. 
In reporting the first development and demonstration of CRISPR for mammalian genome engineering, we hoped 
that this technology would further facilitate the “open-source genome engineering” begun by its TALEN and 
OPEN-ZFN predecessors, allowing any lab to carry out studies functionally validating a gene of interest, generate 
new cell lines for disease and therapeutic modeling, and manipulate model organisms at will. Given its ease of 
application, CRISPR has indeed been widely adopted and used with stunning rapidity in a host of model systems 
and species, proving itself quite efficient and versatile and perhaps even more so than ZFNs and TALENs. 
The specificity of Cas9, however, remains one of the most immediate and important questions that has yet to be 
fully addressed. In reports from bacterial CRISPR manipulation (1, 3-5) as well as our initial mammalian 
experiments, we proposed that a PAM-proximal “seed region” of 8-10 base pairs between the guide sgRNA and 
target DNA was most important to the specificity of Cas9 cleavage: mismatches within this region would disrupt 
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Cas9 cleavage. However, more comprehensive analyses reveal that while specificity is weighted toward the “seed 
region,” it is determined by a combination of factors including the number, identity, spacing, and location of 
mismatches (6, 7), and there doesn’t seem to exist a simple, generalizable design rule. Recently, Joung and 
colleagues reported potentially reduced off-target effects using “tru-sgRNAs” or sgRNAs with truncated guide 
region (e.g. 18-bp instead of 20-bp of total recognition). It is important to stress, however, that most of these 
studies were performed with predicted off-targets based on similarity to the 20-bp target sequence, and an 
unbiased, genome-wide analysis – especially in the case of tru-sgRNAs – has yet to be undertaken. Given the 
breadth of potential off-target sites and depth of coverage needed to differentiate noise from signal, such an 
undertaking based on indel analysis would remain technically exceedingly challenging. For this purpose, perhaps 
alternative approaches such as the recently reported BLESS (direct in situ breaks labeling, enrichment on 
streptavidin and next-generation sequencing) technique might be explored (8). 
Better characterization of Cas9 specificity and toxicity will be especially crucial for certain applications. One 
obvious such example is the field of gene therapy (discussed later), where unintended modifications could lead to 
disastrous consequences. In addition, effects of long term in vivo expression of Cas9 remain unknown: could the 
nuclease co-opt endogenous microRNAs, leading to unpredictable activity? Others, such as the use of dead Cas9 
as a generic DNA-binding module for transcriptional regulation, cannot rely on an obligate dimerization (double-
nicking) strategy to reduce off-target activity, and there the specificity of Cas9 or sgRNA must be better defined. 
To this end, the structural analysis of Cas9:sgRNA:DNA complex might shed light on the possibility of protein 
evolution or rational engineering; for instance, the arginine-rich “bridge helix” in the recognition domain of 
SpCas9 makes extensive non-sequence-specific contacts with the sgRNA backbone, and perhaps an analysis of 
those interactions may contribute to understanding Cas9 specificity. 
For on-target modification, one of the only known requirements for Cas9 activity is the presence of the PAM. For 
SpCas9, the 5’-NGG-3’ motif may occur frequently enough in the genome for many general applications, but 
nevertheless remains a constraint in some cases, e.g. HDR where frequency falls rapidly away from site of DSB and 
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genomic microdeletions where precise boundaries of resection are desired. For other orthologs such as St1Cas9 
(5’-NNAGAAW-3’) or NmCas9 (5’-NNNNGATT-3’), the PAM constraint becomes much more restrictive. The 
possibility of altering or removing the PAM requirement altogether would make Cas9 a truly universal 
programmable nuclease. Again, the structure study of SpCas9 and those of additional orthologs in the future 
might provide some insight on the potential importance of the C’-terminal domain in interactions with the PAM-
bearing DNA strand. It remains to be seen to what degree it may be manipulated and Cas9 chimeras generated. 
Here, the mining for metagenomic diversity of Cas9 for PAM diversity as well as enhanced enzyme specificity and 
efficiency will prove valuable. 
While Cas9 almost invariably cleaves any target with a requisite PAM, we and others have observed some 
differences in cleavage efficiency among targets and that a small number of 20-bp sites do not get cleaved by Cas9. 
Though we have observed from a limited dataset both in vitro and in cells that Cas9 does not appear to be 
sensitive to DNA methylation, other factors that influence Cas9 targeting efficiency remain largely unknown, and 
could arise from properties intrinsic to sgRNA, target DNA, or a combination thereof. Systematic studies 
examining parameters such a guide sequence thermodynamics and structure, genomic context, and chromatin 
state will likely be enlightening. 
It’s also important to note that although Cas9 has enabled the efficient and easy induction of targeted DSBs, we 
still have little control over the downstream repair events. Our ability to make ultraprecise genome modifications 
with pre-determined, predictable outcomes will likely depend on new methods to predispose the cell to undergo 
HDR rather than NHEJ. Although the use of nickase is a step towards this, the efficiency of HDR in most 
contexts, particularly in human and mouse ES cell lines, remains quite low. Meanwhile, studies overexpressing 
HDR proteins to stimulate recombination have found mixed results, with discrepancies potentially arising from 
differences in the model systems, the species from which the transgenes are derived, the dosage of overexpression, 
and the nature of the DNA damage (9-11). Thus, the development of methods for more precise temporal and 
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spatial modulation of the cellular NHEJ and HDR machinery, as well as better delivery and optimization of donor 
templates, may pave the way for higher efficiency of precision gene modification. 
The application of CRISPR-Cas for genome engineering is still nascent; nevertheless, the field has in a relatively 
short time developed a general understanding of Cas9 function and capabilities and, more importantly, begun to 
define what its limitations might be. The answers to these outstanding questions will be integral to advancing 
Cas9 as a tool for genome editing with practical and therapeutic applications.  
Even so, the use of Cas9 to address biological problems has already begun, spanning from quick, targeted 
modification of single genes (12) for functional validation and disease model generation to large-scale, unbiased 
genome-wide screens for contributing factors towards a particular phenotype (13-15). Pooled CRISPR libraries 
and multiplexed approaches represent particularly powerful methods that were previously unattainable with 
either TALENs or ZFNs and provide a more effective knockout-based alternative to genome-wide RNAi screens. 
Given the overwhelming amount of genomic data now available, the ability of CRISPR to cover both ends of the 
spectrum from precise target modification to facilitation of robust, sensitive high-throughput screens creates new 
possibilities in the study of genome structural variations, complex diseases involving multiply interacting 
pathways, and drug target identification, among others. 
Beyond genome modifications 
Beginning with the central dogma, much of twentieth century molecular biology has focused on the elucidation of 
functional genetics. We now know that beyond sequence information, there exists an additional layer of 
information not encoded within the DNA sequence proper that allows cells carrying identical information to 
evolve from a monomorphic population to a complex organism. The information encoded in the methylation of 
DNA or modification of histone proteins account for much of the observable biological variability, and their 
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aberrant regulation can lead to a wide range of diseases from developmental neuropsychiatric disorders to cancer 
(16, 17). 
The identification of the key components involved in creating the different classes of epigenetic markers, together 
with their chemical inhibitors, have allowed us to gain a basic knowledge of how these marks are established and 
maintained on a global scale as well as to appreciate how wide-spread, non-specific manipulation of these marks 
may influence key developmental pathways and cellular functions. Nevertheless, studies regarding the functional 
consequences or induction of focal epigenetic changes have been largely constrained by the limited specificity, 
efficiency, and resolution of available technologies, highlighting the need for a set of tools that can more precisely 
and easily manipulate the epigenome of any organism. 
The ease of multiplexed targeting with Cas9 is particularly attractive for targeted epigenome modifications, given 
that epigenetic regulation is characterized often not by a single mark but a clustering or a series of changes (18, 
19). Thus, coupling epigenetic effector proteins or their component domains to Cas9 – a natural extension of the 
growing Cas9 nuclease, dynamic imaging, and transcriptional modulator toolset – might offer a generalizable 
solution to epigenetic engineering. 
A means towards safer gene therapy? 
The promise of gene therapy – the idea that defective, disease-causing genes could be replaced by the exogenous 
transfer of a good copy – was first described over four decades ago (20). The development and application of gene 
therapy was unfortunately marked by two disheartening clinical trial setbacks (21) (22) that illustrate the major 
challenges in the field: first, concerns about the immunogenicity-related safety of viral vehicles needed to deliver 
the genomic material, and second, the specificity of genome editing, where genes other than the intended target 
might be inadvertently and permanently modified. 
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The in vivo editing of endogenous genes, initiated by ZFNs and TALENs, represents a paradigm shift away from 
gene replacement therapy approach: rather than transient therapies or integrating additional gene copies at 
random, this preserves the native dosage of gene expression and natural splicing variants. Currently, several 
promising studies and trials using designer nucleases are underway (23). 
Meanwhile, AAV has emerged as a promising non-integrating, non-immunogenic therapeutic vehicle. Because of 
its small payload limit, however, AAV is largely incompatible with TALENs (24). Likewise, the best characterized 
and most widely used Cas9 to date, SpCas9, remains barely under its packaging limit, leaving little room for 
promoter choice and none for sgRNA. That the smaller SaCas9 ortholog can mediate mammalian genome editing 
with efficiencies on par with SpCas9, then, is tremendously exciting. Its size allows for flexibility in the selection of 
promoters, which in combination with organ-specific AAV serotypes (25), can be exploited for further achieving 
specificity in delivery and expression. In addition to shrinking Cas9s to fit the AAV payload constraint, the 
development and validation of other novel methods for delivering Cas9 such as safe nanoparticle technologies will 
be fruitful. 
Therapeutics aside, AAV delivery of the CRISPR-Cas system has significant implications for rapid and efficient 
querying of genetic contributions to both normal biology and disease models beyond cell lines and transgenic 
animals. The ability to modify somatic tissues with tissue-specificity and temporal control could more accurately 
model certain processes, such as the post-natal introduction of mutations to simulate the accumulation of genetic 
insults that may contribute to tumorigenesis. We are thus at a fortuitous juncture of opportunities made available 
by the increasingly rapid generation of sequencing and bioinformatic data and the development, described in this 
thesis, of an effective, versatile system for their functional validation: it is my hope then that this ever-expanding 
toolset will facilitate our ability to address some of the most exciting and challenging questions in biology.   
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Supplementary Figures 
 
Supplementary Figure 1 Processing of tracrRNA in mammalian cells 
 (A) Schematic showing the design and sequences of two tracrRNA transcripts tested (short and long). Each 
transcript is driven by a U6 promoter. Transcription start site is marked as +1 and transcription terminator is as 
indicated. Blue line indicates the region whose reverse-complement sequence is used to generate northern blot 
probes for tracrRNA detection. (B) SURVEYOR assay comparing the efficiency of SpCas9-mediated cleavage of 
the EMX1 locus. Two biological replicas are shown for each tracrRNA transcript. (C) Northern blot analysis of 
total RNA extracted from 293FT cells transfected with U6 expression constructs carrying long or short tracrRNA, 
as well as SpCas9 and DR-EMX1(1)-DR. Left and right panels are from 293FT cells transfected without or with 
SpRNase III respectively. U6 indicate loading control blotted with a probe targeting human U6 snRNA. 
Transfection of the short tracrRNA expression construct led to abundant levels of the processed form of 
tracrRNA (~75bp) (11). Very low amounts of long tracrRNA are detected on the northern blot. As a result of 
these experiments, we chose to use short tracrRNA for application in mammalian cells.  
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Supplementary Figure 2 Schematic of SURVEYOR assay 
Schematic of the SURVEYOR assay used to determine Cas9-mediated cleavage efficiency. First, genomic PCR 
(gPCR) is used to amplify the Cas9 target region from a heterogeneous population of modified and unmodified 
cells, and the gPCR products are reannealed slowly to generate heteroduplexes. The reannealed heteroduplexes 
are cleaved by SURVEYOR nuclease, whereas homoduplexes are left intact. Cas9-mediated cleavage efficiency (% 
indel) is calculated based on the fraction of cleaved DNA. 
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surveyor nuclease
gel quantification
a b
c
% indel = 1 - (a + b)/(a + b + c)   *1001-(             )
indel
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Supplementary Figure 3 Processing of crRNA in mammalian cells 
 (A) Schematic showing the expression vector for a single spacer flanked by two direct repeats (DR-EMX1(1)- 
DR). The 30bp spacer targeting the human EMX1 locus protospacer 1 (Supplementary Table 1) is shown in blue 
and direct repeats are in shown in gray. Orange line indicates the region whose reverse- complement sequence is 
used to generate northern blot probes for EMX1(1) crRNA detection. (B) Northern blot analysis of total RNA 
extracted from 293FT cells transfected with U6 expression constructs carrying DR-EMX1(1)-DR. Left and right 
panels are from 293FT cells transfected without or with SpRNase III respectively. DR-EMX1(1)-DR was 
processed into mature crRNAs only in the presence of SpCas9 and short tracrRNA, and was not dependent on the 
presence of SpRNase III. The mature crRNA detected from transfected 293FT total RNA is ~33bp and is shorter 
than the 39-42bp mature crRNA from S. pyogenes (19), suggesting that the processed mature crRNA in human 
293FT cells is likely different from the bacterial mature crRNA in S. pyogenes. 
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Supplementary Figure 4 Bi-cistronic expression vectors for crRNA or chimeric RNA and SpCas9 
 
(A) Schematic showing the design of an expression vector for the pre-crRNA array. Spacers can be inserted 
between two BbsI sites using annealed oligonucleotides. Sequence design for the oligonucleotides are shown 
below with the appropriate ligation adapters indicated. (B) Schematic of the expression vector for chimeric 
crRNA. The guide sequence can be inserted between two BbsI sites using annealed oligonucleotides. The vector 
already contains the partial direct repeat (gray) and partial tracrRNA (red) sequences. WPRE, Woodchuck 
hepatitis virus post- transcriptional regulatory element. 
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Supplementary Figure 5 Selection of loci in human and mouse cells  
Schematic of the human PVALB (A) and mouse Th (B) loci and the location of the three protospacers within the 
last exon of the PVALB and Th genes, respectively. The 30-bp protospacers are indicated by black lines and the 
adjacent PAM sequences are indicated by the magenta bar. Protospacers on the sense and anti-sense strands are 
indicated above and below the DNA sequences respectively. 
  
   
 133 
 
 
Supplementary Figure 6 Distribution frequency of PAM in the human genome 
Histograms of distances between adjacent Streptococcus pyogenes SF370 type II CRISPR PAM (NGG) (A) and 
Streptococcus thermophiles LMD-9 CRISPR1 PAM (NNAGAAW) (B) in the human genome. (C) Distances for 
each PAM by chromosome. Chr, chromosome. Putative targets were identified using both the plus and minus 
strands of human chromosomal sequences. Given that there may be chromatin, DNA methylation-, RNA 
structure, and other factors that may limit the cleavage activity at some protospacer targets, it is important to note 
that the actual targeting ability might be less than the result of this computational analysis. 
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Supplementary Figure 7 Mammalian gene targeting using S. thermophilus CRISPR1 
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(A) Schematic of CRISPR locus 2 from Streptococcus thermophilus LMD-9. (B) Design of the expression system 
for the S. thermophilus CRISPR system. Human codon- optimized StCas9 is expressed using a constitutive EF1a 
promoter. Mature versions of tracrRNA and crRNA are expressed using the U6 promoter to ensure precise 
transcription initiation. Sequences for the mature crRNA and tracrRNA are shown. A single based indicated by 
the lower case “a” in the crRNA sequence was used to remove the polyU sequence, which serves as a RNA Pol III 
transcriptional terminator. Sp, spacer. (C) Schematic showing protospacer and corresponding PAM sequences 
targets in the human EMX1 locus. Two protospacer sequences are highlighted and their corresponding PAM 
sequences satisfying the NNAGAAW motif are indicated by magenta lines. Both protospacers are targeting the 
anti-sense strand. (D) SURVEYOR assay showing StCas9-mediated cleavage in the target locus. RNA guide 
spacers 1 and 2 induced 14% and 6.4% respectively. Statistical analysis of cleavage activity across biological replica 
at these two protospacer sites can be found in Supplementary Table 1. 
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Supplementary Figure 8 Multiplexed gene targeting and microdeletion with optimized sgRNAs 
(A) Multiplexed targeting of endogenous human genes using co-transfection of Cas9 and PCR amplicons 
containing U6-driven sgRNAs. (B) Microdeletion of an exon in the human EMX1 gene mediated by a pair of 
sgRNAs. Gel shows genotypes of representative transfected cells after clonal isolation and expansion, with no 
modification, mono-allelic deletion, and bi-allelic deletion. (C) Table accounting for the frequency of 
modifications using pairs of sgRNAs inducing microdeletions. 
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Supplementary Figure 9 Optimization of sgRNA architecture 
DNA expression vectors carrying SpCas9 and crRNA-tracrRNA pair or single guide RNA (sgRNA) are co-
transfected into 293FT cells. Cleavage efficiency (% indel) is assessed using the SURVEYOR nuclease assay as 
described. Modification efficiencies at (A) 2 EMX1 loci and (B) 1 PVALB locus are shown. Arrows indicate the 
expected SURVEYOR fragments. 
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Supplementary Figure 10 Electron density map 
The 2mFO – DFC electron density map around the three-way junction is shown as a gray mesh (contoured at 
2.5σ). 
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Supplementary Figure 11 The di-cysteine mutant (C80L/C574E) is functional in HEK 293FT cells 
(A) Schematic illustration of the positions of the cysteine mutations (C80L and C574E) in Cas9. (B) Sequence of 
the target site used to test the function of the C80L/C574E mutant of Cas9. The cleavage sites by the HNH and 
RuvC domains are indicated by pink and cyan triangles, respectively. (C) SURVEYOR nuclease assay, showing 
indels generated by either the wild-type or C80L/C574E mutant (n = 3). 
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Supplementary Figure 12 Schematic drawing of the secondary structural element of Cas9 
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Supplementary Figure 13 Sequence alignment of Cas9 orthologs in families II-A and II-C 
The catalytic residues are indicated by red triangles. Critical arginine residues on the Bridge helix are indicated by 
green triangles. The secondary structure of S. pyogenes Cas9 is shown above the sequences. The figure was 
prepared using ClustalW (12) and ESPript (14). Sp, S. pyogenes; Sm, Streptococcus mutans; St3, Streptococcus 
thermophilus CRISPR-3; St1, Streptococcus thermophilus CRISPR-1; Cj, Campylobacter jejuni; Nm, Neisseria 
meningitidis. 
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Supplementary Figure 14 Sequence alignment of Cas9 orthologs in families II-A, II-B, and II-C 
Thirty-five Cas9 orthologs from families IIA, IIB and IIC were aligned (BLOSUM62) and clustered (Jukes-
Cantor model Neighbor-Joining method, with S. pyogenes Cas9 as the outgroup). Bars on the top show amino 
acid conservation. In each line, the black bars show residues with at least 75% consensus, and the gray bars show 
non-conserved residues. 
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Supplementary Figure 15 Comparison of the guide:target heteroduplex with a canonical A-form RNA duplex 
The guide:target heteroduplex was superimposed on an A-form RNA duplex, based on their phosphorus atoms. 
The A-form RNA duplex is colored dark gray. Nucleotides 51–97 of the sgRNA were omitted, for clarity. 
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Supplementary Figure 16 Schematic of Type II CRISPR loci for orthologs 
Spacer or “guide” sequences are shown in blue, followed by direct repeat (gray). Predicted tracrRNAs are shown 
in red, and folded based on the Constraint Generation RNA folding model6. 
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Supplementary Figure 17 Cleavage position of Cas9 orthologs 
Stacked bar graph indicates the fraction of targets cleaved at 2, 3, 4, or 5-bp upstream of PAM for each Cas9 
ortholog; all Cas9s cleave most frequently at 3-bp upstream of PAM (red triangle). 
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Supplementary Figure 18 Mammalian endogenous gene targeting by Cas9 orthologs 
(A) SURVEYOR assays showing indel formation at human endogenous loci from co-transfection of Cas9 
orthologs and sgRNA in HEK 293FT cells. (B) SaCas9 cleaves multiple targets with high efficiency. PAM 
sequences for individual targets are shown above each lane, with consensus sequences for each Cas9 highlighted 
in red. Red triangles indicate cleaved fragments. 
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Supplementary Figure 19 PAM distribution frequency for SaCas9 
(A) Histograms of distances between adjacent Staphylococcus aureus subsp. aureus Type II CRISPR PAM 
(NNGRR) in the human genome (GRCh38). (B) Distances for each PAM by chromosome. 
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Supplementary Figure 20 SaCas9 target loci for Pcsk9 gene 
(A) Location of SaCas9 targets and PAMs within the mouse Pcsk9 gene locus. (B) Indels produced at target sites 
from transfection of mouse liver hepatoma (Hepa1-6) cell line. Red arrows indicate cleavage sites. 
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Supplementary Tables 
Supplementary Table 1 Human and mouse loci targeted in the study 
 
 
Protospacer targets designed based on Streptococcus pyogenes type II CRISPR and Streptococcus thermophilus 
CRISPR1 loci with their requisite PAMs against three different genes in human and mouse genomes. Cells were 
transfected with Cas9 and either pre- crRNA/tracrRNA or chimeric RNA. Cells were analyzed 72 hours after 
transfection. Percent indels are calculated based on SURVEYOR assay results from indicated cell lines, N = 3 for 
all protospacer targets, errors are S.E.M. N.D., not detectable using the SURVEYOR assay; N.T., not tested in this 
study. 
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Supplementary Table 2 List of paired sgRNAs used in the study 
 
          
Top strand-nicking sgRNA 
target site   
Bottom strand-nicking 
sgRNA target site   
Gene 
Overha
ng 
Length 
(bp) 
Overha
ng 
Type 
Offs
et 
Leng
th 
(bp) 
Cas9n 
with 
both 
sgRNAs 
indel 
(%) 
Guide sequence 
(5' to 3') PAM 
Top 
strand- 
sgRNA 
with WT 
Cas9 
indel 
(%) 
Guide sequence 
(5' to 3') PAM 
Bottom 
strand- 
sgRNA 
with WT 
Cas9 
indel 
(%) 
EMX1 147 3' -181 N.D. TGCGCCACCGGTTGATGTGA TGG 13.15 
AGGCCCCAGTG
GCTGCTCTG GGG 27.29 
EMX1 100 3' -134 N.D. ACTCTGCCCTCGTGGGTTTG TGG 24.7 
GAGTCCGAGCA
GAAGAAGAA GGG 21.9 
EMX1 47 3' -81 N.D. ACTCTGCCCTCGTGGGTTTG TGG 24.7 
CACGAAGCAGG
CCAATGGGG AGG 13.57 
EMX1 24 3' -58 N.D. GGAGCCCTTCTTCTTCTGCT CGG 33.17 
CAAACGGCAGA
AGCTGGAGG AGG 26.15 
EMX1 16 3' -50 N.D. GGGGCACAGATGAGAAACTC AGG 26.56 
AGGCCCCAGTG
GCTGCTCTG GGG 27.29 
EMX1 8 3' -42 N.D. GCCGTTTGTACTTTGTCCTC CGG 30.49 
TGAAGGTGTGG
TTCCAGAAC CGG 36.02 
EMX1 26 5' -8 13.7 ± 1.27 
GCCGTTTGTACT
TTGTCCTC CGG 9.82 
CAAACGGCAGA
AGCTGGAGG AGG 26.15 
EMX1 30 5' -4 19.72 ± 0.32 
GCCGTTTGTACT
TTGTCCTC CGG 30.49 
CGGCAGAAGCT
GGAGGAGGA AGG 22.06 
EMX1 31 5' -3 21.35 ± 2.23 
TCACCTGGGCCA
GGGAGGGA GGG 10.75 
TGAAGGTGTGG
TTCCAGAAC CGG 36.02 
EMX1 34 5' 0 26.89 ± 1.54 
TGCGCCACCGGT
TGATGTGA TGG 13.15 
TTGCCACGAAG
CAGGCCAAT GGG 13.77 
EMX1 38 5' 4 36.31 ± 2.97 
TGCGCCACCGGT
TGATGTGA TGG 14.49 
CACGAAGCAGG
CCAATGGGG AGG 13.57 
EMX1 51 5' 17 31.12 ± 0.25 
GGGGCACAGATG
AGAAACTC AGG 26.56 
TGAAGGTGTGG
TTCCAGAAC CGG 36.02 
EMX1 54 5' 20 32.41 ± 3.68 
GGGGCACAGATG
AGAAACTC AGG 26.56 
AGGTGTGGTTC
CAGAACCGG AGG 35.53 
EMX1 65 5' 31 13.45 ± 1.99 
TCACCTGGGCCA
GGGAGGGA GGG 10.75 
CAAACGGCAGA
AGCTGGAGG AGG 26.15 
EMX1 69 5' 35 12.39 ± 1.29 
TCACCTGGGCCA
GGGAGGGA GGG 10.75 
CGGCAGAAGCT
GGAGGAGGA AGG 22.06 
EMX1 76 5' 42 21.71 ± 1.66 
GCCGTTTGTACT
TTGTCCTC CGG 30.49 
AGGGCTCCCAT
CACATCAAC CGG 41.27 
EMX1 85 5' 51 21.89 ± 1.88 
GGGGCACAGATG
AGAAACTC AGG 26.56 
CAAACGGCAGA
AGCTGGAGG AGG 26.15 
EMX1 95 5' 61 5.88 ± 1.81 
TCACCTGGGCCA
GGGAGGGA GGG 10.75 
TGAGTCCGAGC
AGAAGAAGA AGG 29.06 
EMX1 135 5' 101 15.78 ± 2.19 
GGGGCACAGATG
AGAAACTC AGG 26.56 
AGGGCTCCCAT
CACATCAAC CGG 41.27 
EMX1 145 5' 111 N.D. TCACCTGGGCCAGGGAGGGA GGG 10.75 
TTGCCACGAAG
CAGGCCAAT GGG 13.77 
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EMX1 181 5' 147 N.D. TCACCTGGGCCAGGGAGGGA GGG 10.75 
TCACCTCCAAT
GACTAGGGT GGG 25.14 
           
EMX1 201 5' 167 N.D. GGGGCACAGATGAGAAACTC AGG 26.56 
TCACCTCCAAT
GACTAGGGT GGG 25.14 
EMX1 222 5' 188 N.D. TCACCTGGGCCAGGGAGGGA GGG 10.75 
GGCAGAGTGCT
GCTTGCTGC TGG 10.75 
EMX1 242 5' 208 N.D. GGGGCACAGATGAGAAACTC AGG 26.56 
GGCAGAGTGCT
GCTTGCTGC TGG 17.22 
DYRK1A 163 3' -197 N.D. ATCTGGTCAGAATATGATAA AGG 
10.65 ± 
2.05 
AACCTCACTTA
TCTTCTTGT AGG 
19.02 ± 
4.32 
DYRK1A 104 3' -138 N.D. GTCACTGTACTGATGTGAAT TGG 
16.71 ± 
2.47 
AACCTCACTTA
TCTTCTTGT AGG 
17.04 ± 
1.30 
DYRK1A 65 3' -99 N.D. CATCTGAAGGCCAGCAGCAT TGG 
8.82 ± 
1.01 
CTCACTTATCT
TCTTGTAGG AGG 
18.79 ± 
2.71 
DYRK1A 24 3' -58 N.D. GTCACTGTACTGATGTGAAT TGG 
17.83 ± 
0.43 
CCATGCTGCTG
GCCTTCAGA TGG 
17.15 ± 
3.29 
DYRK1A 3 3' -37 N.D. TGATAAGGCAGAAACCTGTT TGG 
4.95 ± 
0.66 
GCCAAACATAA
GTGACCAAC AGG 
16.38 ± 
3.39 
DYRK1A 18 5' -16 N.D. GAAGATAAGTGAGGTTTAAA AGG 
5.30 ± 
1.98 
AACCTCACTTA
TCTTCTTGT AGG 
24.18 ± 
3.22 
DYRK1A 21 5' -13 10.54 ± 0.63 
GTATCATTTGAC
ATATCTAA TGG 
26.90 ± 
1.17 
TGTCAAATGAT
ACAAACATT AGG 
29.69 ± 
0.86 
DYRK1A 26 5' -8 2.33 ± 0.11 
CAGCATGGAATG
AAAATGAC CGG 
3.33 ± 
0.56 
CCATGCTGCTG
GCCTTCAGA TGG 
20.43 ± 
2.40 
DYRK1A 29 5' -5 27.76 ± 0.84 
GCAGCATGGAAT
GAAAATGA CGG 
17.84 ± 
5.46 
GCTGCTGGCCT
TCAGATGGC TGG 
21.92 ± 
3.46 
DYRK1A 34 5' 0 10.42 ± 0.90 
ATCTGGTCAGAA
TATGATAA AGG 
9.13 ± 
2.32 
TCAGCAACCTC
TAACTAACC AGG 
24.14 ± 
2.95 
DYRK1A 36 5' 2 7.63 ± 0.51 
GTGCAAGCCGAA
CAGATGAA AGG 
6.65 ± 
2.19 
TCATTTTCATT
CCATGCTGC TGG 
20.61 ± 
3.64 
DYRK1A 36 5' 2 38.46 ± 0.74 
GAACTTACCTGG
TTAGTTAG AGG 
20.88 ± 
9.09 
GGAGTATCAGA
AATGACTAT TGG 
30.3 ± 
0.7 
DYRK1A 41 5' 7 34.41 ± 0.87 
GGTCACTGTACT
GATGTGAA TGG 
25.68 ± 
5.95 
GCCAAACATAA
GTGACCAAC AGG 
33.1 ± 
0.4 
DYRK1A 41 5' 7 44.22 ± 0.55 
AAAAGACCTAAA
CAAAAGAA TGG 
23.20 ± 
2.10 
TGTGTGAGGAT
AAAAGAGTT GGG 
29.4 ± 
2.7 
DYRK1A 42 5' 8 31.76 ± 1.00 
CCGGCCAAGACC
TTGAAGCC AGG 
32.50 ± 
0.50 
CTGGTTGTAGG
ATTTGAGTT AGG 
26.7 ± 
2.9 
DYRK1A 43 5' 9 38.36 ± 0.32 
TCACTGTACTGA
TGTGAATG GGG 
24.68 ± 
4.58 
GCCAAACATAA
GTGACCAAC AGG 
29.46 ± 
3.30 
DYRK1A 43 5' 9 28.97 ± 0.32 
GTTCCTTAAATA
AGAACTTT AGG 
23.60 ± 
2.56 
TGTCAAATGAT
ACAAACATT AGG 
22.4 ± 
1.6 
DYRK1A 43 5' 9 42.54 ± 1.39 
TCAGAGCTTCCT
GACACCCA TGG 
14.20 ± 
1.50 
AATACCTAGTT
ACAGGCATT TGG 
24.8 ± 
1.0 
DYRK1A 47 5' 13 11.90 ± 1.65 
TCCTACAAGAAG
ATAAGTGA AGG 
6.57 ± 
1.36 
CATGCAAACCT
TCATCTGTT CGG 
30.42 ± 
1.14 
DYRK1A 47 5' 13 34.45 ± 0.45 
TATTACAGAATG
AGAGACTG TGG 
30.90 ± 
1.40 
TTATTTCTGAA
GAATATTAA AGG 
27.6 ± 
2.5 
DYRK1A 78 5' 44 6.63 ± 0.27 
CATCTGAAGGCC
AGCAGCAT TGG 
10.02 ± 
1.17 
GCCAAACATAA
GTGACCAAC AGG 
22.92 ± 
5.16 
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DYRK1A 87 5' 53 N.D. GAAGATAAGTGAGGTTTAAA AGG 
2.90 ± 
0.82 
TCATTTTCATT
CCATGCTGC TGG 
17.30 ± 
1.62 
DYRK1A 98 5' 64 N.D. GAAGATAAGTGAGGTTTAAA AGG 
2.16 ± 
0.48 
CCATGCTGCTG
GCCTTCAGA TGG 
24.75 ± 
2.50 
DYRK1A 132 5' 98 N.D. TATCATTTGACATATCTAAT TGG 
8.21 ± 
2.83 
TCATTTTCATT
CCATGCTGC TGG 
14.61 ± 
4.10 
DYRK1A 156 5' 122 N.D. TCCTACAAGAAGATAAGTGA AGG 
9.99 ± 
4.12 
GCCAAACATAA
GTGACCAAC AGG 
19.74 ± 
2.91 
DYRK1A 192 5' 158 N.D. AACTTTTCTAACTACAAACA AGG 
5.74 ± 
2.24 
TCATTTTCATT
CCATGCTGC TGG 21.37 
GRIN2B 164 3' -198 N.D. CCAACACCAACCAGAACTTG GGG 
2.95 ± 
0.21 
CTGGTAGATGG
AGTTGGGTT TGG 
17.25 ± 
1.30 
GRIN2B 66 3' -100 N.D. ACAGCAATGCCAATGCTGGG GGG 
18.00 ± 
2.31 
AGTGCTGTTCT
CCCAAGTTC TGG 
28.64 ± 
0.69 
GRIN2B 41 3' -75 N.D. GTGGAAATCATCTTTCTCGT TGG 
14.56 ± 
7.84 
GGCATTGCTGT
CATCCTCGT GGG 
21.26 ± 
2.68 
GRIN2B 15 3' -49 N.D. TCTGCTGCCTGACACGGCCA AGG 
4.24 ± 
0.79 
TCCCAAGTTCT
GGTTGGTGT TGG 
19.64 ± 
0.23 
GRIN2B 1 3' -35 N.D. CGAGCTCTGCTGCCTGACAC CGG 
2.99 ± 
0.31 
TTGGCCGTCCT
GGCCGTGTC AGG 
4.74 ± 
0.15 
GRIN2B 10 5' -24 1.04 ± 0.53 
TCCTTGATGGCC
ACCTCGTC CGG 
2.25 ± 
1.08 
TTCCGACGAGG
TGGCCATCA AGG 
17.13 ± 
2.90 
GRIN2B 19 5' -15 5.93 ± 1.25 
ATGACAGCAATG
CCAATGCT TGG 
16.46 ± 
2.28 
TGGCATTGCTG
TCATCCTCG TGG 
16.35 ± 
1.25 
GRIN2B 24 5' -10 2.28 ± 0.34 
AGCAATGCCAAT
GCTGGGGG GGG 
3.19 ± 
0.51 
TGGCATTGCTG
TCATCCTCG TGG 
15.17 ± 
2.02 
GRIN2B 29 5' -5 1.45 ± 0.12 
GCCAACACCAAC
CAGAACTT TGG 
17.80 ± 
2.30 
TTGGCCGTCCT
GGCCGTGTC AGG 
4.46 ± 
1.35 
GRIN2B 31 5' -3 11.80 ± 0.29 
GGAGAACAGCAC
TCCGCTCT TGG 
21.80 ± 
1.40 
TCCCAAGTTCT
GGTTGGTGT TGG 
21.33 ± 
0.63 
GRIN2B 34 5' 0 24.24 ± 0.23 
ATGACAGCAATG
CCAATGCT TGG 
19.48 ± 
1.88 
CCTCGTGGGCA
CTTCCGACG AGG 
21.19 ± 
3.42 
GRIN2B 35 5' 1 20.83 ± 0.95 
TGACAGCAATGC
CAATGCTG GGG 
21.44 ± 
3.02 
CCTCGTGGGCA
CTTCCGACG AGG 
24.11 ± 
0.14 
GRIN2B 39 5' 5 9.60 ± 0.25 
AGCAATGCCAAT
GCTGGGGG GGG 
4.19 ± 
0.58 
CCTCGTGGGCA
CTTCCGACG AGG 
21.78 ± 
1.70 
GRIN2B 46 5' 12 18.96 ± 0.93 
ATGACAGCAATG
CCAATGCT TGG 
20.45 ± 
0.98 
TTCCGACGAGG
TGGCCATCA AGG 
13.21 ± 
0.74 
GRIN2B 51 5' 17 5.33 ± 0.57 
AGCAATGCCAAT
GCTGGGGG GGG 
4.93 ± 
2.06 
TTCCGACGAGG
TGGCCATCA AGG 
12.51 ± 
1.21 
GRIN2B 90 5' 56 7.31 ± 0.83 
GAGAACAGCACT
CCGCTCTG GGG 
3.09 ± 
0.54 
CAGAAGAGCCC
CCCCAGCAT TGG 
25.02 ± 
1.86 
GRIN2B 106 5' 72 10.56 ± 1.21 
GCCAACACCAAC
CAGAACTT TGG 
25.29 ± 
1.65 
CGTGGGCACTT
CCGACGAGG TGG 
23.32 ± 
0.78 
GRIN2B 133 5' 99 2.66 ± 0.89 
CTGCCTGACACG
GCCAGGAC CGG 
4.34 ± 
0.62 
TGATTTCCACC
ATCTCTCCG TGG 
20.95 ± 
0.79 
GRIN2B 176 5' 142 N.D. GAGAACAGCACTCCGCTCTG GGG 
2.96 ± 
0.93 
TGATTTCCACC
ATCTCTCCG TGG 
19.77 ± 
2.20 
GRIN2B 232 5' 198 N.D. CTGCCTGACACGGCCAGGAC CGG 
6.17 ± 
2.09 
TGACCGGAAGA
TCCAGGGGG TGG 
23.36 ± 
2.34 
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MeCP2 38 5' 4 12.16 ± 2.58 
GTCCAACCTTCA
GGCAAGGT GGG 
24.11 ± 
3.48 
AAGCTTAAACA
AAGGAAGTC TGG 
35.76 ± 
2.65 
MeCP2 34 5' 0 11.72 ± 2.40 
GCGCTGTTTGGG
GGAAGCCG AGG N.T 
GGCTCCATTAT
CCGTGACCG GGG N.T 
VEGFA 50 5' 16  23.92 ± 0.54 
GGGTGGGGGGAG
TTTGCTCC TGG 
14.15 ± 
1.07 
TCCCTCTTTAG
CCAGAGCCG GGG 
33.59 ± 
0.88 
VEGFA 54 5' 20 16.32 ± 1.01 
GACCCCCTCCAC
CCCGCCTC CGG 
24.52 ± 
1.80 
GAAACTTTTCG
TCCAACTTC TGG 
10.45 ± 
1.14 
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Supplementary Table 3 List of sgRNAs used in the study 
 
Gene sgRNA ID Guide sequence (5' to 3') PAM Strand Species 
EMX1 1 GAGTCCGAGCAGAAGAAGAA GGG + H. sapiens 
EMX1 2 GGAAGGGCCTGAGTCCGAGCAGAAGAAGAA GGG + H. sapiens 
EMX1 3 GGCCTCCAAGGAGTCCGAGCAGAAGAAGAA GGG + H. sapiens 
EMX1 4 AGGCCCCAGTGGCTGCTCTG GGG + H. sapiens 
EMX1 5 GGGGCACAGATGAGAAACTC AGG —	   H. sapiens 
EMX1 6 TCACCTGGGCCAGGGAGGGA GGG —	   H. sapiens 
EMX1 7 TGAAGGTGTGGTTCCAGAAC CGG +	   H. sapiens 
EMX1 8 AGGTGTGGTTCCAGAACCGG AGG +	   H. sapiens 
EMX1 9 GCCGTTTGTACTTTGTCCTC CGG — H. sapiens 
EMX1 10 CAAACGGCAGAAGCTGGAGG AGG + H. sapiens 
EMX1 11 CGGCAGAAGCTGGAGGAGGA AGG + H. sapiens 
EMX1 12 TGAGTCCGAGCAGAAGAAGA AGG + H. sapiens 
EMX1 13 GGAGCCCTTCTTCTTCTGCT CGG — H. sapiens 
EMX1 14 AGGGCTCCCATCACATCAAC CGG + H. sapiens 
EMX1 15 TGCGCCACCGGTTGATGTGA TGG — H. sapiens 
EMX1 16 TTGCCACGAAGCAGGCCAAT GGG +	   H. sapiens 
EMX1 17 CACGAAGCAGGCCAATGGGG AGG +	   H. sapiens 
EMX1 18 TCACCTCCAATGACTAGGGT GGG +	   H. sapiens 
EMX1 19 GGCAGAGTGCTGCTTGCTGC TGG +	   H. sapiens 
EMX1 20 GACATCGATGTCCTCCCCAT TGG —	   H. sapiens 
EMX1 21 GTCACCTCCAATGACTAGGG TGG + H. sapiens 
EMX1 22 GGGCAACCACAAACCCACGA GGG + H. sapiens 
EMX1 23 ACTCTGCCCTCGTGGGTTTG TGG — H. sapiens 
EMX1 24 CAAGCAGCACTCTGCCCTCG TGG — H. sapiens 
EMX1 25 TTCTTCTTCTGCTCGGACTC AGG — H. sapiens 
EMX1 26 CTCCCCATTGGCCTGCTTCG AGG — H. sapiens 
EMX1 27 GTCACCTCCAATGACTAGGG TGG + H. sapiens 
DYRK1A 28 GAACTTACCTGGTTAGTTAG AGG — H. sapiens 
DYRK1A 29 GGAGTATCAGAAATGACTAT TGG + H. sapiens 
DYRK1A 30 GGTCACTGTACTGATGTGAA TGG — H. sapiens 
DYRK1A 31 GCCAAACATAAGTGACCAAC AGG + H. sapiens 
DYRK1A 32 GTTCCTTAAATAAGAACTTT AGG — H. sapiens 
DYRK1A 33 TGTCAAATGATACAAACATT AGG + H. sapiens 
DYRK1A 34 ATCTGGTCAGAATATGATAA AGG — H. sapiens 
DYRK1A 35 GTCACTGTACTGATGTGAAT TGG — H. sapiens 
DYRK1A 36 CATCTGAAGGCCAGCAGCAT TGG — H. sapiens 
DYRK1A 37 TGATAAGGCAGAAACCTGTT TGG — H. sapiens 
DYRK1A 38 GAAGATAAGTGAGGTTTAAA AGG — H. sapiens 
DYRK1A 39 GTATCATTTGACATATCTAA TGG — H. sapiens 
DYRK1A 40 CAGCATGGAATGAAAATGAC CGG — H. sapiens 
DYRK1A 41 GCAGCATGGAATGAAAATGA CGG — H. sapiens 
DYRK1A 42 GTGCAAGCCGAACAGATGAA AGG — H. sapiens 
DYRK1A 43 TCACTGTACTGATGTGAATG GGG — H. sapiens 
DYRK1A 44 TCCTACAAGAAGATAAGTGA AGG — H. sapiens 
DYRK1A 45 TATCATTTGACATATCTAAT TGG — H. sapiens 
DYRK1A 46 AACTTTTCTAACTACAAACA AGG — H. sapiens 
DYRK1A 47 AACCTCACTTATCTTCTTGT AGG + H. sapiens 
DYRK1A 48 CTCACTTATCTTCTTGTAGG AGG + H. sapiens 
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DYRK1A 49 CCATGCTGCTGGCCTTCAGA TGG + H. sapiens 
DYRK1A 50 GCTGCTGGCCTTCAGATGGC TGG + H. sapiens 
DYRK1A 51 TCAGCAACCTCTAACTAACC AGG + H. sapiens 
DYRK1A 52 TCATTTTCATTCCATGCTGC TGG + H. sapiens 
DYRK1A 53 CATGCAAACCTTCATCTGTT CGG + H. sapiens 
DYRK1A 54 TATTACAGAATGAGAGACTG TGG — H. sapiens 
DYRK1A 55 TTATTTCTGAAGAATATTAA AGG + H. sapiens 
DYRK1A 56 AAAAGACCTAAACAAAAGAA TGG — H. sapiens 
DYRK1A 57 TGTGTGAGGATAAAAGAGTT GGG + H. sapiens 
DYRK1A 58 CCGGCCAAGACCTTGAAGCC AGG — H. sapiens 
DYRK1A 59 CTGGTTGTAGGATTTGAGTT AGG + H. sapiens 
DYRK1A 60 TCAGAGCTTCCTGACACCCA TGG — H. sapiens 
DYRK1A 61 AATACCTAGTTACAGGCATT TGG + H. sapiens 
GRIN2B 62 GGTGATGATGCTCTTTGGGT CGG — H. sapiens 
GRIN2B 63 TCTGTGATCTCATGTCTGAC CGG + H. sapiens 
GRIN2B 64 CAGCAATGCCAATGCTGGGG GGG — H. sapiens 
GRIN2B 65 CCTCGTGGGCACTTCCGACG AGG + H. sapiens 
GRIN2B 66 TTTCTCGTGGGCATCCTTGA TGG — H. sapiens 
GRIN2B 67 TGATTTCCACCATCTCTCCG TGG + H. sapiens 
GRIN2B 68 GGAGAACAGCACTCCGCTCT GGG — H. sapiens 
GRIN2B 69 CTGGTTGGTGTTGGCCGTCC TGG + H. sapiens 
GRIN2B 70 CCAACACCAACCAGAACTTG GGG — H. sapiens 
GRIN2B 71 ACAGCAATGCCAATGCTGGG GGG — H. sapiens 
GRIN2B 72 GTGGAAATCATCTTTCTCGT TGG — H. sapiens 
GRIN2B 73 TCTGCTGCCTGACACGGCCA AGG — H. sapiens 
GRIN2B 74 CGAGCTCTGCTGCCTGACAC CGG — H. sapiens 
GRIN2B 75 TCCTTGATGGCCACCTCGTC CGG — H. sapiens 
GRIN2B 76 ATGACAGCAATGCCAATGCT TGG — H. sapiens 
GRIN2B 77 AGCAATGCCAATGCTGGGGG GGG — H. sapiens 
GRIN2B 78 GCCAACACCAACCAGAACTT TGG — H. sapiens 
GRIN2B 79 TGACAGCAATGCCAATGCTG GGG — H. sapiens 
GRIN2B 80 GAGAACAGCACTCCGCTCTG GGG — H. sapiens 
GRIN2B 81 CTGCCTGACACGGCCAGGAC CGG — H. sapiens 
GRIN2B 82 CTGGTAGATGGAGTTGGGTT TGG + H. sapiens 
GRIN2B 83 AGTGCTGTTCTCCCAAGTTC TGG + H. sapiens 
GRIN2B 84 GGCATTGCTGTCATCCTCGT GGG + H. sapiens 
GRIN2B 85 TCCCAAGTTCTGGTTGGTGT TGG + H. sapiens 
GRIN2B 86 TTGGCCGTCCTGGCCGTGTC AGG + H. sapiens 
GRIN2B 87 TTCCGACGAGGTGGCCATCA AGG + H. sapiens 
GRIN2B 88 TGGCATTGCTGTCATCCTCG TGG + H. sapiens 
GRIN2B 89 CAGAAGAGCCCCCCCAGCAT TGG + H. sapiens 
GRIN2B 90 CGTGGGCACTTCCGACGAGG TGG + H. sapiens 
GRIN2B 91 TGACCGGAAGATCCAGGGGG TGG + H. sapiens 
MeCP2 92 GTCCAACCTTCAGGCAAGGT GGG — M. musculus 
MeCP2 93 AAGCTTAAACAAAGGAAGTC TGG + M. musculus 
MeCP2 94 GCGCTGTTTGGGGGAAGCCG AGG — M. musculus 
MeCP2 95 GGCTCCATTATCCGTGACCG GGG + M. musculus 
VEGFA 96 GGGTGGGGGGAGTTTGCTCC TGG — H. sapiens 
VEGFA 97 TCCCTCTTTAGCCAGAGCCG GGG + H. sapiens 
VEGFA 98 GACCCCCTCCACCCCGCCTC CGG — H. sapiens 
VEGFA 99 GAAACTTTTCGTCCAACTTC TGG + H. sapiens 
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Supplementary Table 4 Data collection and refinement statistics 
 
 
Native Cas9 SeMet Cas9 
Data collection   
Beamline SPring-8 BL32XU SPring-8 BL41XU 
Wavelength (Å) 1.0000 0.97911 
Space group P1 P1 
Cell dimensions     
a, b, c (Å) 76.7, 105.7, 126.8 76.2, 104.5, 125.5 
α, β, γ  (°)  97.7, 98.4, 100.3 97.0, 98.2, 101.1 
Resolution (Å) 50–2.5 50–2.6 
  (2.65–2.5)  (2.67–2.6) 
Rsym 0.06 (1.06) 0.17 (1.96) 
I/σI 25.3 (2.1) 12.6 (1.4) 
Completeness (%) 98.2 (96.2) 99.9 (99.9) 
Redundancy 7.9 (7.9) 19.1 (15.9) 
CC(1/2) 1.00 (0.795) 1.00 (0.736) 
   
Refinement   
Resolution (Å) 50–2.5  
No. reflections 130,396  
Rwork/ Rfree 0.222 / 0.253  
No. atoms   
    Protein 18,997  
    Nucleic acid 5,012  
    Solvent 144  
B-factors (Å2)   
    Protein 80.2  
    Nucleic acid 82.4  
    Solvent 51.4  
R.m.s. deviations   
    Bond lengths (Å)  0.002  
    Bond angles (º) 0.526  
Ramachandran plot   
    Favored region 97.0%  
    Allowed region 3.0%  
    Outlier region 0.0%  
*Highest resolution shell is shown in parentheses. 
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Supplementary Table 5 List of sgRNA pairs used with Cas9 nickases 
 
  sgRNA 1 target site sgRNA 2 target site 
Gene Offset length (bp) Guide sequence (5' to 3') PAM Guide sequence (5' to 3') PAM 
EMX1 20 GGGGCACAGATGAGAAACTC AGG AGGTGTGGTTCCAGAACCGG AGG 
EMX1 17 GGGGCACAGATGAGAAACTC AGG TGAAGGTGTGGTTCCAGAAC CGG 
EMX1 4 TGCGCCACCGGTTGATGTGA TGG CACGAAGCAGGCCAATGGGG AGG 
EMX1 0 TCACCTGGGCCAGGGAGGGA GGG AGGTGTGGTTCCAGAACCGG AGG 
EMX1 -29 GGGCAACCACAAACCCACGA GGG ACTCTGCCCTCGTGGGTTTG TGG 
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Supplementary Table 6 List of Cas9 orthologs and predicted RNA components 
 
Cas9 class direct repeat tracrRNA sgRNA 
P. lavamentivorans IIC GCUGCGGAU
UGCGGCCGU
CUCUCGAUU
UGCUACUCU 
UAGCAAAUCGAGAGGCGGUCGCUU
UUCGCAAGCAAAUUGACCCCUUGU
GCGGGCUCGGCAUCCCAAGGUCAG
CUGCCGGUUAUUAUCGAAAAGGCC
CACCGCAAGCAGCGCGUGGGCCUU
UUU 
GCUGCGGAUUGCGGGAA
AUCGCUUUUCGCAAGCA
AAUUGACCCCUUGUGCG
GGCUCGGCAUCCCAAGG
UCAGCUGCCGGUUAUUA
UCGAAAAGGCCCACCGC
AAGCAGCGCGUGGGCCU
UUU 
C. diphtheriae IIC ACUGGGGUU
CAGUUCUCA
AAAACCCUG
AUAGACUUC 
AGUCACUAACUUAAUUAAAUAGAA
CUGAACCUCAGUAAGCAUUGGCUC
GUUUCCAAUGUUGAUUGCUCCGCC
GGUGCUCCUUAUUUUUAAGGGCGC
CGGCUUUCUU 
ACUGGGGUUCAGGAAAC
UGAACCUCAGUAAGCAU
UGGCUCGUUUCCAAUGU
UGAUUGCUCCGCCGGUG
CUCCUUAUUUUUAAGGG
CGCCGGCUUUU 
S. pasteurianus IIA GUUUUUGUA
CUCUCAAGA
UUUAAGUAA
CCGUAAAAC 
CUUGCACGGUUACUUAAAUCUUGC
UGAGCCUACAAAGAUAAGGCUUUA
UGCCGAAUUCAAGCACCCCAUGUU
UUGACAUGAGGUGCUUUU 
GUUUUUGUACUCGAAAG
AGCCUACAAAGAUAAGG
CUUUAUGCCGAAUUCAA
GCACCCCAUGUUUUGAC
AUGAGGUGCUUUU 
N. cinerea IIC GUUGUAGCU
CCCAUUCUC
AUUUCGCAG
UGCUACAAU 
AUUGUCGCACUGCGAAAUGAGAAC
CGUUGCUACAAUAAGGCCGUCUGA
AAAGAUGUGCCGCAACGCUCUGCC
CCUUAAAGCUUCUGCUUUAAGGGG
CAUCGUUUAUUUCGGUUAAAAAUG
CCGUCUGAAACCGGUUUUU 
GUUGUAGCUCCCAUUCU
CGAAAGAGAACCGUUGC
UACAAUAAGGCCGUCUG
AAAAGAUGUGCCGCAAC
GCUCUGCCCCUUAAAGC
UUCUGCUUUAAGGGGCA
UCGUUUAUUUCGGUUAA
AAAUGCCGUCUGAAACC
GGUUUUUAGGUUUCAGA
CGGCAUUUU 
S. aureus IIA GUUUUAGUA
CUCUGUAAU
UUUAGGUAU
GAGGUAGAC 
AUUGUACUUAUACCUAAAAUUACA
GAAUCUACUAAAACAAGGCAAAAU
GCCGUGUUUAUCUCGUCAACUUGU
UGGCGAGAUUUUU 
GUUUUAGUACUCUGGAA
ACAGAAUCUACUAAAAC
AAGGCAAAAUGCCGUGU
UUAUCUCGUCAACUUGU
UGGCGAGAUUUU 
C. lari IIC GUUUUAGUC
UCUUUUUAA
AUUUCUUUA
UGAUAAAAU 
AAUUCUUGCUAAAGAAAUUUAAAA
AGAGACUAAAAUAAGUGGUUUUUG
GUCAUCCACGCAGGGUUACAAUCC
CUUUAAAACCAUUAAAAUUCAAAU
AAACUAGGUUGUAUCAACUUAGUU
UUUU 
GUUUUAGUCUCUGAAAA
GAGACUAAAAUAAGUGG
UUUUUGGUCAUCCACGC
AGGGUUACAAUCCCUUU
AAAACCAUUAAAAUUCA
AAUAAACUAGGUUGUAU
CAACUUAGUUUU 
S. pyogenes IIA GUUUUAGAG
CUAUGCUGU
UUUGAAUGG
UCCCAAAAC 
GUUGGAACCAUUCAAAACAGCAUA
GCAAGUUAAAAUAAGGCUAGUCCG
UUAUCAACUUGAAAAAGUGGCACC
GAGUCGGUGCUUUUU 
GUUUUAGAGCUAGAAAU
AGCAAGUUAAAAUAAGG
CUAGUCCGUUAUCAACU
UGAAAAAGUGGCACCGA
GUCGGUGCUUUU 
S. thermophilus IIA GUUUUUGUA
CUCUCAAGA
UUUAAGUAA
CUGUACAAC 
CUUACACAGUUACUUAAAUCUUGC
AGAAGCUACAAAGAUAAGGCUUCA
UGCCGAAAUCAACACCCUGUCAUU
UUAUGGCAGGGUGUUUU 
GUUUUUGUACUCGAAAG
AAGCUACAAAGAUAAGG
CUUCAUGCCGAAAUCAA
CACCCUGUCAUUUUAUG
GCAGGGUGUUUU 
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Supplementary Table 7 Targets used for in vitro (cell lysate) PAM validation 
 
Cas9 Consensus in vitro lysate targets (Dyrk1a) PAM Gene (PCR amplicon) 
P. lavamentivorans NNNCATN TAATCACTATGGATCTTCTA TACCATT DYRK1A 
P. lavamentivorans NNNCATN TCTTGTAGGAGGAGAGACTT CAGCATG DYRK1A 
C. diphtheriae NGGNNNN GGTGCAAGCCGAACAGATGA TGGACAG DYRK1A 
C. diphtheriae NGGNNNN TATCCTAAAGTTCTTATTTA AGGTTTG DYRK1A 
S. pasteurianus NNGTGAN TTAATTTATGAAAATCTCGT AGGTGAA DYRK1A 
S. pasteurianus NNGTGAN ATGCCCCATTCACATCAGTA CAGTGAC DYRK1A 
N. cinerea NNNNGAT GTGTTGAGTAACATATACCT GTTTGTA DYRK1A 
N. cinerea NNNNGAT TAACTAACCAGGTAAGTTCA TGGAGTA DYRK1A 
S. aureus NNGRRNN AATGATACAAACATTAGGAT ATGAATA DYRK1A 
S. aureus NNGRRNN ATGTCAAATGATACAAACAT TAGGATA DYRK1A 
C. lari NNGGGNN GGTCACTGTACTGATGTGAA TGGGGCA DYRK1A 
C. lari NNGGGNN CGGTCACTGTACTGATGTGA ATGGGGC DYRK1A 
S. pyogenes NGGNNNN TGTCAAATGATACAAACATT AGGATAT DYRK1A 
S. pyogenes NGGNNNN AACCTCACTTATCTTCTTGT AGGAGGA DYRK1A 
S. thermophilus NNAGAAW CCAGGTAAGTTCATGGAGTA TCAGAAA DYRK1A 
S. thermophilus NNAGAAW TAACATATACCTGTTTGTAG TTAGAAA DYRK1A 
 
 
  
   
 161 
Supplementary Table 8 Targets used for testing ortholog activity in human cells 
 
Cas9 Consensus Targets PAM Gene Cell type indel (%) 
C. diphtheriae NGGNNNN TCACCTCCAATGACTAGGGT GGGCAAC EMX1 293FT N.D. 
C. diphtheriae NGGNNNN TGACGGTGCAAGCCGAACAGATGA TGGACAG DYRK1A 293FT N.D. 
C. diphtheriae NGGNNNN ACCTGGTGGGCGACGTGCTG GGGAGTC DYRK1A 293FT N.D. 
C. diphtheriae NGGNNNN ATGGAGCAGTCTCAGTCTTC GGGCACC DYRK1A 293FT N.D. 
N. cinerea NNNNGAT GAATGAAAATGACGGTGCAAGCCG AACAGAT DYRK1A 293FT N.D. 
N. cinerea NNNNGAT TTAATGGTATAGAAGATCCA TAGTGAT DYRK1A 293FT N.D. 
C. lari NNGGGNN TGTCACCTCCAATGACTAGG GTGGGCA EMX1 293FT N.D. 
C. lari NNGGGNN CCATGGAGCAGTCTCAGTCT TCGGGCA DYRK1A 293FT N.D. 
C. lari NNGGGNN GCACCAGCATCGGCACAGTG GTGGGCA DYRK1A 293FT N.D. 
C. lari NNGGGNN CGACGGTCACTGTACTGATGTGAA TGGGGCA DYRK1A 293FT N.D. 
P. lavamentivorans NNNCATN CCGAGCAGAAGAAGAAGGGC TCCCATC EMX1 293FT N.D. 
P. lavamentivorans NNNCATN ATTTTAATCACTATGGATCTTCTA TACCATT DYRK1A 293FT N.D. 
P. lavamentivorans NNNCATN CCAAAACTCGAATTCAACCT GGTCATA DYRK1A 293FT N.D. 
P. lavamentivorans NNNCATN TGCAGCACAGTTTCTTCAAG GAGCATA DYRK1A 293FT N.D. 
S. pasteurianus NNGTGAN GTTCTTAATTTATGAAAATCTCGT AGGTGAA DYRK1A 293FT N.D. 
S. pyogenes NGGNNNN GAGTCCGAGCAGAAGAAGAA GGGCTCC EMX1 293FT 33.3 
S. pyogenes NGGNNNN TGACGGTGCAAGCCGAACAGATGA TGGACAG DYRK1A 293FT 3.0 
S. pyogenes NGGNNNN ATCAGAAAAGAAAGAACAGC TGGAGTC Sqle Hepa1-6 14.5 
S. pyogenes NGGNNNN GCAACAACAAGATCTGTGGC TGGAATT HmgCR Hepa1-6 13.5 
S. pyogenes NGGNNNN TGTTCCCACAATAACTTCCC AGGGGTG HmgCR Hepa1-6 11.6 
S. thermophilus NNAGAAW TGAGTAACATATACCTGTTTGTAG TTAGAAA DYRK1A 293FT 5.0 
S. aureus NNGRRNN CAACCACAAACCCACGAGGG CAGAGTG EMX1 293FT 15.9 
S. aureus NNGRRNN TAGGGTTAGGGGCCCCAGGC CGGGGTC EMX1 293FT 13.0 
S. aureus NNGRRNN CCTCTAACTAACCAGGTAAGTTCA TGGAGTA DYRK1A 293FT 6.7 
S. aureus NNGRRNN TAAGAGAGTAGGCTGGTAGA TGGAGTT GRIN2B 293FT 24.2 
S. aureus NNGRRNN GAGTAGGCTGGTAGATGGAG TTGGGTT GRIN2B 293FT 31.7 
S. aureus NNGRRNN GTTGAAGATGAAGCCCAGAG CGGAGTG GRIN2B 293FT 13.4 
S. aureus NNGRRNN TGGATGCCCAGGATGGGGGT GAGAGTA GRIN2B 293FT 18.7 
S. aureus NNGRRNN AAAGAAAGAGCATGTTAAAA TAGGATA GRIN2B 293FT N.D. 
S. aureus NNGRRNN TCAGACATGAGATCACAGAT GCGGGTG GRIN2B 293FT 29.3 
S. aureus NNGRRNN GATGCGGGTGATGATGCTCT TTGGGTC GRIN2B 293FT 17.6 
S. aureus NNGRRNN TCATGGCTACCAGTTCCACC CGGGGTA GRIN2B 293FT 26.6 
S. aureus NNGRRNN CCCGGGTGGAACTGGTAGCC ATGAATG GRIN2B 293FT 26.2 
S. aureus NNGRRNN CTTCCGACGAGGTGGCCATC AAGGATT GRIN2B 293FT 7.6 
S. aureus NNGRRNN CACCATCTCTCCGTGGTACC CCGGGTG GRIN2B 293FT 18.2 
S. aureus NNGRRNN ATCTCTTAGATACCAGCATC CAGGGTG Pcsk9 Hepa1-6 4.6 
S. aureus NNGRRNN TCAATCTCCCGATGGGCACC CTGGATG Pcsk9 Hepa1-6 2.6 
S. aureus NNGRRNN GCCCATCGGGAGATTGAGGG CAGGGTC Pcsk9 Hepa1-6 9.7 
S. aureus NNGRRNN ACTTCAACAGCGTGCCGGAG GAGGATG Pcsk9 Hepa1-6 6.2 
S. aureus NNGRRNN CCGCTGACCACACCTGCCAG GTGGGTG Pcsk9 Hepa1-6 8.3 
S. aureus NNGRRNN TGGCAGGTGTGGTCAGCGGC CGGGATG Pcsk9 Hepa1-6 3.4 
S. aureus NNGRRNN ATCAGAAAAGAAAGAACAGC TGGAGTC Sqle Hepa1-6 21.1 
S. aureus NNGRRNN GCAACAACAAGATCTGTGGC TGGAATT HmgCR Hepa1-6 7.1 
S. aureus NNGRRNN TGTTCCCACAATAACTTCCC AGGGGTG HmgCR Hepa1-6 9.5 
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Supplementary Table 9 Targets used for SaCas9 PAM determination in mammalian cells 
 
Cas9 Targets PAM Gene Cell type indel (%) 
S. aureus GAGGACCGCCCTGGGCCTGG GAGAAT Rosa26 Hepa1-6 9 
S. aureus CACGAGGGGAAGAGGGGGCA AGGGAT Rosa26 Hepa1-6 12 
S. aureus CGCCCATCTTCTAGAAAGAC TGGAGT Rosa26 Hepa1-6 16 
S. aureus AGTCTTTCTAGAAGATGGGC GGGAGT Rosa26 Hepa1-6 14 
S. aureus GTGTGGGCGTTGTCCTGCAG GGGAAT Rosa26 Hepa1-6 13 
S. aureus TAGGGGCAAATAGGAAAATG GAGGAT Rosa26 Hepa1-6 0 
S. aureus CAAATAGGAAAATGGAGGAT AGGAGT Rosa26 Hepa1-6 24 
S. aureus AATGGAGGATAGGAGTCATC TGGGGT Rosa26 Hepa1-6 17 
S. aureus TCCTCATGGAAATCTCCGAG GCGGAT Rosa26 Hepa1-6 17 
S. aureus AGGAGATAAAGACATGTCAC CCGAGT Rosa26 Hepa1-6 0 
S. aureus CTAAGCAGGAGAGTATAAAC TCGGGT Rosa26 HEK 293FT 0 
S. aureus CTGTAGTAGGATCTAAGCAG GAGAGT Rosa26 HEK 293FT 0 
S. aureus CACTGTATTTCATACTGTAG TAGGAT Rosa26 HEK 293FT 0 
S. aureus CTGCAGAAGGAGCGGGAGAA ATGGAT Rosa26 HEK 293FT 17 
S. aureus GAGTGTTGCAATACCTTTCT GGGAGT Rosa26 HEK 293FT 17 
S. aureus CCTGGACACCCCGTTCTCCT GTGGAT AAVS1 HEK 293FT 5 
S. aureus ACAGCATGTTTGCTGCCTCC AGGGAT AAVS1 HEK 293FT 13 
S. aureus GTGGTCCCAGCTCGGGGACA CAGGAT AAVS1 HEK 293FT 30 
S. aureus CGGTTAATGTGGCTCTGGTT CTGGGT AAVS1 HEK 293FT 35 
S. aureus TGTCCCTAGTGGCCCCACTG TGGGGT AAVS1 HEK 293FT 31 
S. aureus TCCTTCCTAGTCTCCTGATA TTGGGT AAVS1 HEK 293FT 34 
S. aureus CCTGAAGTGGACATAGGGGC CCGGGT AAVS1 HEK 293FT 0 
S. aureus GAGAGATGGCTCCAGGAAAT GGGGGT AAVS1 HEK 293FT 16 
S. aureus TTGCTTACGATGGAGCCAGA GAGGAT AAVS1 HEK 293FT 0 
S. aureus GAGCCACATTAACCGGCCCT GGGAAT AAVS1 HEK 293FT 32 
S. aureus CACAGTGGGGCCACTAGGGA CAGGAT AAVS1 HEK 293FT 27 
S. aureus GACTAGGAAGGAGGAGGCCT AAGGAT AAVS1 HEK 293FT 23 
S. aureus GAATCTGCCTAACAGGAGGT GGGGGT AAVS1 HEK 293FT 26 
S. aureus TGGGGGTGTGTCACCAGATA AGGAAT AAVS1 HEK 293FT 15 
S. aureus CCCTGCCAAGCTCTCCCTCC CAGGAT AAVS1 HEK 293FT 18 
S. aureus CTGGGAGGGAGAGCTTGGCA GGGGGT AAVS1 HEK 293FT 0 
S. aureus CAGGGGGTGGGAGGGAAGGG GGGGAT AAVS1 HEK 293FT 0 
S. aureus GGTGGCTAAAGCCAGGGAGA CGGGGT AAVS1 HEK 293FT 0 
S. aureus TAGGGTTAGGGGCCCCAGGC CGGGGT EMX1 HEK 293FT 0 
S. aureus ATGGGAAGACTGAGGCTACA TAGGGT EMX1 HEK 293FT 0 
S. aureus CATCAGGCTCTCAGCTCAGC CTGAGT EMX1 HEK 293FT 0 
S. aureus GTGGCTGCTCTGGGGGCCTC CTGAGT EMX1 HEK 293FT 29 
S. aureus GAAGCTGGAGGAGGAAGGGC CTGAGT EMX1 HEK 293FT 8 
S. aureus TCGATGTCACCTCCAATGAC TAGGGT EMX1 HEK 293FT 15 
S. aureus GCAAGCAGCACTCTGCCCTC GTGGGT EMX1 HEK 293FT 8 
S. aureus CAACCACAAACCCACGAGGG CAGAGT EMX1 HEK 293FT 32 
S. aureus AAGCCTGGCCAGGGAGTGGC CAGAGT EMX1 HEK 293FT 7 
S. aureus GCCTCCCCAAAGCCTGGCCA GGGAGT EMX1 HEK 293FT 28 
S. aureus GGCCAGGCTTTGGGGAGGCC TGGAGT EMX1 HEK 293FT 24 
S. aureus CAGGCTGAGCTGAGAGCCTG ATGGGA EMX1 HEK 293FT 9 
S. aureus CTCAACACTCAGGCTGAGCT GAGAGC EMX1 HEK 293FT 9 
S. aureus GCCTCAACACTCAGGCTGAG CTGAGA EMX1 HEK 293FT 9 
S. aureus CTGGGGCCTCAACACTCAGG CTGAGC EMX1 HEK 293FT 8 
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S. aureus GAGGCCCCCAGAGCAGCCAC TGGGGC EMX1 HEK 293FT 20 
S. aureus GGAGGCCCCCAGAGCAGCCA CTGGGG EMX1 HEK 293FT 21 
S. aureus TGAGAAACTCAGGAGGCCCC CAGAGC EMX1 HEK 293FT 15 
S. aureus GGGGCACAGATGAGAAACTC AGGAGG EMX1 HEK 293FT 10 
S. aureus AGGGGCACAGATGAGAAACT CAGGAG EMX1 HEK 293FT 2 
S. aureus AGGGAGGGAGGGGCACAGAT GAGAAA EMX1 HEK 293FT 5 
S. aureus CCAGGGAGGGAGGGGCACAG ATGAGA EMX1 HEK 293FT 3 
S. aureus TTCACCTGGGCCAGGGAGGG AGGGGC EMX1 HEK 293FT 1 
S. aureus CTTCACCTGGGCCAGGGAGG GAGGGG EMX1 HEK 293FT 8 
S. aureus ACCTTCACCTGGGCCAGGGA GGGAGG EMX1 HEK 293FT 7 
S. aureus CACCTTCACCTGGGCCAGGG AGGGAG EMX1 HEK 293FT 6 
S. aureus ACCACACCTTCACCTGGGCC AGGGAG EMX1 HEK 293FT 5 
S. aureus ACACCTTCACCTGGGCCAGG GAGGGA EMX1 HEK 293FT 5 
S. aureus CCACACCTTCACCTGGGCCA GGGAGG EMX1 HEK 293FT 8 
S. aureus AACCACACCTTCACCTGGGC CAGGGA EMX1 HEK 293FT 6 
S. aureus TTCTGGAACCACACCTTCAC CTGGGC EMX1 HEK 293FT 7 
S. aureus TGTACTTTGTCCTCCGGTTC TGGAAC EMX1 HEK 293FT 2 
S. aureus TTGTACTTTGTCCTCCGGTT CTGGAA EMX1 HEK 293FT 2 
S. aureus GGGAGCCCTTCTTCTTCTGC TCGGAC EMX1 HEK 293FT 0 
S. aureus GCGCCACCGGTTGATGTGAT GGGAGC EMX1 HEK 293FT 2 
S. aureus TGCGCCACCGGTTGATGTGA TGGGAG EMX1 HEK 293FT 7 
S. aureus ATGCGCCACCGGTTGATGTG ATGGGA EMX1 HEK 293FT 0 
S. aureus CTCTCAGCTCAGCCTGAGTG TTGAGG EMX1 HEK 293FT 11 
S. aureus TTGAGGCCCCAGTGGCTGCT CTGGGG EMX1 HEK 293FT 0 
S. aureus TGAGGCCCCAGTGGCTGCTC TGGGGG EMX1 HEK 293FT 0 
S. aureus GAGGCCCCAGTGGCTGCTCT GGGGGC EMX1 HEK 293FT 0 
S. aureus CCCCTCCCTCCCTGGCCCAG GTGAAG EMX1 HEK 293FT 4 
S. aureus CCCAGGTGAAGGTGTGGTTC CAGAAC EMX1 HEK 293FT 4 
S. aureus GTGAAGGTGTGGTTCCAGAA CCGGAG EMX1 HEK 293FT 0 
S. aureus TGAAGGTGTGGTTCCAGAAC CGGAGG EMX1 HEK 293FT 12 
S. aureus AAGGTGTGGTTCCAGAACCG GAGGAC EMX1 HEK 293FT 10 
S. aureus GGAGGACAAAGTACAAACGG CAGAAG EMX1 HEK 293FT 3 
S. aureus CAAAGTACAAACGGCAGAAG CTGGAG EMX1 HEK 293FT 2 
S. aureus AAAGTACAAACGGCAGAAGC TGGAGG EMX1 HEK 293FT 3 
S. aureus AGTACAAACGGCAGAAGCTG GAGGAG EMX1 HEK 293FT 3 
S. aureus GTACAAACGGCAGAAGCTGG AGGAGG EMX1 HEK 293FT 8 
S. aureus ACAAACGGCAGAAGCTGGAG GAGGAA EMX1 HEK 293FT 3 
S. aureus CAAACGGCAGAAGCTGGAGG AGGAAG EMX1 HEK 293FT 4 
S. aureus ACGGCAGAAGCTGGAGGAGG AAGGGC EMX1 HEK 293FT 26 
S. aureus GGAGGAGGAAGGGCCTGAGT CCGAGC EMX1 HEK 293FT 5 
S. aureus AGGAAGGGCCTGAGTCCGAG CAGAAG EMX1 HEK 293FT 13 
S. aureus AAGGGCCTGAGTCCGAGCAG AAGAAG EMX1 HEK 293FT 8 
S. aureus GGCCTGAGTCCGAGCAGAAG AAGAAG EMX1 HEK 293FT 1 
S. aureus CTGAGTCCGAGCAGAAGAAG AAGGGC EMX1 HEK 293FT 1 
S. aureus TCAACCGGTGGCGCATTGCC ACGAAG EMX1 HEK 293FT 7 
S. aureus GGCCACTCCCTGGCCAGGCT TTGGGG EMX1 HEK 293FT 0 
S. aureus GCCACTCCCTGGCCAGGCTT TGGGGA EMX1 HEK 293FT 0 
S. aureus CCACTCCCTGGCCAGGCTTT GGGGAG EMX1 HEK 293FT 5 
S. aureus CACTCCCTGGCCAGGCTTTG GGGAGG EMX1 HEK 293FT 7 
S. aureus TGGCCAGGCTTTGGGGAGGC CTGGAG EMX1 HEK 293FT 0 
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S. aureus GGCCTCCCCAAAGCCTGGCC AGGGAG EMX1 HEK 293FT 5 
S. aureus AGGCCTCCCCAAAGCCTGGC CAGGGA EMX1 HEK 293FT 9 
S. aureus TGTCACCTCCAATGACTAGG GTGGGC EMX1 HEK 293FT 1 
S. aureus GTGGGCAACCACAAACCCAC GAGGGC EMX1 HEK 293FT 5 
S. aureus TGGTTGCCCACCCTAGTCAT TGGAGG EMX1 HEK 293FT 1 
S. aureus GTGGTTGCCCACCCTAGTCA TTGGAG EMX1 HEK 293FT 1 
S. aureus GGCCTGGAGTCATGGCCCCA CAGGGC EMX1 HEK 293FT 5 
S. aureus GAGTCATGGCCCCACAGGGC TTGAAG EMX1 HEK 293FT 7 
S. aureus GCCCCGGGCTTCAAGCCCTG TGGGGC EMX1 HEK 293FT 0 
S. aureus GGCCCCGGGCTTCAAGCCCT GTGGGG EMX1 HEK 293FT 3 
S. aureus CATTGCCACGAAGCAGGCCA ATGGGG EMX1 HEK 293FT 16 
S. aureus ATTGCCACGAAGCAGGCCAA TGGGGA EMX1 HEK 293FT 10 
S. aureus TTGCCACGAAGCAGGCCAAT GGGGAG EMX1 HEK 293FT 0 
S. aureus TGCCACGAAGCAGGCCAATG GGGAGG EMX1 HEK 293FT 15 
S. aureus CCACGAAGCAGGCCAATGGG GAGGAC EMX1 HEK 293FT 30 
S. aureus GGGTGGGCAACCACAAACCC ACGAGG EMX1 HEK 293FT 6 
S. aureus GCTGCTGGCCAGGCCCCTGC GTGGGC EMX1 HEK 293FT 3 
S. aureus GAGTCCAGCTTGGGCCCACG CAGGGG EMX1 HEK 293FT 6 
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Supplementary Table 10 Predicted GWOTs for SaCas9 and SpCas9 specificity analysis 
 
Tar-
get # 
Genome-wide 
off target site PAM 
Mis-
matches 
Forward priming 
site 
Reverse priming 
site 
SpCas9 
indel 
(%) 
SaCas9 
indel 
(%) 
On-
target 
TAGGGTTAGGG
GCCCCAGGC CGGGG NA 
CACTGTGTCCTCT
TCCTGCC 
ATGAGAAACTCA
GGAGGCCC 12.88 13.60 
1 TAGGGTTAGGG
TCCCCAGGT TTGAA 2 
AGGTTTCTGCCCA
TCCTTTC 
GCCCAGGAAATC
CTAAAGGT 0.044 0.039 
2 GAGGGTTAGGG
CCCCCAGGC AGGGA 2 
CCTACCAGCAGGA
AAGGACA 
CATCGTAACCGA
AAGGTCCA 6.58 0.25 
3 TAAGGTTCTGG
GCCCCAGGC AAGAA 3 
CAGTGACTCACAG
GGTCAGG 
GGCGTTCCTATT
TCACAAGC 0.052 0.046 
4 AAGAGCTAGGG
GCCCCAGGC CTGAG 3 
AAAAGGGGGTGGA
CTAGAGC 
CACCAGGCCTGA
GAGAGAAG 0.011 0.037 
5 TATGTTTCGGG
GCCCCAGGC CGGAA 3 
CACCTTCTGCATT
CTGCCTA 
TCCAGACCCTCA
AAGACCAC 0.023 0.006 
6 GAGGGGAAGGG
GCCCCAGGC TGGAG 3 
GCAAAGACGGAAA
GAGAAGC 
CAGAGCCTTCAG
AAATTCTCC 0.145 0.022 
7 TAGGGGCAGGG
GCACCAGGC GGGGA 3 
CCGTCTTGCTGTG
TGACCTA 
ATACGGACGCTC
TGATCCTG 0.466 0.052 
8 CCGGGTGAGTG
GCCCCAGGC CTGGG 4 
CGACGTGAAGGAG
AAATTCG 
GCCAGTCGGAAC
ACTCTGA 0.10 0.051 
9 GAGGGTGAGTG
GCCCCAGGG CAGAA 4 
AACCTGGAGTGGG
ATGACAG 
CCACAGGGACTC
TGAGGAGA 0.032 0.010 
10 CAGGTTTAGGG
GCTCCAGGA CTGGG 4 
TCTGTCCTCTGGG
AGCTGAC 
GCTTTGCAGACA
CCATCTCA 0.025 0.024 
11 TGGGTTTAGGG
GCCACAGGT GGGAG 4 
GGGCTCTGGCTTC
TGAGAG 
CTGGGTGCTCTC
TACGTGGT 0.055 0.12 
12 TGGGGTCAGGG
GACCCAGGG TGGGG 4 
GGGGAGTGTTTTC
CTTCCAT 
GCCAGGGCTCAC
AGTTATTG 0.031 0.047 
13 TAGGGTTAGGG
GCCTGCAGC CAGGG 4 
CAGTCCTATGCTC
GGGAGAG 
GGGAACTGTAGC
CTGTGGAG 0.015 0.024 
14 TGGGGTGAGGG
GCCCCGGCC AGGAG 4 
CAGAGGCTTCAGG
AGGAAGG 
TGGGGATATGCA
ACCCTTAG 0.13 0.15 
15 GAGGATTAGGG
TCACCAGGC ATGAG 4 
CTGGCAGGGGAAG
TCAAATA 
ATTCCGTCTGTC
TGGAATGC 0.058 0.083 
16 TGGGGCCAGGG
GCCGCAGGC AGGGG 4 
CCCGTTCTCTCTC
CTTCCTC 
TGCACCAAGTAG
CAGAGGTG 0.009 0.004 
17 ACGGGTTAGGG
GACACAGGC CTGAG 4 
CCTCTCTGAGCCC
AGTGTTC 
TCTTGTTCTCCA
CCCCTCAG 0.033 0.028 
18 GAGGGGCAGGG
GGCCCAGGC TGGGG 4 
GTCTGCTGGGATT
CTGGGTA 
CAGCTTTGTGGC
TCTGGAAT 0.044 0.054 
19 GAGCGTTGGGG
GCCCCAGGA CAGGA 4 
CTCGTGAGCAACG
GGACTAT 
GTGGAAACACGG
TGCTCTTT 0.066 0.062 
20 TAGAGTTAGGA
GACCCAGGA ATGAG 4 
CAACCAAGATCAG
GCAACAA 
AACTTGGTAAGT
GCCCAGCA 0.12 0.066 
21 TGGGGAGGGGG
GCCCCAGGC AGGGG 4 
GGCCTCTGAAATA
ACGTTGG 
CCCTGCTTTCTT
CACTCCAG 0.043 0.057 
22 AAGGGTTAGGG
GCCCAAAGG TAGAG 4 
GGACCCTGGGAAC
ATTTTGT 
AAAGGGCAGAGG
AAAGAAGG 0.046 0.066 
23 GAGGCTGAGTG
GCCCCAGGC CTGAG 4 
CCCAGTTTGAGGA
CAGTGGT 
GGGCTTAGGGAC
TCAGGAGA 0.11 0.092 
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24 TCGGGTGTGGGG
CTCCAGGC CCGGG 4 
CAAGAGAGGGAGG
ATGCAAG 
GCTGCTGAGGGA
TGGAGTT 0.036 0.061 
25 GAGGGTGAGTGG
CCCCAGGA CTGGG 4 
CACAGACTCAGGC
CATCTCA 
GCAGTGAAAGAA
GGCTAGATCC 0.084 0.031 
26 TAGTGTTAGGAG
CTCCAGGG AAGGG 4 
CCTACAGCCATTG
GACCCTA 
CGAAGGGCTCAA
ACATCTTC 0.0030 0.0040 
27 TAGGGTCAGGGG
CTCAAGGG ATGGG 4 
GTCAGTGCTGACA
CCTCACC 
AGTGCCTCCTCT
TCCCACTC 0.015 0.005 
28 CAGGGATAGCAG
CCCCAGGC AGGGG 4 
TGCTAGGGTGGGG
AAATTCT 
AAATCCAGCAGA
GCAGCAAT 0.029 0.023 
29 TAGGGGTAGGGG
GGCCATGC AGGGG 4 
ACAGAAGGTAAGG
GGGAAGG 
TCTCTCTCTGCT
GCACCTCA 0.074 0.058 
30 TGGGGGTAGGGG
TCCCAGGA GAGAG 4 
ATACCTGGGGGAA
CTGCTCT 
GTAGGCCACCTT
GACCTCTG 0.015 0.015 
31 CAGGCTTGGGGG
CCCCAGGT AGGGG 4 
TCTGAGAACACCA
GGAAGCA 
TCTTGGCCTCCT
CACATAGG 0.009 0.013 
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Cell culture and transfection 
Human embryonic kidney (HEK) cell line 293FT (Life Technologies) or mouse Neuro 2a (Sigma-Aldrich) cell 
line was maintained in Dulbecco’s modified Eagle’s Medium (DMEM) supplemented with 10 % fetal bovine 
serum (HyClone), 2mM GlutaMAX (Life Technologies), 100 U/mL penicillin, and 100μg/mL streptomycin at 
37 °C with 5 % CO2 incubation. 
Cells were seeded onto 24-well plates (Corning) at a density of 120,000 cells/well, 24 hours prior to transfection. 
Cells were transfected using Lipofectamine 2000 (Life Technologies) at 80-90 % confluency following the 
manufacturer’s recommended protocol. A total of 500 ng Cas9 plasmid and 100 ng of U6-sgRNA PCR product 
was transfected. 
Human embryonic stem cell line HUES62 (Harvard Stem Cell Institute core) was maintained in feeder-free 
conditions on GelTrex (Life Technologies) in mTesR medium (Stemcell Technologies) supplemented with 100 
ug/ml Normocin (InvivoGen). HUES62 cells were transfected with Amaxa P3 Primary Cell 4-D Nucleofector Kit 
(Lonza) following the manufacturer’s protocol. 
SURVEYOR nuclease assay for genome modification 
293FT and HUES62 cells were transfected with DNA as described above. Cells were incubated at 37 ºC for 72 
hours post-transfection prior to genomic DNA extraction. Genomic DNA was extracted using the QuickExtract 
DNA Extraction Solution (Epicentre) following the manufacturer’s protocol. Briefly, pelleted cells were 
resuspended in QuickExtract solution and incubated at 65 ºC for 15 minutes, 68 °C for 15 minutes, and 98 ºC for 
10 minutes. 
The genomic region flanking the CRISPR target site for each gene was PCR amplified, and products were purified 
using QiaQuick Spin Column (Qiagen) following the manufacturer’s protocol. 400 ng total of the purified PCR 
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products were mixed with 2ml 10X Taq DNA Polymerase PCR buffer (Enzymatics) and ultrapure water to a final 
volume of 20ml, and subjected to a re-annealing process to enable heteroduplex formation: 95 ºC for 10 min, 95 
ºC to 85 ºC ramping at – 2 ºC/s, 85 ºC to 25 ºC at – 0.25 ºC/s, and 25 ºC hold for 1 minute. After re-annealing, 
products were treated with SURVEYOR nuclease and SURVEYOR enhancer S (Transgenomics) following the 
manufacturer’s recommended protocol, and analyzed on 4-20% Novex TBE poly-acrylamide gels (Life 
Technologies). Gels were stained with SYBR Gold DNA stain (Life Technologies) for 30 minutes and imaged 
with a Gel Doc gel imaging system (Bio-rad). Quantification was based on relative band intensities. Indel 
percentage was determined by the formula, 100 x (1 - (1 - (b + c) / (a + b + c))1/2), where a is the integrated 
intensity of the undigested PCR product, and b and c are the integrated intensities of each cleavage product. 
Northern blot analysis of tracrRNA and sgRNA expression in 
human cells 
Northern blots were performed as previously described (1). Briefly, RNAs were extracted using the mirPremier 
microRNA Isolation Kit (Sigma) and heated to 95 ºC for 5 min before loading on 8 % denaturing polyacrylamide 
gels (SequaGel, National Diagnostics). Afterwards, RNA was transferred to a pre-hybridized Hybond N+ 
membrane (GE Healthcare) and cross-linked with Stratagene UV Crosslinker (Stratagene). Probes were labeled 
with [gamma-32P] ATP (Perkin Elmer) with T4 polynucleotide kinase (New England Biolabs). After washing, 
membrane was exposed to phosphor screen for one hour and scanned with phosphorimager (Typhoon). 
In vitro transcription and cleavage assay 
Whole cell lysates from 293FT cells were prepared with lysis buffer (20 mM HEPES, 100 mM KCl, 5 mM MgCl2, 
1 mM DTT, 5% glycerol, 0.1% Triton X-100) supplemented with Protease Inhibitor Cocktail (Roche). T7-driven 
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sgRNA was transcribed in vitro using custom oligos and HiScribe T7 In Vitro Transcription Kit (NEB), following 
the manufacturer’s recommended protocol. To prepare methylated target sites, pUC19 plasmid was methylated 
by M.SssI and tested by digestion with HpaII. Unmethylated and successfully methylated pUC19 plasmids were 
linearized by NheI. The in vitro cleavage assay was performed as follows: for a 20 uL cleavage reaction, 10 uL of 
cell lysate was incubated with 2 uL cleavage buffer (100 mM HEPES, 500 mM KCl, 25 mM MgCl2, 5 mM DTT, 
25% glycerol), 1 ug in vitro transcribed RNA, and 300 ng pUC19 plasmid DNA. 
Bisulfite sequencing to assess DNA methylation status 
Genomic DNA from 293FT cells was isolated with the DNeasy Blood & Tissue Kit (Qiagen) and bisulfite 
converted with EZ DNA Methylation-Lightning Kit (Zymo Research). Bisulfite PCR was conducted using 
KAPA2G Robust HotStart DNA Polymerase (KAPA Biosystems) with primers designed using the Bisulfite 
Primer Seeker (Zymo Research). Resulting PCR amplicons were gel-purified, digested with EcoRI and HindIII, 
and ligated into a pUC19 backbone prior to transformation. Individual clones were then Sanger sequenced to 
assess DNA methylation status. 
Deep sequencing to assess targeting specificity 
HEK 293FT cells were plated and transfected as described above, 72 hours prior to genomic DNA extraction. The 
genomic region flanking the CRISPR target site for each gene was amplified by a fusion PCR method to attach the 
Illumina P5 adapters as well as unique sample-specific barcodes to the target. PCR products were purified using 
EconoSpin 96-well Filter Plates (Epoch Life Sciences) following the manufacturer’s recommended protocol. 
Barcoded and purified DNA samples were quantified by Qubit 2.0 Fluorometer (Life Technologies) and pooled 
in an equimolar ratio. Sequencing libraries were then sequenced with the Illumina MiSeq Personal Sequencer 
(Life Technologies). 
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Sequencing data analysis and indel detection 
MiSeq reads were filtered by requiring an average Phred quality (Q score) of at least 23, as well as perfect 
sequence matches to barcodes and amplicon forward primers. Reads from on- and off-target loci were analyzed by 
first performing Smith-Waterman alignments against amplicon sequences that included 50 nucleotides upstream 
and downstream of the target site (a total of 120 bp). Alignments, meanwhile, were analyzed for indels from 5 
nucleotides upstream to 5 nucleotides downstream of the target site (a total of 30 bp). Analyzed target regions 
were discarded if part of their alignment fell outside the MiSeq read itself, or if matched base-pairs comprised less 
than 85% of their total length(2). 
Negative controls for each sample provided a gauge for the inclusion or exclusion of indels as putative cutting 
events. For each sample, an indel was counted only if its quality score exceeded  𝜇 − 𝜎, where 𝜇 was the mean 
quality-score of the negative control corresponding to that sample and 𝜎 was the standard deviation of the same. 
This yielded whole target-region indel rates for both negative controls and their corresponding samples. Using the 
negative control’s per-target-region-per-read error rate, 𝑞, the sample’s observed indel count 𝑛, and its read-count 𝑅, a maximum-likelihood estimate for the fraction of reads having target-regions with true-indels, 𝑝, was derived 
by applying a binomial error model, as follows. 
Letting the (unknown) number of reads in a sample having target regions incorrectly counted as having at least 1 
indel be 𝐸, we can write (without making any assumptions about the number of true indels) 
Prob 𝐸 𝑝 = 𝑅 1 − 𝑝𝐸 𝑞!(1 − 𝑞)! !!! !!  
since 𝑅(1 − 𝑝) is the number of reads having target-regions with no true indels. Meanwhile, because the number 
of reads observed to have indels is 𝑛, 𝑛 = 𝐸 + 𝑅𝑝, i.e. the number of reads having target-regions with errors but 
no true indels plus the number of reads whose target-regions correctly have indels. We can then re-write the above 
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Prob 𝐸 𝑝 = Prob 𝑛 = 𝐸 + 𝑅𝑝 𝑝 =    𝑅 1 − 𝑝𝑛 − 𝑅𝑝 𝑞!!!"(1 − 𝑞)!!!  
Taking all values of the frequency of target-regions with true-indels 𝑝  to be equally probable a priori, 
Prob 𝑛 𝑝 ∝ Prob(𝑝|𝑛). The maximum-likelihood estimate (MLE) for the frequency of target regions with 
true-indels was therefore set as the value of 𝑝 that maximized Prob(𝑛|𝑝). This was evaluated numerically. 
 
In order to place error bounds on the true-indel read frequencies in the sequencing libraries themselves, Wilson 
score intervals(3) were calculated for each sample, given the MLE-estimate for  true-indel target-regions, 𝑅𝑝, and 
the number of reads 𝑅. Explicitly, the lower bound 𝑙 and upper bound 𝑢 were calculated as 
𝑙 = 𝑅𝑝 + 𝑧!2 − 𝑧 𝑅𝑝 1 − 𝑝 + 𝑧!/4 𝑅 + 𝑧!  
𝑢 = 𝑅𝑝 + 𝑧!2 + 𝑧 𝑅𝑝 1 − 𝑝 + 𝑧!/4 𝑅 + 𝑧!  
where 𝑧, the standard score for the confidence required in normal distribution of variance 1, was set to 1.96, 
meaning a confidence of 95%.  
Microinjection into mouse zygotes 
Cas9 mRNA and sgRNA templates were amplified with T7 promoter sequence-conjugated primers. After gel 
purification, Cas9 and Cas9n were transcribed with mMESSAGE mMACHINE T7 Ultra Kit (Life technologies). 
sgRNAs were transcribed with MEGAshortscript T7 Kit (Life technologies). RNAs were purified by MEGAclear 
Kit (Life technologies) and frozen at -80 °C. 
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MII-stage oocytes were collected from 8-week old superovulated BDF1 females by injecting 7.5 I.U. of PMSG 
(Harbor, UCLA) and hCG (Millipore). They were transferred into HTF medium supplemented with 10 mg/ml 
bovine serum albumin (BSA; Sigma-Aldrich) and inseminated with capacitated sperm obtained from the caudal 
epididymides of adult C57BL/6 male mice. Six hours after fertilization, zygotes were injected with mRNAs and 
sgRNAs in M2 media (Millipore) using a Piezo impact-driven micromanipulator (Prime Tech Ltd., Ibaraki, 
Japan). The concentrations of Cas9 and Cas9n mRNAs and sgRNAs are described in the text. After 
microinjection, zygotes were cultured in KSOM (Millipore) in a humidified atmosphere of 5 % CO2 and 95 % air 
at 37 °C. 
Genome extraction from blastocyst embryos 
Following in vitro culture of embryos for 6 days, the expanded blastocysts were washed with 0.01 % BSA in PBS 
and individually collected into 0.2 mL tubes. Five microliters of genome extraction solution (50 mM Tris-HCl, 
pH 8.0, 0.5 % Triton-X100, 1 mg/ml Proteinase K) were added and the samples were incubated in 65 °C for 3 
hours followed by 95 °C for 10 min. Samples were then amplified for targeted deep sequencing as described above. 
Western blot analysis 
HEK 293FT cells were transfected and lysed in 1X RIPA buffer (Sigma-Aldrich) supplemented with Protease 
Inhibitor (Roche). The lysates were loaded onto Bolt 4–12% Bis-Tris Plus Gels (Invitrogen) and transferred to 
nitrocellulose membranes. The membranes were blocked in Tris-buffered saline containing 0.1% Tween-20 and 
5% blocking agent (G-Biosciences). The membranes were probed with rabbit anti-FLAG (1:5,000, Abcam), 
HRP-conjugated anti-GAPDH (1:5,000 Cell Signaling Technology), and HRP-conjugated anti-rabbit (1:1,000) 
antibodies and visualized with a Gel Doc XR+ System (Bio-Rad). 
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Sample preparation for crystallography 
 The gene encoding full-length S. pyogenes Cas9 (residues 1–1368) was cloned between the NdeI and XhoI sites of 
the modified pCold-GST vector (TaKaRa), and mutations were introduced by a PCR-based method. The S. 
pyogenes Cas9 D10A/C80L/C574E/H840A mutant was expressed at 20°C in Escherichia coli Rosetta 2 (DE3) 
(Novagen), and was purified by chromatography on Ni-NTA Superflow resin (QIAGEN). The eluted protein 
was incubated overnight at 4°C with TEV protease to remove the His6–GST-tag, and was further purified by 
chromatography on Ni-NTA, Mono S (GE Healthcare) and HiLoad Superdex 200 16/60 (GE Healthcare) 
columns. The SeMet-labeled Cas9 protein was expressed in E. coli B834 (DE3), and was purified using a similar 
protocol to that for the native protein. The 98-nt sgRNA was transcribed in vitro with T7 polymerase using a 
PCR-amplified DNA template, and was purified by 10% denaturing polyacrylamide gel electrophoresis. The 23-nt 
target DNA was purchased from Sigma-Aldrich. The purified Cas9 protein was mixed with sgRNA and DNA 
(molar ratio, 1:1.5:2.3), and then the complex was purified by gel filtration chromatography on a Superdex 200 
Increase column (GE Healthcare), in a buffer consisting of 10 mM Tris-HCl, pH 8.0, 150 mM NaCl and 1 mM 
DTT. 
Crystallography 
The purified Cas9–sgRNA–DNA complex was crystallized at 20°C by the hanging-drop vapor diffusion method. 
Crystals were obtained by mixing 1 µl of complex solution (A260 nm, 15) and 1 µl of reservoir solution (13% PEG 
3,350, 100 mM Tris-HCl, pH 8.0, 200 mM ammonium acetate and 100 mM NDSB-256). The SeMet-labeled 
protein was crystallized under conditions similar to those for the native protein. X-ray diffraction data were 
collected at 100 K on beamlines BL32XU and BL41XU at SPring-8 (Hyogo, Japan). The crystals were 
cryoprotected in reservoir solution supplemented with 25% ethylene glycol. X-ray diffraction data were processed 
using XDS (4). The structure was determined by the SAD method, using a 2.6 Å resolution data set from the 
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SeMet-labeled crystals. Forty of the potential 44 Se atoms were located using SHELXD (5) and autoSHARP (6). 
The initial phases were calculated using autoSHARP, and further improved by 2-fold NCS averaging using DM 
(7). The model was automatically built using PHENIX AutoSol (8), followed by manual model building using 
COOT (9) and structural refinement using PHENIX (8). The resulting model was further refined, using the 2.5 
Å resolution native data set. 
in vitro PAM screen and sgRNA prediction 
Rho-independent transcriptional termination was predicted using the ARNold terminator search tool(10, 11). 
For the PAM library, a degenerate 7-bp sequence was cloned into a pUC19 vector. For each ortholog, the in vitro 
cleavage assay was carried out as above with 1 μg T7-transcribed sgRNA and 400ng pUC19 with degenerate PAM. 
Cleaved plasmids were linearized by NheI, gel extracted, and ligated with Illumina proprietary sequencing 
adaptors. Barcoded and purified DNA libraries were quantified by Quant-iT PicoGreen dsDNA Assay Kit or 
Qubit 2.0 Fluorometer (Life Technologies) and pooled in an equimolar ratio for sequencing using the Illumina 
MiSeq Personal Sequencer (Life Technologies). sgRNA secondary structure prediction was based on the 
Constraint Generation RNA folding model(12), and Sequence logos were generated using WebLogo(13).  
AAV Production 
For viral production, 293FT cells (Life Technologies) were maintained as recommended by the manufacturer in 
antibiotic-free media (DMEM, high glucose with GlutaMax and Sodium Pyruvate, supplemented with 10% FBS, 
and a final concentration of 10mM HEPES). For each vector, cells were grown in at least ten 15 cm tissue culture 
dishes and incubated until they reach around 70% - 80% confluence at 37oC and 5% CO2. For transfection of virus 
production plasmids, PEI “Max” (Polysciences) was dissolved in water at 1 mg/mL and the pH of the solution 
was adjusted to 7.1.  
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For transfection, 8 ug of pAAV8 serotype packaging plasmid, 10 ug of pDF6 helper plasmid, and 6 ug of pAAV 
plasmid carrying the construct of interest were added to 1mL of serum-free DMEM. 125 uL of PEI “Max” solution 
was then added to the mixture. The resulting final transfection mixture was vortexed briefly and incubated at 
room temperature for 5 to 10 seconds. After incubation, the mixture was added to 20 mL of maintenance media, 
mix well, and applied to each dish to replace the old growth media. Cells were harvested between 48h and 72h 
post transfection. Cells were scraped from the dishes and pelleted by centrifugation. The AAV8 viral particle were 
then purified from the pellet according to previous published protocol(14).  
Viruses were also produced by vector core facilities at University of Pennsylvania and Children's Hospital Boston, 
and titered by qPCR using a customized TaqMan probe against the SaCas9 transgene to match in house 
production. 
Animal Injection and Processing 
All mice were maintained at animal facility following IRB-approved protocols. AAV was delivered to at 8-10 week 
old C57/BL6 mice via tail vein injection. All dosages of AAV were adjusted to 100 uL or 200uL with sterile 
phosphate buffered serum, pH 7.4 (Gibco).  
Tissue was harvested at the described time points post injection. Mice were anesthetized using 
Ketamine/Xylazine and subjected to transcardial perfusion with 30ml PBS. The median lobe of liver was removed 
and fixed in 4% paraformaldehyde for histological analysis, while the remaining lobes were sliced in small blocks of 
size less than 1x1x3mm3 and frozen at -80C for subsequent genomic DNA extraction, or immersed in RNALater 
(Ambion) for RNA extraction. 
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